---
document_datetime: 2023-09-21 19:09:54
document_pages: 97
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/vitekta-epar-public-assessment-report_en.pdf
document_name: vitekta-epar-public-assessment-report_en.pdf
version: success
processing_time: 118.4904583
conversion_datetime: 2025-12-29 22:14:02.890259
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

<!-- image -->

19 September 2013 EMA/701401/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Vitekta International non-proprietary name: ELVITEGRAVIR Procedure No. EMEA/H/C/002577/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorised

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Product information

| Name of the medicinal product:         | Vitekta                                                                                                                                                                                                                                            |
|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Applicant:                             | Gilead Sciences International Ltd Flowers Building Granta Park Abington Cambridge CB21 6GT UNITED KINGDOM                                                                                                                                          |
| Active substance:                      | ELVITEGRAVIR                                                                                                                                                                                                                                       |
| International Nonproprietary Name:     | ELVITEGRAVIR                                                                                                                                                                                                                                       |
| Pharmaco-therapeutic group (ATC Code): | Other antivirals, HIV-1 integrase strand transfer inhibitors (J05AX11)                                                                                                                                                                             |
| Therapeutic indication(s):             | In co-administration with a ritonavir-boosted protease inhibitor and with other antiretroviral agent, treatment of HIV-1 infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir longer |
| Pharmaceutical form:                   | Film-coated tablet                                                                                                                                                                                                                                 |
| Strengths:                             | 85 mg and 150 mg no                                                                                                                                                                                                                                |
| Route of administration:               | Oral use                                                                                                                                                                                                                                           |
| Packaging:                             | bottle (HDPE)                                                                                                                                                                                                                                      |
| Package size:                          | 30 tablets                                                                                                                                                                                                                                         |

<!-- image -->

Pharmaco-therapeutic group (ATC Code): In co-administration with a ritonavir-boosted protease inhibitor and with other antiretroviral agent, treatment of HIV-1 infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir Strengths: 85 mg and 150 mg Route of administration: Oral use Packaging: bottle (HDPE) Package size: 30 tablets Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..................................................................6                |                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................6        |                                                                                                          |
| 1.2. Manufacturers......................................................................................................7    |                                                                                                          |
| 1.3. Steps taken for the assessment of the                                                                                   | product.........................................................7                                        |
| 2. Scientific discussion                                                                                                     | ................................................................................8                        |
| 2.1. Introduction.........................................................................................................8  |                                                                                                          |
| 2.2. Quality aspects                                                                                                         | ..................................................................................................10     |
| 2.2.1. Introduction....................................................................................................10    | authorised                                                                                               |
| 2.2.2. Active Substance.............................................................................................10       |                                                                                                          |
| 2.2.3. Finished Medicinal Product                                                                                            | ................................................................................12                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................14                         |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                    | ......................15                                                                                 |
| 2.3. Non-clinical aspects                                                                                                    | ............................................................................................15           |
| 2.3.1. Introduction....................................................................................................15    |                                                                                                          |
| 2.3.2. Pharmacology                                                                                                          | .................................................................................................15      |
| 2.3.3. Pharmacokinetics.............................................................................................16       |                                                                                                          |
| 2.3.4. Toxicology                                                                                                            | ......................................................................................................18 |
| 2.3.5. Ecotoxicity/environmental risk assessment .........................................................20 longer          |                                                                                                          |
| 2.3.6. Discussion on non-clinical aspects......................................................................21            |                                                                                                          |
| 2.3.7. Conclusion on the non-clinical aspects................................................................22 no           |                                                                                                          |
| 2.4. Clinical aspects                                                                                                        | ..................................................................................................22     |
| 2.4.1. Introduction....................................................................................................22    |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................27       |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................47          |                                                                                                          |
| 2.4.4. Discussion on clinical pharmacology...................................................................49 product      |                                                                                                          |
| 2.4.5. Conclusions on clinical pharmacology.................................................................52               |                                                                                                          |
| 2.5. Clinical efficacy ..................................................................................................52  |                                                                                                          |
| 2.5.1. Dose response studies......................................................................................53         |                                                                                                          |
| 2.5.2. Main study (GS-US-183-0145)..........................................................................53               |                                                                                                          |
| 2.5.3. Supportive studies...........................................................................................74       |                                                                                                          |
| 2.5.4. Discussion on clinical efficacy............................................................................75         |                                                                                                          |
| 2.5.5. Conclusions on the clinical efficacy.....................................................................76           |                                                                                                          |
| 2.6. Clinical safety                                                                                                         | ....................................................................................................76   |
| 2.6.1. Discussion on clinical safety                                                                                         | ..............................................................................87                         |
| 2.6.2. Conclusions on the clinical safety.......................................................................87 Medicinal |                                                                                                          |
| 2.7. Pharmacovigilance system...................................................................................87           |                                                                                                          |
| 2.8. Risk Management Plan........................................................................................87          |                                                                                                          |
| 2.9. User consultation                                                                                                       | ...............................................................................................93        |
| 3. Benefit-Risk Balance..............................................................................94                      |                                                                                                          |
| 4. Recommendations.................................................................................96                        |                                                                                                          |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ABC

abacavir

AE

adverse event

AIDS

acquired immune deficiency syndrome

ALT alanine aminotransferase ARV antiretroviral AST aspartate aminotransferase ATV atazanavir AUC area under the plasma concentration-time curve BID twice daily BLLQ below lower limit of quantification BMI body mass index BSA body surface area CC50 concentration that results in 50% cytotoxicity CHMP Committee for Medicinal Products for Human Use CI confidence interval CL/F apparent oral clearance Cmax maximum observed concentration COBI, /co cobicistat CRF case report form CSR clinical study report Ctau or Ctrough observed drug concentration at the end of the dosing interval CV coefficient of variation d4T stavudine DAVG difference between time-weighted average post baseline and baseline DC discontinuation of the study drug ddI didanosine DDI drug-drug interaction DNA deoxyribonucleic acid DRV darunavir ECxx concentration of a compound inhibiting virus replication by xx% EE ethinyl oestradiol EFV efavirenz eGFR estimated glomerular filtration rate EMA European Medicines Agency EVG elvitegravir FBRM focus beam reflectance measurement FDA US Food and Drug Administration FDC fixed dose combination FPV fosamprenavir FTC emtricitabine GCP Good clinical practices GFR glomerular filtration rate GGT gamma-glutamyltransferase GI gastrointestinal GLP Good laboratory practices GMP Good manufacturing practices genotypic sensitivity score HAART highly active antiretroviral therapy HBV, HCV hepatitis B or C virus, respectively HDPE high-density polyethylene HIV human immunodeficiency virus Medicinal product no longer authorised

GSS

IDMC

Independent Data Monitoring Committee

INSTI

integrase strand-transfer inhibitor

IQ

inhibitory quotient

ITT

intent-to-treat

KTZ

ketoconazole

LLQ

lower limit of quantification

LPV

lopinavir

LSM

least-squares mean

<!-- image -->

<div style=\"page-break-after: always\"></div>

| LTFU      | lost to follow-up                                                          |
|-----------|----------------------------------------------------------------------------|
| M = E     | missing = excluded                                                         |
| M = F     | missing = failure                                                          |
| M/S = F   | missing or antiretroviral therapy switch = failure                         |
| M1        | elvitegravir metabolite (hydroxylation of the chlorofluorophenyl group)    |
| M4        | elvitegravir metabolite (glucuronide conjugate of the carboxylic acid)     |
| MDZ       | midazolam                                                                  |
| MedDRA    | Medical Dictionary for Regulatory Activities                               |
| MIC       | minimum inhibitory concentration                                           |
| MVC       | maraviroc                                                                  |
| NAS       | new active substance                                                       |
| NORs      | normal acceptable ranges                                                   |
| NRTI      | nucleoside reverse transcriptase inhibitor                                 |
| NtRTI     | nucleotide reverse transcriptase inhibitor                                 |
| OATP      | organic anion transporting polypeptide                                     |
| OBR       | optimised background regimen authorised                                    |
| PARs      | proven acceptable ranges                                                   |
| PD        | pharmacodynamics                                                           |
| Pgp       | P glycoprotein                                                             |
| PI        | protease inhibitor                                                         |
| PIP       | Paediatric Investigation plan                                              |
| PK        | pharmacokinetics                                                           |
| PRAC      | Pharmacovigilance Risk Assessment Committee                                |
| PSS       | phenotypic sensitivity score                                               |
| PVF       | pure virological failure                                                   |
| PVRs      | pure virological responders                                                |
| QUAD, STR | elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate longer |
| RAL       | raltegravir                                                                |
| RMP       | Risk Management Plan                                                       |
| RNA       | ribonucleic acid                                                           |
| RTV, /r   | ritonavir                                                                  |
| S9        | tissue post-mitochondrial (9,000 x g) supernatant no                       |
| SAE       | serious adverse event                                                      |
| SD        | standard deviation                                                         |
| SmPC      | Summary of Product Characteristics                                         |
| t½        | estimate of the terminal elimination half-life of the drug product         |
| T20       | enfuvirtide                                                                |
| TDF       | tenofovir disoproxil fumarate                                              |
| TEAE      | treatment emergent adverse event                                           |
| TLOVR     | time to loss of virological response                                       |
| UGT       | uridine glucuronosyltransferase                                            |
| VF        | virological failure                                                        |
| ZDV       | zidovudine                                                                 |

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The  applicant  Gilead  Sciences  International  Ltd  submitted  on  22  May  2012  an  application  for Marketing Authorisation to the European Medicines Agency (EMA) for Vitekta, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 19 May 2011. The applicant applied for the following indication: in co-administration with a ritonavir-boosted protease inhibitor and with other antiretroviral agent, treatment of HIV-1 infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir. The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC - complete and independent application. The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and bibliographic literature supporting certain tests or studies. Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0010/2012 on the agreement of a paediatric investigation plan (PIP). At the time of submission of the application, the PIP P/0010/2012 was not yet completed as all measures were deferred. Information relating to orphan market exclusivity Similarity Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication. New active Substance status The applicant requested the active substance elvitegravir contained in the above medicinal product to be considered as a new active substance in itself, as the applicant claims that it is not a constituent of a product previously authorised within the Union. Medicinal product no longer authorised

## Scientific Advice

The applicant did not seek scientific advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## Licensing status

The product was not licensed in any country at the time of submission of the application.

## 1.2. Manufacturers

Manufacturer responsible for batch release Gilead Sciences Limited IDA Business &amp; Technology Park Carrigtohill, County Cork Ireland 1.3. Steps taken for the assessment of the product · The application was received by the EMA on 22 May 2012. · The procedure started on 20 June 2012. · The Rapporteur's first Assessment Report including Assessment report on the claim of new active substance (NAS) was circulated to all CHMP members on 3 September 2012 (Annex 1). The CoRapporteur's first Assessment Report including Assessment report on the claim of new active substance (NAS) was circulated to all CHMP members on 17 September 2012 (Annex 2). · During the meeting on 18 October 2012, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 19 October 2013 (Annex 3). · The applicant submitted the responses to the CHMP consolidated List of Questions on 17 April 2013. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 27 May 2013 (Annex 4). · During the meeting on 13 June 2013, the PRAC agreed RMP Advice and assessment overview. · During the CHMP meeting on 27 June 2013, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant (Annex 6). · The applicant submitted the responses to the CHMP List of Outstanding Issues on 16 August 2013. · During the meeting on 5 September 2013, PRAC endorsed PRAC Rapporteur assessment report on the RMP. · During the meeting on 19 September 2013, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Vitekta. Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## Problem statement

2. endonucleolytic processing of the viral DNA ends (the U3 and U5 LTRs),

There are approximately 33 million people worldwide living with HIV-1. HIV-1 infection remains a lifethreatening disease in infected persons who do not receive adequate treatment sufficiently early in the course of the infection and/or are infected with virus that is resistant to anti-retroviral agents of several classes such that an adequate treatment regimen cannot be constructed from approved agents. Therapeutic strategies for the treatment of HIV-1 disease have been significantly advanced by the availability of highly active antiretroviral (ARV) therapy (HAART). The introduction of HAART was associated with a dramatic decrease in AIDS-related mortality and morbidity in the US and Europe. The goal of ARV therapy for HIV-1 infection is to delay disease progression and prolong survival by achieving maximal and durable suppression of HIV-1 replication. In treatment naïve subjects who have not acquired multi-resistant virus de novo , suppression of HIV RNA to &lt; 50 copies/ml has been achieved in ~80% of subjects in clinical studies. Current treatment guidelines suggest that initial therapy for ARV treatment-naïve HIV-1 infected patients should consist of 2 NRTIs/NtRTIs and either an NNRTI (usually efavirenz-a boosted protease inhibitor (PI)) or the integrase inhibitor (INSTI) raltegravir (RAL), which is currently the only licensed medicine in this class. Ritonavir (RTV) - boosted PIs are also used in treatment-experienced subjects infected with virus susceptible to the specific PI to be used. Advantages of PI-based regimens include excellent anti-viral activity, a relatively high barrier for development of drug resistance (i.e. requires multiple mutations) and sparing treatment with NNRTIs. However, PIs have the potential for multiple drug interactions and may be associated with metabolic complications such as dyslipidaemia, lipodystrophy and insulin resistance. In addition, they require coadministration of low-dose ritonavir (RTV) to boost exposure through inhibition of CYP3A-mediated metabolism, which adds to the potential for DDIs to occur. About the product Elvitegravir (EVG; JTK-303, GS-9137) blocks HIV-1 replication by inhibiting the strand transfer activity of the HIV-encoded enzyme integrase and as such is an Integrase Strand Transfer Inhibitor (InSTI). Integration of the viral genome is an essential and characteristic step in the life cycle of all retroviruses including HIV-1. The virally-encoded protein integrase is one of three HIV-1 enzymes required for viral replication and it is the only protein known to be required to catalyse each of the specific steps necessary for integration including: 1. assembly of a stable complex with the viral DNA, Medicinal product no longer authorised

3. strand transfer or joining of the viral and cellular DNA.

In HIV-1 infected cells, the specific interaction between integrase and the viral DNA end results in the formation of a stable pre-integration complex. The uncoupled strand transfer assay has been shown to be a good surrogate for integration assays using pre-integration complexes isolated from HIV-1

<div style=\"page-break-after: always\"></div>

infected cells. Raltegravir has been shown to inhibit integrase-mediated strand transfer using staged biochemical assays and purified recombinant HIV-1 integrase. Co-administration of EVG with RTV was shown to result in considerable increases in the EVG plasma levels and changed the plasma profile. Further development of EVG has focussed on its co-administration with the pharmaco-enhancer cobicistat (COBI), as part of QUAD STR and on co-administration with RTV-boosted PIs, in which case the RTV affects the PK profiles of both the EVG and the companion PI in parallel.

| Dose of elvitegravir   | Dose of co-administered ritonavir-boosted protease inhibitor   |
|------------------------|----------------------------------------------------------------|
| 85 mg once daily       | atazanavir/ritonavir 300/100 mg once daily                     |
| 150 mg once daily      | darunavir/ritonavir 600/100 mg twice daily                     |

This Phase 3 study is supported by a Phase 2 study plus a rollover follow-on study (GS-US-183-0105 and 0130) in which treatment-experienced subjects were initially randomised to EVG/RTV or a PI/RTV, each with OBR and then offered open label EVG/RTV as a follow-on. It is also supported by the efficacy data derived from COBI-boosted EVG administered with TDF/FTC as Stribild (STB, QUAD STB).

The EVG 85 mg and 150 mg single tablets are intended for once daily dosing in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir, in combination with one of the following ritonavir (RTV)-boosted protease inhibitors (PIs): darunavir (DRV), fosamprenavir (FPV), atazanavir (ATV) or lopinavir (LPV). The choice of dose of EVG depends on the co-administered protease inhibitor (see Table below). Table 1. Proposed recommended dosing regimens Due to the integrated nature of the EVG, COBI and QUAD STR development programmes this application includes studies that were conducted with: · EVG alone and in conjunction with PIs, · COBI-boosted elvitegravir (EVG/COBI), · QUAD STR (EVG/COBI, tenofovir, emtricitabine). This assessment report focuses on presenting and discussing the data most relevant to the use of EVG in conjunction with the RTV-boosted PIs specifically mentioned in the proposed SmPC. Data generated with each of EVG/COBI or with the QUAD STR are described only where considered essential to support this application. Type of Application and aspects of development The application has been made via the centralised procedure according to Regulation (EC) No 726/2004, within mandatory scope for a new active substance. The application contains a single pivotal Phase 3 efficacy study GS-US-183-0145. The current application contains a report on data to Week 96. This study was conducted in treatment-experienced HIV-infected subjects and directly compared EVG/RTV with RAL when each was given in conjunction with an optimised background regimen (OBR). EVG and RAL were used in regimens that included RTVboosted PI plus one other agent (NRTI or T20 or maraviroc). Medicinal product no longer authorised

The following sections focus on the data pertaining to manufacture of EVG 85 and 150 mg tablets and the non-clinical and clinical studies performed with EVG when not incorporated into STB. While the

<div style=\"page-break-after: always\"></div>

clinical safety and efficacy data relating to STB have some implications for this application and a few of the Phase 1 studies with STB provide data not available for EVG alone (with COBI as the pharmacoenhancer and not RTV), the clinical data specific to EVG/RTV are regarded to be the most critical.

## 2.2. Quality aspects

2.2.1. Introduction The finished product is presented as immediate release film-coated tablets containing 85 mg or 150 mg of elvitegravir as active substance. Vitekta has the following composition: Tablet core: Croscarmellose sodium Hydroxypropyl cellulose Lactose monohydrate Magnesium stearate Microcrystalline cellulose Sodium lauryl sulfate Film-coating: Indigo carmine (FD&amp;C blue #2) aluminium lake (E132) Polyethylene glycol (Macrogol) Polyvinyl alcohol Talc (E553B) Titanium dioxide (E171) Iron oxide yellow (E172) The product is available in high density polyethylene (HDPE) bottles with a child-resistant closure. 2.2.2. Active Substance The chemical name of elvitegravir is 6-(3-Chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and has the following structure: Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

The molecular formula is C23H23ClFNO5 and its relative molecular mass 447.9 g/mol.

Elvitegravir appears as a white to pale yellow crystalline non-hygroscopic powder, sparingly soluble in methanol and ethanol and practically insoluble in water and aqueous solutions at pH 2.0 to 8.3. Its pKa is 6.6 and the distribution coefficient LogD 4.5 (at pH 6.8).

Elvitegravir exhibits polymorphism and appears in three polymorphs. The most thermodynamically stable polymorphic form has been determined and the crystallisation process is designed to consistently deliver this form.  It contains a single asymmetric centre at C-11. The absolute configuration was established by single crystal X-ray crystallography and has been determined to be of 'S' configuration. Enantiomeric purity is controlled routinely by chiral HPLC. Manufacture Elvitegravir is manufactured in six well defined synthetic steps using commercially available starting materials. Three sites are involved in the manufacture of this active substance. The route of synthesis has been described in sufficient detail and adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented. Information about the formation, presence, origin and fate of impurities during manufacture has been satisfactorily discussed. Representative batch analysis data provided for all three proposed manufacturing sites produced with the proposed synthetic route show that the active substance can be manufactured reproducibly. Specification The active substance specification includes tests and limits for appearance (visual inspection), identity (UV, IR, HPLC), water content (KF), assay (HPLC, UPLC), impurities (HPLC), enantiomeric purity (chiral HPLC), residual solvents (GC), residue on ignition (Ph. Eur.), heavy metals (ICP-MS), particle size (laser light scattering) and polymorphic form (DSC-Ph. Eur.) Impurities, including genotoxic impurities, have been evaluated and qualified where necessary. The proposed limits are found to be acceptable from a safety point of view and therefore they are considered justified. A microbial limit test for the active substance is not required in accordance with ICH Q6A because the latter steps of the active substance manufacturing process conducted in aqueous organic solvent mixtures and are expected to limit microbial content. In addition confirmatory testing demonstrated that elvitegravir is moderately to completely inhibitory to microbial growth. The analytical methods have been well described and validated according to ICH Q2 (R1) and are suitable to control the quality of the active substance. Batch analysis data on 23 commercial scale batches of the active substance manufactured by all three proposed manufacturers have been provided. The results comply with the specifications and confirm consistency and uniformity of the manufacturing process regardless of the manufacturing site. Medicinal product no longer authorised

## Stability

Stability studies have been conducted for three commercial scale batches from the first manufacturer and one batch from the secondunder ICH long term (25 °C/60% RH) and accelerated conditions (40 °C/75% RH) in the proposed packaging. Results at long term conditions for three batches were

<div style=\"page-break-after: always\"></div>

submitted for up 36 months and for one batch for up to 12 months. Results under accelerated conditions were submitted for up to 9 months.

Long term and accelerated stability samples were tested for appearance, assay, impurity content, and water content. The enantiomeric purity and polymorphic form were tested annually during the long term studies. Enantiomeric purity was determined for one batch, at the beginning and end of the accelerated study and polymorphic form was tested at the end of the accelerated study. The analytical methods used are stability indicating.

During clinical studies, compatibility studies between the active substance and excipients were carried out between two formulations, dispersion and tablet. Modifications to the excipient matrix were made to the tablet and it was determined that the bioavailability from the conventional tablet was sufficient to achieve efficacy when co-administered with food and when ritonavir was used as a pharmacoenhancing agent.

All parameters remained within the specification limits under both conditions over the duration of study for all four batches. The data show no discernible trends for assay, total impurity content, individual specified impurities, degradation products or any other tested parameter. In addition, a photostability study of elvitegravir has been assessed as per the ICH Q1B Guideline on one batch from the second manufacturer. No significant difference was observed between the control sample and exposed sample in appearance, assay, impurity content, polymorphic form and enantiomeric purity. The data indicate that elvitegravir is not sensitive to light. Based on the presented stability data, the proposed re-test period and storage when the active substance is packed in the proposed packaging materials is acceptable. 2.2.3. Finished Medicinal Product Pharmaceutical Development Vitekta is an immediate-release film-coated tablet developed in two strengths, 85 mg and 150 mg. The principal factors considered during the pharmaceutical development were: · Developing an immediate-release tablet formulation · Optimizing the biopharmaceutical performance of elvitegravir · Developing a robust and scalable formulation and manufacturing process The film-coated immediate release tablet was chosen as the pharmaceutical form for its physical properties and suitable shelf-life. The small physical dimension of the tablets was pursued to enhance dosing compliance as Vitekta will be administered at the same time as a ritonavir-boosted protease inhibitor The oral bioavailability of elvitegravir is limited by solubility and dissolution; therefore, various formulation and process development strategies were implemented to improve the manufacturing process and the biopharmaceutical performance of elvitegravir. All the excipients used in this formulation are commonly used and meet the standards defined in the current Ph. Eur. monographs used in coating which is tested according to in-house standards based on compendial requirements. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

The proposed commercial formulation and manufacturing process were optimised to identify the critical process parameters, critical quality attributes and to define the manufacturing operating ranges. Design of experiments was used to establish proven acceptable ranges (PARs) and normal acceptable ranges (NORs) within the operating ranges, with a focus on the fluid-bed granulation of elvitegravir and the following variables were studied:  spray rate, inlet air temperature and quantity of water in the binder solution. PARs and NORs for the tablet compression, and aqueous film-coating processes have also been established.  Moving inside the PARs would be acceptable without regulatory post approval change assessment. However, it is reminded that in case of excursion of one process parameter out of its normal operating range, but within the proven acceptable range, the other process parameters should be maintained at their target/ normal operating value.

Process analytical technology was incorporated into the analysis using an at-line Focused Beam Reflectance Measurement (FBRM) to monitor the granule growth throughout the granulation process. The formulation and the manufacturing process used to prepare primary stability and clinical batches are identical to the proposed commercial formulation and manufacturing process, except for differences in the subclass of three types of equipment (fluid-bed processors, tumble blenders and pan coaters) required to accommodate a larger batch size. Bioequivalence study was performed showing bioequivalence between the clinical formulation and the proposed commercial formulation. The primary packaging is a high density polyethylene (HDPE) bottle with a child-resistant closure. The material complies with Ph. Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product. Adventitious agents Among excipients present in the finished product only lactose is of animal origin. It has been confirmed that lactose is produced from milk from healthy animals in the same conditions as those used to collect milk for human consumption and that lactose has been prepared without use of ruminant material other than calf rennet according to the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products. Manufacture of the product The manufacturing process of the film-coated tablets involves the following steps: blending, granulation, drying, blending, compression and film coating. The process is considered to be a standard manufacturing process. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls are adequate for the manufacturing of a film coated tablet. PARs and NORs for the granulation, tablet compression and film-coating steps have been established. The available development data, the proposed control strategy and batch analysis data from commercial scale batches fully support the proposed PARs. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Product specification

The finished product release specifications include appropriate tests for appearance (visual examination), identification (HPLC and UV), assay (UPLC), uniformity of dosage unit (Ph. Eur.), degradation products (UPLC), water content (Ph. Eur.) and dissolution (Ph. Eur.).

The non-compendial analytical procedures have been validated according to ICH Q2A guidelines.

Batch analysis results are submitted for 14 clinical batches used throughout development. The batch analysis data are within the set specification limits and show that the Vitekta tablets can be manufactured reproducibly. Stability of the product Stability data of one production scale batch of finished product stored under long term conditions during 48 months and of two production scale batches stored during 36 months  at long term conditions 25 ºC / 60% RH and under accelerated conditions at 40 ºC / 75% RH according to the ICH guidelines were provided. Additional stress studies at high temperature and humidity conditions were performed at 50 °C/ambient humidity and at 25 °C/80% RH for six weeks. Samples were also tested for microbial contamination and to assess the in-use stability. Vitekta tablets were also stored in open dishes at 25 °C/60% RH and 30 °C/75% RH for six weeks. In addition, two batches were exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products. The batches of Vitekta are representative to those proposed for marketing and were packed in the primary packaging proposed for marketing. The analytical procedures used are stability indicating and no degradation was observed in the tablets when stored at any condition. Based on available stability data, the shelf-life with no special storage conditions as stated in the SmPC are acceptable. 2.2.4. Discussion on chemical, pharmaceutical and biological aspects Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use. The applicant has applied QbD principles in the development of the finished product and its manufacturing process. However, no design space was claimed for the manufacturing process of the finished product. PARs have been defined for the following steps: dry granulation, tablet compression and film-coating. The available development data, the proposed control strategy and batch analysis data from commercial scale batches fully support the proposed PARs. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

<!-- image -->

EVG was weakly cytotoxic to human macrophages, primary T lymphocytes, primary PBMCs and primary moncocytes/macrophages (CC50 25.6 to &gt;500 µM). Specifically, in a [ 3 H]thymidine incorporation assay, following exposure to PBMCs for 7 days, EVG was cytotoxic, whereby the CC50 was 9.7 µM and 170 µM in the absence and presence of human serum. Selectivity indices (CC50/EC50) for EVG with and without human serum were high: 48,500 and 113,400, respectively. In addition, in HepG2 hepatoma cells, EVG had no significant effect on the content of mitochondrial DNA following exposure for 14 days.

2.3. Non-clinical aspects 2.3.1. Introduction The dossier included in vitro PD and PK studies. Results from a series of safety pharmacology studies have been provided. In vivo pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of EVG were assessed primarily in the CD-1 mouse, Sprague Dawley rat, and beagle dog. The toxicology data were provided from single-dose oral toxicity studies in rats and dogs; repeat-dose oral toxicity studies in mice (up to 13 weeks), rats (up to 26 weeks), dogs (up to 39 weeks), genotoxicity tests both in vitro and in vivo; and a developmental and reproductive toxicity program. Two-year oral carcinogenicity studies in mice and rats have also been provided. The pivotal toxicology and the majority of the safety pharmacology studies conducted by the applicant were reported to be GLP compliant. The safety studies that were not conducted to GLP are regarded as conducted to an appropriate scientific standard. 2.3.2. Pharmacology Primary pharmacodynamic studies EVG belongs to the new class of HIV-1 integrase strand transfer inhibitors, which inhibit the insertion of the viral genome into the DNA of the host cell. In vitro , EVG inhibited viral replication in laboratory strains and various clinical isolates of HIV-1 with mean EC50 values of 0.35 nM to 0.62 nM and also showed some activity against HIV-2. Primary pharmacodynamics are further discussed in the clinical part of the report. Secondary pharmacodynamic studies During a screen for binding and/or activity at a total of 32 secondary targets (receptors, enzymes and cell-based assay systems), no significant inhibition was observed at a concentration which is 333-fold higher than the clinical Cmax (free) at proposed doses. Elvitegravir did not inhibit the activity of human topoisomerase I and II enzymes up to 50 and 150 μM, respectively. As the observed effect on HIV-1 occurred primarily in the nanomolar range, these data suggest that elvitegravir does not inhibit HIV viral replication via effects on topoisomerases I and II. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Safety pharmacology programme

Single oral doses of EVG at up to 2000 mg/kg had no effects on the central nervous system in the rat. The corresponding Cmax at the no-effect level was 43.5 ug/mL, which is approximately 23-fold higher than that observed clinically.

<!-- image -->

The applicant suggested that EVG exposures were higher when EVG was co-administered with cobicistat. However, close examination of the toxicokinetic report and the actual data reveal that following co-administration with COBI (30 mg/kg/day), exposures to EVG were similar in females and only slightly increased in males (when compared to that observed when EVG was administered alone). The applicant clarified that co-administration with cobicistat increased exposures to EVG on Day 1, that the magnitude of pharmacokinetic enhancement is sex-dependent (males &gt; females) and that the enhancement effect is reduced upon repeated dosing, due to COBI's ability to induce EVG metabolism

In vitro electrophysiology studies indicated that EVG inhibited the hERG potassium current at the maximum concentration tested (10 µM) and the major metabolites, M1 and M4 inhibited the hERG potassium current with IC50 values of 81 µM and &gt;100 µM, respectively. The effective concentrations or the IC50 values were substantially above those observed clinically. EVG (at up to 3 µM) had no effect on action parameters in isolated papillary muscle and in vivo , had no effect on cardiovascular (or respiratory) parameters at up to 100 mg/kg; where the corresponding Cmax was ~4.2-fold higher than that observed clinically. Overall, these data do not suggest a potential for QT prolongation. Ex vivo , EVG at 30 µM caused a slight inhibition of single contractions induced by histamine, acetylcholine and barium chloride; however, in vivo , EVG had no effect on gastrointestinal transport at up to 2000 mg/kg. In addition, in the rat, similar doses of EVG had no effect on the urine volume or urinary excretion of electrolytes or the central nervous system. The corresponding Cmax at the no-effect level of 2000 mg/kg was 43.5 µg/mL, which is approximately 23-fold higher than that observed clinically. Pharmacodynamic drug interactions The potential for pharmacodynamic drug interactions is discussed in the Clinical section of the report. 2.3.3. Pharmacokinetics A series of method validation, absorption, distribution, metabolism, excretion and pharmacokinetic drug interaction studies have been conducted with EVG. Absorption In male animals, the absolute oral bioavailability for EVG was moderate and was estimated to be 30 to 35% in the rat and 26 to 33% in the dog. The systemic clearance in the rat was low relative to hepatic blood flow and intermediate in the dog, which indicates a low extent/degree of hepatic first pass metabolism following oral absorption. In general, following single or repeated oral administration in the mouse, rat and/or dog, systemic exposures increased in a dose-related manner and exposures to EVG did not appear to change significantly over time. Moreover, hepatic microsomal fractions from rats treated with EVG for up 3 months showed no notable change in activity, which confirms a lack of evidence for auto induction of CYP3A in these species. Nevertheless, there is evidence to suggest that EVG is a modest inducer of CYP3A in man ( in vitro and in vivo ). In the mouse and rat (but not in the dog), exposures were higher in females. This is consistent with the known gender difference in CYP3A expression (i.e. higher expression in males) in rodents. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

in rodents. There was a difference in the increase in EVG exposures observed in the mouse (up to 7-fold) when compared to the rat (1 to 3-fold) when co-administered with ritonavir/cobicistat. However, it is noted that although EVG is metabolised via a combination of oxidation and glucuronidation; in the mouse, EVG oxidation by CYP3A may play a greater role.

## Distribution

The binding to plasma proteins ( in vitro ) was considered to be high (fraction unbound in the rat, dog, monkey and human was 0.1, 0.8, 1.5 and ~0.7 %, respectively) and there is evidence to suggest that albumin is the major plasma binding protein. The distribution to red blood cells ( in vitro and in vivo ) was low. Following single oral administration of radiolabeled-EVG to the Sprague Dawley rat, drug related radioactivity was rapidly distributed within 0.25 hours post-dose to the highly perfused organs (liver, adrenal gland, kidney, heart, lung and pancreas), with relative exclusion from the eye and brain. The tissue:plasma concentration ratios were generally &lt;1, with the exception of the liver and gastrointestinal tract, which correlates with the route of elimination and the principal findings from the toxicity studies. The tissue concentrations of radioactivity largely declined in parallel with those of the plasma, reaching undetectable or trace levels by 96 hours post-dose. Pre-treatment of the CYP3A inhibitor, ritonavir, increased the blood and tissue concentrations of drug related material, but had no effect on the overall pattern of distribution. The placental transfer of EVG and its distribution into foetal tissues have not been evaluated. Data from a pre/post-natal study in the rat indicate that low levels of EVG distribute into the milk of lactating rats, with a milk:plasma ratio of 0.1. Given the potential for serious adverse reactions in nursing infants and the potential for HIV transmission, Section 4.6 of the SmPC indicates that women should not to breastfeed during treatment with EVG, which is supported. Metabolism The in vitro and in vivo studies indicate that EVG is extensively metabolized by oxidation, glucuronidation and combinations of the two. The most abundant metabolites the p hydroxylated metabolite (M1, GS-9202); the acyl glucuronide (M4, GS-9200) and M5 (rabbit) were generally common between mouse, rat, rabbit, dog, and human. Excretion Following administration of radiolabeled-EVG to the rat and dog, parent compound accounted for the majority of radioactivity in plasma and the predominant metabolite was M1 with lesser amounts of M4 and M7 (glucuronide of M1). Small amounts of the glucuronides, M4 and M7, were detected in urine but these metabolites were more abundant in bile. However, parent compound and the oxidative metabolites, M1 and M2, were the most abundant in the faeces, with no detectable glucuronide, which suggests that biliary glucuronide metabolites are cleaved within the intestine before being excreted via the faeces. Pharmacokinetic interactions Medicinal product no longer authorised

<!-- image -->

The oxidative metabolism of EVG is catalysed primarily by CYP3A4 (with minor contributions from CYP3A5 and CYP1A1), which makes EVG a suitable partner for a pharmacokinetic enhancer, such as ritonavir (RTV) or with cobicistat (when administered as QUAD STR), which inhibit CYP3A enzymes. The applicant has investigated the effects of a number of medicinal products on EVG oxidation. The CYP3A4 inhibitor, ketoconazole was the most potent inhibitor (IC50 = 0.099 µM), followed by the protease inhibitors ritonavir, indinavir, nelfinavir, amprenavir, lopinavir and saquinavir (IC50 values

<div style=\"page-break-after: always\"></div>

ranged from 0.079 µM to 4.5 µM). The conjugative metabolism (glucuronidation) of EVG is catalysed primarily by UGT1A1 and to a lesser extent UGT1A3. Both atazanavir and ketoconazole inhibited EVG glucuronidation with IC50 values of 0.4 µM and 9.6 µM, respectively. The SmPC captures some of these potential pharmacokinetic interactions and clarifies whether they are of clinical relevance or whether dose adjustments are necessary. Given the observed inhibitory effects of indinavir (IC50 0.51 µM), nelfinavir (IC50 1.1 µM) and saquinavir (IC50 4.5 µM) a pharmacokinetic interaction would be expected; however, the relevant interaction studies have not been performed in man. Section 4.5 of the SmPC has been amended and does not recommend the co-administration of saquinavir, nelfinavir or indinavir with EVG.

## 2.3.4. Toxicology

The potential to inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, UGT1A1, UGT1A3 and UGT2B7 was investigated in human hepatic microsomes. The data suggest that EVG should not cause any clinically significant pharmacokinetic drug interactions via inhibition of any of these enzymes at therapeutic concentrations, since the unbound mean Cmax of EVG (0.03 µM) is substantially below the observed IC50 values (≥14 µM). Studies were conducted to evaluate the potential of EVG to cause pharmacokinetic interactions via enzyme induction. In vivo (humans), repeated co-administration of EVG/COBI had no effect on the pharmacokinetics or pharmacodynamics of the CYP2B6 substrate, methadone. In vitro, EVG did not activate human aryl hydrocarbon receptor (AhR; &lt;2-fold increase in CYP1A2 activity) in human hepatocytes, but showed some potential to induce enzymes such as CYP3A (up to 10.6-fold) and to a lesser extent CYP2C9 (up to 2.72-fold), which are controlled by pregnane X receptor (PXR), at concentrations within range of those observed clinically. In clinical practice, the effect of the coadministered pharmacokinetic enhancer would appear to offset induction of CYP3A. There are clinical data to suggest that exposures to atazanavir are reduced upon co-administration with EVG and RTV and it is likely that this is due to the induction of CYP3A4 (by EVG) upon repeated administration. However, the magnitude of the observed effect is small; hence, the overall net effect will depend upon the induction liability of the pharmacokinetic enhancer itself and the other co-administered products. Elvitegravir was earlier identified as a P-gp/MDR1 substrate; however, there was no evidence of saturation of intestinal efflux transport in vivo. EVG also shows weak inhibition of this efflux transporter (IC50 &gt;30 µM); however, systemic concentrations would be insufficient to inhibit transporter activity. High concentrations of EVG present relatively briefly in the intestinal lumen during drug absorption can inhibit intestinal efflux transporters, such as P-gp. However, the effect on these transporters will most likely be limited by the poor solubility of EVG and hence, the potential for a clinically relevant interaction at the level of the small intestine is unlikely. Elvitegravir is a weak inhibitor of OATP1B1 and a more potent inhibitor of OATP1B3 (IC50 values of &gt;2 μM and 0.44 μM, respectively). The observed inhibition of OATP transporters is consistent with results of a clinical drug interaction study in which, after dosing with 150 mg COBI and 150 mg EVG (which inhibit both transporters), there was a modest increase in exposure of the OATP substrate, rosuvastatin and these data feature within Section 4.5 of the SmPC. The Applicant has also provided data to suggest that the potential for a clinically relevant interaction at the level of the BCRP, OAT1, OAT3, OCT2 or MATE-1 transporter is low. Medicinal product no longer authorised

## Single dose toxicity

Following single oral administration in the rat and dog, no mortality or changes in body weight/food consumption were observed at up to 2000 mg/kg and 1000 mg/kg respectively.  Emesis was observed

<div style=\"page-break-after: always\"></div>

in the dog and this was considered to be a direct effect on the digestive tract as no emesis was observed at comparable exposures following intravenous administration.

## Repeat dose toxicity

The repeated-dose studies demonstrated that EVG is well tolerated for up to 6 months in the rat and 9 months in the dog at doses producing systemic exposure levels that are 25.2 to 45.7-fold higher (rat) and 3- to 3.6-fold higher (dog) than those observed clinically. None of the observed findings as reported during the single- or repeated-dose non-clinical studies with EVG were considered to be adverse. Treatment-related effects included changes in caecum weights, dilation of the caecum, and the presence of lipid vacuoles in the lamina propria of the upper small intestines of rats and dogs. In these species, changes in the caecum were not accompanied by any histological changes or gastrointestinal (GI) adverse events. In the rat, increased caecal weight and/or dilatation of the caecum was observed at ≥300 mg/kg/day where the systemic exposures (AUC) were at least 12.6-fold higher than that observed clinically. In the dog, dilation of the caecum was observed at exposures that were 3.6-fold higher than that observed clinically. The incidence and severity of lipid vacuoles in the upper small intestines did not appear to increase with repeated dosing of EVG. The applicant maintains that the severity and the incidence of the vacuolization did not increase with dose, but it is noted that results from the 13-week rat study for example suggest otherwise. However, there was no evidence of toxicity or other histopathological correlate associated with these vacuoles. The vacuolization is considered related to the high local EVG concentrations to which the GI epithelium was exposed. These effects were not considered adverse and in most cases, these minor effects were slowly reversible after a recovery period. It is noted that this finding occurred at exposures similar and in excess to those observed clinically. Combination studies where EVG was co-administered with RTV or COBI did not result in any additive or unexpected toxicity. Based upon the clinical data provided, the potential for additive toxicities is low when EVG is used in combination with darunavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir or lopinavir/ritonavir. Genotoxicity In vitro , EVG caused a slight increase in chromosomal aberrations with a 6-hour treatment in the absence of S9 in Chinese hamster lung (CHL) cells at 55 to 75 µg/mL. However, EVG did not cause any chromosomal aberrations in the presence of S9 or following incubation for 24 hours without S9. Moreover, in a bacterial reverse mutation test and in a rat micronucleus assay, EVG was not considered to be mutagenic. The exposures observed in the rat micronucleus assay were estimated to be similar to the effective concentrations for the chromosomal aberration assay and at least 3-fold higher than that observed clinically. Carcinogenicity Medicinal product no longer authorised

In the mouse, following repeated oral administration for 104 weeks, EVG was not carcinogenic at up to 2000 mg/kg/day. On the basis of AUC0-t the corresponding exposures were 1.7- to 4.7-fold higher than those observed clinically. In combination studies where EVG is co-administered with RTV and the exposures to EVG were higher than those observed with EVG alone, the combination of EVG and RTV was not carcinogenic. In the rat, following repeated oral administration for up to 88 weeks in males

<div style=\"page-break-after: always\"></div>

and 90 weeks in females, EVG was not carcinogenic at up to 2000 mg/kg/day. On the basis of AUC, the corresponding exposures were 10.7- to 34.6-fold higher than that observed clinically.

## Reproduction Toxicity

No adverse effects on male or female fertility and reproductive performance were observed at up to 2000 mg/kg/day, where the corresponding exposures (AUC) are approximately 21-38-fold higher than that observed clinically. In the rat, there were no treatment-related effects on embryofoetal development, reproduction or viability and growth of the offspring at systemic exposures that were ~22 to 29-fold higher than that proposed clinically. In addition, when EVG was administered in combination with RTV, no effects on embryofoetal development were observed; the exposures at the no-effect level were also higher than those observed clinically. During a preliminary embryofoetal development study in the rabbit, increased resorptions were noted at ≥300mg/kg/day and the number of live foetuses was reduced at 600 mg/kg/day. In the definitive study, the no-effect level for embryofoetal development was 450 mg/kg/day; the corresponding exposures were below that observed clinically and this is reflected in the SmPC. Other toxicity studies Elvitegravir was not phototoxic or immunotoxic and did not demonstrate the potential to cause hypersensitivity or irritancy to the skin/eye. 2.3.5. Ecotoxicity/environmental risk assessment The applicant has conducted environmental risk assessment and the data provided are summarised in the table below. Table 2. Summary of studies submitted in support of the Environmental risk Assessment for Elvitegravir Substance (INN/Invented Name): EVG PBT assessment Bioaccumulation potentiallog K ow BCF Persistence Toxicity PBT-statement Phase I Calculation PEC surfacewater , default or refined (e.g. prevalence, literature) Phase II Physical-chemical properties and fate Study type Adsorption-Desorption Ready Biodegradability Test Medicinal product no longer authorised

| Substance (INN/Invented Name): EVG                                  | Substance (INN/Invented Name): EVG                | Substance (INN/Invented Name): EVG                                                                                           | Substance (INN/Invented Name): EVG                                                                                           | Substance (INN/Invented Name): EVG                                                                      |
|---------------------------------------------------------------------|---------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| PBT assessment                                                      |                                                   | Result                                                                                                                       | Result                                                                                                                       | Conclusion                                                                                              |
| Bioaccumulation potential- log K ow BCF                             | OECD117 OECD 305                                  | 3.39-4.33                                                                                                                    | 3.39-4.33                                                                                                                    | < 4.5; Not Bioaccumulative                                                                              |
| Persistence                                                         | OECD 308                                          | Not readily biodegradable                                                                                                    | Not readily biodegradable                                                                                                    | Persistent                                                                                              |
| Toxicity                                                            |                                                   | Generally NOEC values >0.01 mg/L                                                                                             | Generally NOEC values >0.01 mg/L                                                                                             | Not overtly toxic                                                                                       |
| PBT-statement                                                       | The compound is not considered as PBT             | The compound is not considered as PBT                                                                                        | The compound is not considered as PBT                                                                                        | The compound is not considered as PBT                                                                   |
| Phase I                                                             |                                                   |                                                                                                                              |                                                                                                                              |                                                                                                         |
| Calculation                                                         | Value                                             | Value                                                                                                                        | Unit                                                                                                                         | Conclusion                                                                                              |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | For Fpen (1%) 0.75 For refined Fpen (0.28%): 0.21 | For Fpen (1%) 0.75 For refined Fpen (0.28%): 0.21                                                                            | µg/L                                                                                                                         | PEC sw > 0.01 µg/l. Progress to Phase II                                                                |
| Phase II Physical-chemical properties and fate                      | Phase II Physical-chemical properties and fate    | Phase II Physical-chemical properties and fate                                                                               | Phase II Physical-chemical properties and fate                                                                               | Phase II Physical-chemical properties and fate                                                          |
| Study type                                                          | Test protocol                                     | Results                                                                                                                      | Results                                                                                                                      | Remarks                                                                                                 |
| Adsorption-Desorption Medicinal                                     | OECD 106                                          | K oc soil: 25500-104000 L/Kg Kd sludge: 10400 L/Kg                                                                           | K oc soil: 25500-104000 L/Kg Kd sludge: 10400 L/Kg                                                                           | K oc >10000 L/Kg Progress to Phase IIb                                                                  |
| Ready Biodegradability Test                                         | OECD 301                                          | 28 days: 0 - 2.5% mineralisation                                                                                             | 28 days: 0 - 2.5% mineralisation                                                                                             | EVG is not biodegradable.                                                                               |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems    | OECD 308                                          | System DT 50 6-53 days Water DT 50 2-3 days Sediment DT 50 (degradation) >100 days >10% associated with sediment from Day 7. | System DT 50 6-53 days Water DT 50 2-3 days Sediment DT 50 (degradation) >100 days >10% associated with sediment from Day 7. | > 10% radioactivity associated with sediment at Day 14 or beyond. Progress to Sediment-dwelling studies |

<div style=\"page-break-after: always\"></div>

| Phase IIa Effect studies                                  | Phase IIa Effect studies   | Phase IIa Effect studies   | Phase IIa Effect studies   | Phase IIa Effect studies   | Phase IIa Effect studies   |
|-----------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| Study type                                                | Test protocol              | Endpoint                   | Value                      | Unit                       | Remarks                    |
| Algae Growth Inhibition Pseudokirchneriella subcapitata ) | OECD 201                   | NOEC                       | 162                        | µg/L                       |                            |
| Daphnia sp . Reproduction Test                            | OECD 211                   | NOEC                       | 390                        | µg/L                       |                            |
| Fish, Early Life Stage Toxicity                           | OECD 210                   | NOEC                       | 206                        | µg/L                       |                            |
| Activated Sludge                                          | OECD 209                   | NOEC                       | >500                       | mg/L                       |                            |
| Phase IIb Studies                                         | Phase IIb Studies          | Phase IIb Studies          | Phase IIb Studies          | Phase IIb Studies          | Phase IIb Studies          |
| Bioaccumulation                                           | OECD 305                   | BCF                        | <10                        |                            | Minimal bioconcentration   |

None of the observed findings as reported during the single- or repeated-dose non-clinical studies with EVG were considered to be adverse. After single dose emesis was observed in the dog, considered a result of direct effect on the digestive tract. Treatment-related effects after repeat doses included changes in caecum weights, dilation of the caecum, and the presence of lipid vacuoles in the lamina propria of the upper small intestines of rats and dogs. Similar changes in the caecum have been reported with antibacterial quinolones which affect the GI microflora. Elvitegravir has a quinolone moiety and was confirmed to have antibacterial activity in the reverse mutation assay. Although the

Activated Sludge Phase IIb Studies Bioaccumulation In the context of the obligation of the MAH to take due account of technical and scientific progress, the CHMP recommends the following points for further investigation: · As sediment shifting of the drug substance was demonstrated (sediment shifting &gt; 10%), it is recommended to investigate the effects on sediment organisms (to what the Applicant has agreed). A statement to declare its persistence in the environment is included in Section 5.3 of the SmPC. · The results of the adsorption/desorption study indicate an affinity of the drug substance to bind to sewage sludge; hence, it is recommended to conduct an environmental risk assessment for the terrestrial compartment (to what the applicant has agreed). The additional studies along with a revised environmental risk assessment are expected to be provided by Q2 2015. 2.3.6. Discussion on non-clinical aspects EVG inhibited viral replication in laboratory strains and various clinical isolates of HIV-1 and also showed some activity against HIV-2. The data from secondary pharmacology studies suggest that the potentials for interaction at the range of secondary targets evaluated and to cause cytotoxicity and mitochondrial toxicity are low. The observed margins between the no-effect concentrations/effective concentrations in safety pharmacology studies and those observed clinically are considered acceptable and the pharmacology package is considered adequate from a non-clinical point of view. Data on absorption, distribution, metabolism, excretion and pharmacokinetic drug interactions of EVG have been provided. Given that EVG is to be used in combination with darunavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir or lopinavir/ritonavir (and possibly others), the potential for additive effects at the level of the enzymes and transporter systems has been investigated. It is acknowledged that the interaction at the level of the CYP and UGT enzymes appear to be primarily responsible for the observed interactions, although interaction at the level of the transporter may also play a contributory role. The interactions which result in clinically significant interactions/ those which warrant dose adjustment are reflected within the SmPC. Overall, the package of pharmacokinetic studies are considered adequate to support the marketing authorisation of EVG. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

activity was much weaker than that of the antibacterial quinolones, the changes in the caecum were considered to be due to the anti-bacterial activity of high local concentrations of EVG in the GI tract.

Interestingly, in man, there was an increase in the incidence of diarrhoea when EVG was coadministered with a protease inhibitor, while there was no excess of diarrhoea in the QUAD STR (EVG/COBI/FTC/TDF) groups vs . comparators during the Phase 3 studies. The CHMP recommends conducting additional studies to determine the EVG MIC for common bacteria in the human gut and assess MICs in light of estimated intra-colonic concentrations, to which the applicant has agreed and intends to provide the results by March 2014. Performing these additional studies alone is not expected to confirm what effects long-term oral dosing with EVG may have on gut flora (and whether EVG could select for fluoroquinolone-resistant organisms), however, once the results of these are provided then the potential need to recommend conducting additional studies can be revisited. In absence of evidence of toxicity and clinical findings, this is deemed acceptable.

<!-- image -->

There was no evidence of toxicity or other histopathological correlate associated with lipid vacuoles in the upper small intestines, and in the 2-year rat carcinogenicity study there were no notable findings in the upper small intestine, further suggesting that the presence of the vacuoles was not of toxicological significance. During a preliminary embryofoetal development study in the rabbit, increased resorptions were noted at ≥300mg/kg/day and the number of live foetuses was reduced at 600 mg/kg/day, and in the definitive study, the no-effect level for embryofoetal development was 450 mg/kg/day. There were no other adverse findings in reproduction toxicity studies. Other toxicity studies indicated that the potential to cause genotoxicity in man is low, that EVG does not pose a carcinogenic risk to humans and that EVG was not phototoxic or immunotoxic and did not demonstrate the potential to cause hypersensitivity or irritancy to the skin/eye. The applicant has conducted environmental risk assessment. The CHMP made recommendations for further investigations. 2.3.7. Conclusion on the non-clinical aspects Overall, the nonclinical aspects have been sufficiently studied, information has been reflected appropriately in the proposed Product Information and there are no objections to the approval of this application from the nonclinical point of view. The CHMP recommends addressing minor outstanding issues regarding impact of EVG on gut flora and regarding the environmental risk assessment. 2.4. Clinical aspects 2.4.1. Introduction The Clinical trials were performed in accordance with GCP as claimed by the applicant. Medicinal product no longer authorised

The  applicant  has  provided  a  statement  to  the  effect  that  clinical  trials  conducted  outside  the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

## Overview of clinical studies

Table 3. Overview of phase 1 studies

| PK and DDI          | PK and DDI                                                                                                                                     |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| EVG                 | XAX1-1 safety and PK of EVG after single oral administration                                                                                   |
|                     | XAX1-2 safety and PK of EVG after single oral administration of solid dispersion formulation of EVG                                            |
|                     | GS-US-183-0152 steady-state PK; confirmed dose of EVG/r in HIV-1 infected ARV-experienced adolescents authorised                               |
|                     | GS-US-183-0126 mass-balance study of EVG/r                                                                                                     |
|                     | GS-US-183-0103 evaluated PK of EVG, FTC or TFV on co-administration of EVG/r and TVD                                                           |
|                     | GS-US-183-0104 multiple-dose DDI EVG/r and zidovudine (ZDV)                                                                                    |
|                     | GS-US-183-0111 multiple-dose DDI EVG/r and didanosine (ddI) or d4T                                                                             |
|                     | GS-US-183-0112 multiple-dose DDI EVG/r and etravirine                                                                                          |
|                     | GS-US-183-0115 multiple-dose DDI EVG/r and abacavir (ABC) sulfate                                                                              |
|                     | GS-US-183-0118 multiple-dose DDI EVG/r and maraviroc                                                                                           |
|                     | GS-US-183-0146 effect of a second, potent CYP3A (and UGT1A1) inhibitor (ketoconazole) on boosted EVG longer                                    |
|                     | GS-US-183-0125 multiple-dose DDI EVG and rifabutin                                                                                             |
|                     | GS-US-183-0119 effect of acid-reducing agents on EVG                                                                                           |
|                     | GS-US-183-0102 EVG 100 mg after single and multiple oral dosing +/- RTV 100 mg no                                                              |
|                     | GS-US-183-0113 dose response of RTV on CYP3A activity and EVG PK                                                                               |
|                     | GS-US-183-0109 multiple dose DDI boosted EVG and lopinavir (LPV/r)                                                                             |
|                     | GS-US-183-0116 multiple-dose DDI EVG/r and LPV/r                                                                                               |
|                     | GS-US-183-0110 multiple-dose DDI EVG/r and tipranavir (TPV/r)                                                                                  |
|                     | GS-US-183-0123 multiple-dose DDI EVG/r and fosamprenavir (FPV)/r                                                                               |
|                     | GS-US-183-0120 multiple-dose DDI EVG/r and darunavir (DRV)/r                                                                                   |
|                     | GS-US-183-0147 multiple-dose DDI EVG and ATV                                                                                                   |
| EVG and COBI        | GS-US-183-0106 and -0108 effect of ATV/r on boosted EVG GS-US-201-0104 evaluated the PK of EVG and COBI when co- administered with DRV product |
|                     | GS-US-216-0123 evaluated unboosted ATV, rosuvastatin and dose-reduced rifabutin on EVG and COBI.                                               |
| Medicinal           | GS-US-216-0120 and -0122 evaluated the effect of acid-reducing agents on EVG and EVG/COBI.                                                     |
| QUAD STR            | GS-US-236-0106 evaluated the drug-drug interaction of the QUAD STR and hormonal contraceptives.                                                |
| Special Populations | Special Populations                                                                                                                            |
| EVG and COBI        | GS-US-183-0133 evaluated the PK of EVG/COBI in subjects with moderate hepatic impairment.                                                      |
|                     | GS-US-216-0124 evaluated the PK of EVG/COBI in subjects with varying degrees of renal impairment.                                              |

<div style=\"page-break-after: always\"></div>

| Food Effect (see also XAX-1 above)   | Food Effect (see also XAX-1 above)                                                              |
|--------------------------------------|-------------------------------------------------------------------------------------------------|
| QUAD STR                             | GS-US-236-0105 effect of food on EVG, COBI, FTC, and TFV when administered as the QUAD STR.     |
| Biopharmaceutics                     | Biopharmaceutics                                                                                |
| EVG                                  | GS-US-183-0140 multiple-dose relative bioavailability of a test formulation of EVG/r.           |
| EVG                                  | GS-US-183-0121 relative bioavailability of various formulations of EVG/r.                       |
| Secondary PD                         | Secondary PD                                                                                    |
| EVG                                  | GS-US-183-0128 effect of EVG/RTV at therapeutic and supratherapeutic doses on the QTcF interval |

<!-- image -->

Secondary PD EVG The studies shown in bold involved co-administration of EVG with RTV and with the PIs proposed for coadministration In addition, results of A Phase 1 Study Evaluating the Drug Interaction Potential Between Once-Daily Cobicistat-Boosted Elvitegravir and Methadone or Buprenorphine/Naloxone (GS-US-216-0125) were provided. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 4. Tabular Summary of Phase 2 and 3 Clinical Studies

| Study Number    | Study Objective(s)                                                                                                                                                                                                                                                                                              | Design                                                                                                                | Study and Control Drug Regimens                                                                                                                                                                                          | Duration of Treatment                                                                                                                                                                 | Number of Subjects by Treatment                                                                                                                                                            | Study Population/ Entry Criteria                                                                                                                                                                                                                                                                                                                                                 |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| GS-US- 183-0145 | Assess the noninferiority of EVG versus RAL, each administered with a BR containing a fully active PI/r and a second agent in HIV-1 infected, antiretroviral treatment- experienced adults. Additionally, the efficacy, safety, and tolerability of the 2 treatment regimens, EVG and RAL, are being evaluated. | Phase 3, double-blind, double- dummy, multicentre, randomized, active- controlled study                               | Treatment Group (TG) 1: EVG 150 mg once daily (EVG 85 mg once daily for subjects taking ATV/r or LPV/r as part of their BR) + RAL placebo twice daily + BR TG 2: RAL 400 mg twice daily + EVG placebo once daily + BR no | Blinded Phase: 96 weeks until unblinding Open-Label Extension Phase: 96 weeks, 96 weeks + 30 days or until EVG development is terminated (UK), or until commercially available longer | Randomized: 724 TG 1: 361 TG 2: 363 Received Study Drug: 712 TG 1: 354 TG 2: 358 Continuing Study Drug at Week 96: TG 1: 208 TG 2: 208 Continuing in Study at Week 96: TG 1: 216 TG 2: 223 | Antiretroviral treatment- experienced, HIV-1 infected adults ≥ 18 years old and life expectancy ≥ 1 year with plasma HIV-1 RNA levels ≥ 1000 copies/mL who had documented resistance from 2 or more different classes of antiretroviral agents or at least 6 months experience before screening with at least 1 antiretroviral agent and were fully sensitive to the selected PI |
| GS-US- 183-0105 | Assess noninferiority of EVG/r relative to CPI/r, both in combination with a background ARV regimen                                                                                                                                                                                                             | Phase 2, randomized, partially blinded (EVG dose), multicenter, multiple-dose, active- controlled, dose-finding study | CPI/r (A) EVG/r 20/100 mg QD (B) EVG/r 50/100 mg QD (C) EVG/r 125/100 mg QD (D) CPI/r switch to EVG (blinded dose of 20, 50, or 125 mg) or EVG 125 mg open label (E) product                                             | 48 weeks                                                                                                                                                                              | Randomized: 297 Treated : 278 Completed: 211 Safety Analysis Set: A: 63 B: 71 C: 71 D: 73 E: 30                                                                                            | HIV-1 infected, treatment- experienced subjects on a stable ARV regimen                                                                                                                                                                                                                                                                                                          |
| GS-US-          | Investigate safety,                                                                                                                                                                                                                                                                                             | Phase 1/2,                                                                                                            | EVG 200 mg BID PO                                                                                                                                                                                                        | 10 days per cohort                                                                                                                                                                    | Randomized: 48                                                                                                                                                                             | HIV-1 infected, ARV                                                                                                                                                                                                                                                                                                                                                              |

<!-- image -->

Page 25/97 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study Number    | Study Objective(s)                                                                                                                      | Design                                                                                                                             | Study and Control Drug Regimens                                                                                                                                | Duration of Treatment                                                   | Number of Subjects by Treatment                                                   | Study Population/ Entry Criteria                                                                     |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| 183-0101        | tolerability, antiviral activity, and PK/PD of EVG                                                                                      | randomized, double-blind, multicentre, multiple-dose, placebo controlled, proof-of concept, sequential cohort, dose- ranging study | (A) EVG 400 mg BID PO (B) EVG 800 mg QD PO (C) EVG 800 mg BID PO (D) EVG 50 mg + RTV 100 mg QD PO (E) Placebo, BID or QD PO (F) Placebo + RTV 100 mg QD PO (G) | longer                                                                  | Treated: 40 Completed: 40 Safety Analysis Set: A: 6 B: 6 C: 6 D: 6 E: 6 F: 8 G: 2 | Treatment naïve or treatment experienced adult subjects who were not currently receiving ARV therapy |
| GS-US- 183-0130 | Observe the long-term safety of EVG/r in combination with other ARV agents in subjects who have completed a prior EVG/r treatment study | Phase 2, rollover, open-label, multicentre, multiple-dose, single-arm extension study                                              | EVG/r 85/100 mg QD PO EVG/r 150/100 mg QD PO EVG/r 300/100 mg QD PO (substudy; subjects from EVG 150 mg group) no                                              | Until EVG becomes commercially available or study terminated by sponsor | Enrolled: 192 Treated : 192 Ongoing: 113 Substudy: 40 enrolled and treated        | HIV-1 infected adult and adolescent subjects                                                         |

Page 26/97 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Results of several other studies from the development programmes of QUAD STB and COBI have been provided in the application.

## 2.4.2. Pharmacokinetics

<!-- image -->

The pharmacokinetic properties of EVG were assessed in Phase 1 studies with EVG alone, on coadministration with RTV or COBI and as a component of QUAD STB (i.e. with COBI plus TDF/FTC). Phase 2 and 3 studies of efficacy included intensive sampling sub-studies and sparse sampling. A population PK analysis was conducted. PK data were also collected in some PD studies. Phase 1 studies mostly used conventional tablets of various sizes (early formulations). In Phase 3 (GSUS-183-0145) the commercial formulation (F2) tablets containing 85 mg or 150 mg EVG were used. The 150 mg tablet was shown to be bioequivalent to the 125 mg early formulation reference tablet. The original EVG bioanalytical method involved solid phase extraction from human plasma followed by LC-MS/MS with positive ionisation. For the fully validated bioanalytical method calibration curves for EVG and metabolites M4 and M1 the range was from 20-10,000 ng/mL. A similar assay method applied to urine samples gave calibration curves that ranged from 32.5 (LLQ) to 1300 ng/mL. Absorption The absolute bioavailability of EVG, with or without RTV, has not been determined. In an early study (XAX1-1) single unboosted doses of EVG (100-800 mg; early formulation) were administered in the fasting state. There was rapid conversion of some of the EVG dose to M4 but AUCinf was always &lt; 10% of EVG exposure. The EVG dose proportionality constants (β) were 0.723 (95% CI, 0.544 to 0.902) for Cmax and 0.789 (95% CI, 0.582 to 0.995) for AUCinf. Figure 1. EVG concentrations in study XAX1-1 In GS-US-183-0102 EVG 100 mg (early formulation) and EVG/RTV (100/100 mg) were given twice daily for 10 days in the fed state. Medicinal product no longer authorised

Without RTV the EVG steady-state (D10) mean AUCtau was ~ 20% lower vs. a single dose on D1 (AUCinf), indicating auto-induction of its metabolism. Non-linear RTV PK occurred on dosing to steady state, most likely due to its time-dependent, mechanism-based inhibition of CYP3A.

<div style=\"page-break-after: always\"></div>

Table 1. PK parameters in study GS-US-183-0102

|                     | EVG Alone (N = 12)   | EVG Alone (N = 12)     | EVG + RTV (N = 12)   | EVG + RTV (N = 12)     |
|---------------------|----------------------|------------------------|----------------------|------------------------|
| Plasma PK Parameter | Day 1 (Single Dose)  | Day 10 (Multiple Dose) | Day 11 (Single Dose) | Day 20 (Multiple Dose) |

<!-- image -->

After the first dose of EVG/RTV (D11) there were higher EVG plasma concentrations that remained at plateau through 12 h, resulting in an 8.58-fold increase in exposure vs. D10 of EVG alone. This large increase in EVG exposure was attributed to improved oral bioavailability resulting from decreased first pass metabolism and reduced systemic clearance. Administration of EVG/RTV to steady state (D20) resulted in an 11-fold increase in Cmax and a greater than predicted (20-fold) increase in AUCtau. There was an increase in T½ (9.5 h EVG/r vs. 3.5 h EVG alone) and some drug accumulation due to net inhibition of EVG metabolism by RTV. These observations underlined the importance of conducting the DDI studies with EVG/RTV at steady-state. GS-US-183-0113 evaluated co-administration of RTV (oral solution, mixed with 25 mL Ensure) doses from 20-200 mg with 125 mg EVG, each given once daily for 10 days in the fed state. Midazolam (MDZ) 1 mg intravenous was given in the afternoon on Days 1, 11 and 21. The increases in EVG Cmax, AUCtau and Ctau observed with RTV doses from 20 mg to 200 mg were less than RTV-dose proportional. The apparent clearance of EVG decreased and T½ increased with RTV dose with a plateau around 100 mg suggesting near maximal inhibition of CYP3A between 50-100 mg RTV. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 2. Statistical Comparisons of Pharmacokinetic Parameters for EVG with Increasing Doses of Ritonavir (PK Analysis Set)

| TestVersusReference Comparison of GS-9137Plasma PK Parametersa   |
|------------------------------------------------------------------|

| Ctau (ng/mL)   | 379.4 (40.7)   | 397.2 (38.0)   | 93.73 (81.40, 107.93)   |
|----------------|----------------|----------------|-------------------------|
| Cmax (ng/mL)   | 2253.0 (18.4)  | 2048.3 (24.1)  | 111.26 (103.30, 119.85) |

Plasma levels of the EVG metabolite M1 (GS-9202; chlorofluorophenyl group hydroxide) were BLLQ at most time points. Plasma exposure to M4 (GS-9200; acyl glucuronide conjugate) increased with RTV dose in a similar fashion to EVG. M4 concentrations were &lt; 10% of parent drug with a fairly constant ratio maintained, suggesting that RTV did not affect the formation or elimination of M4. Mean MDZ plasma concentrations increased with increasing doses of RTV but not in a doseproportional fashion. The dose-response curve ED50 for hepatic CYP3A4 (as assessed using intravenous MDZ) was 12.2 mg. Plasma levels of 1′-OH MDZ were BLLQ at most time points. It was concluded that RTV doses of 50 mg and 100 mg provided near maximal CYP3A4 inhibition, supporting further evaluation of EVG/r 125/100 mg once daily. The mean clearance (CL/F) of EVG when given with RTV 100 mg was 0.119 L/min, which is ~ 7.9 % of hepatic blood flow, supporting the hypothesis that RTV-boosted EVG is a very low clearance compound. In GS-US-216-0116 EVG/COBI 150/150 mg (F2) and EVG/r 150/100 mg were each given for 10 days. EVG concentrations demonstrated bioequivalence between EVG/COBI and EVG/RTV. Table 3. PK parameters in study GS-US-216-0116 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

EVG plasma exposures on Day 10 resembled those reported after 10 days dosing with EVG/RTV 125/100 mg in GS-US-183-0113 (AUCtau 20,236 ng.h/mL, Cmax 1830 ng/mL, Ctau 380 ng/mL). On this basis it was concluded that near maximal inhibition of CYP3A4-mediated EVG metabolism (F2, 150 mg) was achieved with RTV 100 mg or COBI 150 mg.

GS-US-183-0140 compared the bioavailability of the EVG 125 mg tablet used in the Phase 2 study (GS-US-183-0105) with the 150 mg F2 tablet (commercial) administered in the Phase 3 study (GS-US183-0145). EVG was administered daily with 100 mg RTV within 5 minutes of a standard breakfast. The EVG results on Day 10 met the BE criteria (AUCtau, Cmax and Ctau). The comparisons of RTV exposures on co-administration with the two EVG formulations also fell within the bounds of 80% to 125%.

Table 4. Statistical Comparisons of Elvitegravir Steady-State Pharmacokinetic Parameters for Test versus Reference Treatment in study GS-US-183-0140 (PK Analysis Set). The effect of food on the EVG commercial formulation was not studied. Unboosted EVG 400 mg early formulation tablets administered in the fed state (575 kcal, 33% fat) gave ~3-fold higher Cmax and AUCinf compared to the fasted state. There was a similar effect of food on plasma levels of M4 but the AUC was still &lt; 10% that of EVG. Table 5. Effect of food on EVG PK GS-US-236-0105 evaluated the effect of food (fasted, light [373 kcal, 20% fat] and high-fat [800 kcal, 50% fat] meal) when a single dose of the F1 formulation of STB (EVG 150 mg, COBI 150 mg, FTC 200 mg, TDF 300 mg) was administered. Maximum increases in EVG exposure vs. fasted state were seen following a high-calorie/high-fat meal (AUCinf 87%, AUClast 91% and Cmax 56%). Modest increases in EVG exposure occurred with a light meal vs. fasted state (AUCinf 34%, AUClast 36%, and Cmax 22%). The %CV was similar under fed conditions regardless of meal type. There was slightly greater variability in the fasted state, consistent with solubility-limited dissolution of EVG. Medicinal product no longer authorised

Table 6. GS-US-236-0105: Mean (%CV) EVG PK after a single dose of STB

| PK Parameter (N)   | Meal Condition   | AUC inf (ng•h/mL)   | C max (ng/mL)   | C last (ng/mL)   |
|--------------------|------------------|---------------------|-----------------|------------------|
| EVG                | HC/HF Meal       | 28800 (22)          | 2230 (27)       | 95.1 (75)        |

<div style=\"page-break-after: always\"></div>

| (N = 24)   | Light Meal   | 21100 (28)   | 1760 (32)   | 82.0 (115)   |
|------------|--------------|--------------|-------------|--------------|
|            | Fasted       | 16400 (39)   | 1490 (40)   | 79.3 (95)    |

HC, high calorie; HF, high fat; Data are mean (%CV) and are shown to 3 significant digits.

Based on these data EVG was administered with food (type unspecified) in Phase 2 and 3 studies to achieve a high mean EVG IQ95 (~ 10).

In-vitro studies showed that EVG was metabolised by CYP1A1, CYP3A4 and CYP3A5 at rates of metabolism of 0.9, 9.4 and 0.4 pmol/min/pmol P450, respectively, but was not metabolised by other isoenzymes tested (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A5). The main metabolite formed in human liver microsomes (M1) was produced by these CYP isoenzymes and the highest formation rate occurred with CYP3A4. Among the minor metabolites M2 was produced by CYP1A1 while M5 and M8 were only produced by CYP3A4.

Distribution Equilibrium dialysis studies using plasma from HIV-1 infected patients, healthy subjects and subjects with renal or hepatic impairment showed that EVG was ~98% to 99% bound to human plasma proteins regardless of concentration, with preferential binding to albumin over AAG. After a single oral 50 mg dose of RTV-boosted [14C] EVG (GS-US-183-0126) the blood-to-plasma ratio of total 14Cradioactivity was time-independent and ~ 0.73, indicating that EVG and its metabolites are predominantly distributed to plasma relative to the cellular components of the blood. Elimination Excretion In GS-US-183-0126, using RTV 100 mg and [14C] EVG 50 mg, the T½ of the administered radioactivity from pooled plasma samples was similar to that observed for EVG (9.64 vs. 9.59 hours). The combined faecal and urinary recovery accounted for 101% of the administered radioactive dose, which was almost exclusively recovered in faeces (94.8% of the radioactive dose). EVG and M1 accounted for 30.8% and 33.9%, respectively, of the total quantitated radioactive dose in pooled faeces. Low levels of minor hydroxylation products were also observed (M9, M13 and M15). The total amount of EVG in faeces likely resulted from a combination of unabsorbed drug, biliary secretion of EVG itself and biliary secretion of M4 converted back to EVG by the β-glucuronidases in the intestinal microflora. Renal elimination accounted for 6.7% of the administered dose, mostly as glucuronidated metabolites and with no unchanged EVG. The radioactivity recovered in pooled urine was present as the glucuronide of EVG (M4) or as glucuronides of EVG hydroxylation products (M7, M19 and M20) in roughly equal proportions. Metabolism In-vitro studies indicated that biotransformation of EVG is primarily via CYP-mediated aromatic and aliphatic hydroxylation and/or primary or secondary glucuronidation. Human liver microsome studies in the presence of NADPH indicated that EVG was primarily metabolised to M1 (GS-9202 - a chlorofluorophenyl group hydroxide) and also to small amounts of M5 and M8. Similar studies in the presence of UDPGA resulted in formation of the acyl glucuronide conjugate M4 (GS-9200). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

In GS-US-183-0126 on dosing with EVG/r the predominant circulating species in plasma was EVG (~ 94% of radioactivity). Metabolic profiling showed that M1, M4, M7 and M19 accounted for the nonEVG-associated radioactivity in plasma. All observed metabolites constituted &lt; 10% relative systemic exposure (AUCtau) to EVG. Taking into account all of the above, the proposed biotransformation pathway in man is summarised as shown below.

<!-- image -->

Figure 2. Proposed Biotransformation Pathway for [ 14 C] EVG Dose proportionality and time dependencies Multiple-dose data showed less than proportional increases in EVG exposure with increasing doses, which is thought to be most likely due to solubility-limited dissolution. Doubling the dose from 125 mg to 250 mg resulted in ~ 40% increase in mean EVG trough concentrations in healthy subjects. Administration of EVG/r 300/100 mg in HIV-1 infected subjects resulted in ~17% increase in EVG trough concentrations compared to EVG/r 150/100 mg. Intra- and inter-individual variability GS-US-236-0105 using the F1 QUAD STB formulation generally gave smaller CV% values for EVG AUC and Cmax in the fed vs. fasting state. The smallest CV% was observed with the high fat/high calorie meal. CV% values were numerically higher in the small numbers of HIV-infected subjects who underwent intensive sampling (n = 12-19) than in healthy subjects but the population PK estimations of %CV were low and were comparable between HIV-1 infected subjects and healthy subjects. Medicinal product no longer authorised

Intra-subject variability for EVG cannot be estimated from Phase 3 data because intensive sampling was on a single occasion. Intra-subject variability for Cmax, AUC and Ctau in the Phase 1 study GS-US-183-0140 was estimated at 12%, 13% and 22%, respectively.

<div style=\"page-break-after: always\"></div>

## Population PK analysis

The population PK report specific to use of EVG/r used pooled data from 19 studies in healthy subjects and three in HIV-infected subjects. A two-compartment PK model with first-order absorption rate constant and absorption lag-time provided a good description of the pharmacokinetics of EVG in healthy and HIV-infected subjects. No differences in EVG exposures were observed between healthy and HIV-1 infected subjects based on population PK modelling.

Body surface area (BSA) had a statistically significant effect on EVG clearance and affected intercompartmental clearance. However, the BSA effect was modest and the resulting decrease in the interindividual variability term associated with EVG clearance was only 25%. The 85 mg dose was identified as a covariate for EVG clearance. Subjects who received 85 mg EVG in combination with ATV/r or LPV/r had a 28% lower EVG clearance compared with subjects who received EVG 150 mg, resulting in similar EVG AUC and Cmax and slightly higher Ctrough across the two EVG dose levels. These results were in line with the inhibitory effect of ATV/r or LPV/r on UGT1A1 and supported dose reduction to 85 mg with these PI/r combinations (see PK interaction studies). A statistically significant relationship was observed between RTV AUC and EVG bioavailability but the effect at the clinically relevant RTV dose was not considered to be clinically meaningful. PK data obtained from HIV-infected subjects In the monotherapy PK/PD study (GS-US-183-0101) EVG was administered alone and as EVG/r 50/100 mg once daily for 10 days in the fed state. EVG dosing alone at 200, 400 and 800 mg BID gave 31%, 23% and 52% lower exposures, respectively, at steady state vs. a single dose, consistent with autoinduction of CYP3A. The EVG AUCtau on Day 10 of dosing with EVG/r was ~2-fold the AUC0-last 4615 ng.h/mL on Day 1. The EVG T½ increased from ~3h unboosted to ~9h with RTV. Table 7. GS-US-183-0101: Summary of EVG Steady-State PK Parameters (PK Analysis Set) In the Phase 2 study GS-US-183-0105 EVG/r was administered initially at 20/100 mg, 50/100 mg and 125/100 mg, each with OBR. The Week 8 intensive PK sub-study showed that EVG exposures increased in a less than dose proportional manner between 50 and 125 mg (~ 2-fold higher AUCtau over a 2.5-fold dose increase). The CV% decreased as dose increased. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 8. EVG PK parameters in study GS-US-183-0105

| EVGPlasmaPK Parameter a     | EVG/r 20/100mg (N =11)   | EVG/r 50/100mg (N =12)   | EVG/r 125/100mg (N =12)   |
|-----------------------------|--------------------------|--------------------------|---------------------------|
| Cmax (ng/mL) Mean (%CV)     | 265.79 (72.77)           | 753.71 (30.10)           | 1442.20 (33.97)           |
| AUCtau (ng*h/mL) Mean (%CV) | 3029.25 (84.58)          | 8701.86 (40.84)          | 16,789.54 (33.06)         |

| Cu (ng/mL), Mean (%CV)   | 759.6 (73.3)         | 378.2 (67.4)       |
|--------------------------|----------------------|--------------------|
| Tms (h), Median (Q1, Q3) | 4.75 (1.50, 9.09)    | 3.00 (1.17, 4.50)  |
| T%(h),Medlian (Q1,Q3)    | 13.72 (8.69, 17.20)b | 8.67 (7.10, 13.75) |

Plasma M1 concentrations were BLLQ in all subjects. Plasma M4 increased in a less than doseproportional manner while the AUCtau ratios vs. EVG were in the range from 14% to 24%. RTV peak and overall exposures were comparable across the 50 mg and 100 mg EVG doses. In study GS-US-183-0130 increasing the dose to EVG/RTV 300/100 mg gave a ~17% higher Ctau relative to EVG/RTV 150/100 mg. In comparison to data obtained in GS-US-183-0145 at the 300/100 mg dose the Cmax and AUCtau were increased by 33% and 31%, respectively. Thus, the data showed a markedly less than dose-proportional increase in plasma EVG exposure, consistent with a solubilitylimited absorption profile. Based on this data subjects in the PK sub-study reverted to 150/100 mg dose. In the Phase 3 study GS-US-183-0145 there was a PK sub-study in small numbers that generated intensive PK profiles at Week 2. The steady-state mean EVG AUCtau and Cmax were comparable following administration of 85 mg EVG (with LPV/r or ATV/r) or 150 mg EVG (with DRV/r, TPV/r or FPV/r). Table 9. EVG PK parameters in PK sub-study of study GS-US-183-0145 Table 10. EVG Summary Statistics of PK Parameters at Week 2 by EVG Dose in study  GS-US-1830145 (PK Substudy Analysis Set) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Ctau was higher with the 85 mg vs. 150 mg dose (see figure below) but following either dose the mean trough level was ~ 8.5- to 17.1-fold above the protein binding-adjusted IC95 (45 ng/mL).

Figure 3. EVG Plasma Concentrations (Mean and SD) at Week 2 by EVG Dose in study GS-US-1830145 (PK Substudy Analysis Set)

<!-- image -->

<!-- image -->

Concentrations of M4 were clearly and consistently lower following administration of EVG 85 mg vs. 150 mg, which was thought to reflect inhibition of UGT1A1 by the co-administered PIs (i.e. ATV and LPV). The AUCtau ratios for M4 vs. EVG were 10.8% with the 85 mg dose and 21.2% with the 150 mg dose. During the study the sparse sampling showed that: · Mean EVG 85 mg trough concentrations were 9.7- to 12.0-fold above the IC95-target between Week 2 and Week 48 (n = 57 to 111) · Mean EVG 150 mg trough concentrations were 6.9- to 9.2-fold above the IC95-target between Week 2 and Week 48 (n = 58 to 186). Dosing with EVG/r 150/100 mg (EVG F2 formulation) in healthy (GS-US-183-0140) and HIV-1 infected subjects (GS-US-183-0145) showed that: · In GS-US-183-0140 the EVG Cmax was 1998 ng/mL, AUCtau was 21086 ng.h/mL and Ctau was 397 ng/mL. · In GS-US-183-0145 the corresponding values were 1722 ng/mL, 20298 ng.h/mL and 378 ng/mL. RTV levels were stated to be consistent with historical (published) data, with a reference to ATV/RTV and LPV/RTV as measured during the CASTLE study. US-GS-183-0145 did not generate any data on the other PI drug levels. Special populations Medicinal product no longer authorised

## Impaired renal function

GS-US-216-0124 evaluated EVG/COBI 150/150 mg given once daily in the fed state for 10 days to subjects with severe renal impairment (eGFR &lt; 30 mL/min; not on dialysis) and controls (eGFR ≥ 90

<div style=\"page-break-after: always\"></div>

mL/min) matched by age, sex, BMI. The actual mean eGFRCG values at baseline were 23.5 mL/min and 97.2 mL/min in respective groups.

The EVG AUCtau, Cmax, and Ctau were lower (by 25%, 33% and 31%, respectively) in subjects with severe renal impairment vs. controls. However, EVG exposure in controls on Day 7 was substantially higher than in previous clinical studies with EVG/co at these doses and exposures in subjects with severe renal impairment were higher than usually observed in normal controls. The EVG mean (SD) % free fraction on Day 7 was 1.42 (0.17) in renally impaired subjects and 1.16 (0.16) in controls.

|                                                                 |                                             | EVG PK Parameter   | EVG PK Parameter   | EVG PK Parameter   |
|-----------------------------------------------------------------|---------------------------------------------|--------------------|--------------------|--------------------|
| Study No.                                                       | Subject Population (N)                      | AUC tau (ng•h/mL)  | C max (ng/mL)      | C tau (ng/mL)      |
| GS-US-183-0133                                                  | Moderate Hepatic Impaired Subjects (N = 10) | 29,800 (41)        | 2820 (34)          | 741 (65)           |
|                                                                 | Matched Healthy Control Subjects (N = 10)   | 21,300 (28)        | 1950 (30)          | 370 (44)           |
| GS-US-236-0110                                                  | Healthy Subjects (N = 36)                   | 22,500 (27)        | 1920 (24)          | 508 (41)           |
| GS-US-236-0102, GS-US-236-0103, and GS-US-236- 0104 a Medicinal | HIV-1 Infected Subjects (N = 419)           | 23,000 (33)        | 1730 (23)          | 451 (58)           |

Table 11. Statistical Analysis of EVG Pharmacokinetic Parameters on Day 7 Between Severely Renally Impaired and Normal Subjects in study GS-US-183-0124 (EVG PK Analysis Set). Impaired hepatic function GS-US-183-0133 evaluated EVG/co 150/150 mg once daily for 10 days in the fed state in subjects with moderate hepatic impairment (CPT B; actual scores 7-9) and healthy controls matched by age, sex, BMI. Mean creatinine clearance was 98.7 ml/min and 116.8 ml/min in respective groups. The steady-state AUCtau, Ctau and Cmax of EVG were 35%, 80% and 41% higher, respectively, in subjects with moderate hepatic impairment. It was proposed that the increase in Cmax with moderate hepatic impairment may have reflected higher oral bioavailability. The mean (SD) % free fraction EVG was 1.15 (0.14) in the control group and 1.22 (0.23) in the CPT B group, indicating the lack of effect of hepatic impairment on EVG protein binding. Table 12. Mean (%CV) EVG PK Following EVG/co or STB in Healthy and HIV-1 Infected Subjects Medicinal product no longer authorised

Population PK analyses: All the STB-treated subjects in GS-US-236-0103 and GS-US-236-0104 and all the STB-treated subjects who participated in the PK sub-study in GS-US-236-0102 were included.

<div style=\"page-break-after: always\"></div>

## Other intrinsic factors

In the population PK analysis for EVG/r age, gender, race, health status (HIV-infected vs. healthy), body weight, BMI, RCMIN, eGFR, formulation, background treatment and HBV and/or HCV co-infection were not found to have significant effects on any of the model parameters.

There are no data in children or the elderly with the exception of the PK data from GS-US-183-0152 in which EVG 85 mg or 150 mg was administered in the fed state to HIV-1 infected subjects aged 12-17 years taking a PI/r-containing background regimen.

EVG is a substrate for and weak inhibitor of human P-gp/MDR1 but there was no evidence of saturation of intestinal efflux transport. Co-administration with inhibitors or inducers of MDR1 is not expected to affect EVG plasma levels.

The initial PK study involved dosing for 10 days with EVG 85 mg (ATV/r or LPV/r) or 150 mg (other protocol-specified PIs). Mean EVG AUCtau and Cmax were slightly higher and mean Ctau significantly higher with 85 mg vs. 150 mg EVG, consistent with data from adults. Adolescents showed slightly higher exposures vs. HIV-infected adults. Comparisons for adolescents vs. healthy adults for the 150 mg dose showed that the AUCtau ratio was 93.43 % [75.81, 115.14]. The 85 mg dose in adolescents also gave modestly higher AUCtau and Cmax vs. adult data. The mean Ctau in adolescents was 7- to 13-fold above the in-vitro protein binding-adjusted IC95 (45 ng/mL). Consistent with data from adult studies, M4 was a minor metabolite with low exposures relative to EVG. M1 levels were BLLQ. Pharmacokinetic interaction studies Drug-drug interactions In vitro EVG showed no detectable inhibition of human hepatic microsomal CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6 or CYP2E1 activity. The IC50 value for CYP3A4 (testosterone substrate) was 28.32 μg/mL (63.19 μmol/L), suggesting weak inhibition. For other isoforms the IC50 values were more than 30 μg/mL (67.0 μmol/L). At clinically relevant concentrations EVG was considered to be a weak inducer of CYP3A. EVG did not induce CYP1A2 but it had some ability to induce CYP2C9 at 1 and 10 µg/mL. The metabolism of EVG to M1 in human liver microsomes in the presence of NADPH was decreased by approximately 97% with 2 μmol/L of ketoconazole. In human liver microsomes the IC50 values of tested agents for conversion of EVG to M1 were: amprenavir 1.1 μmol/L; indinavir sulfate 0.51 μmol/L; ketoconazole 0.099 μmol/L; lopinavir 3.1 μmol/L; nelfinavir 1.1 μmol/L, ritonavir 0.079 μmol/L; saquinavir 4.5 μmol/L. For efavirenz, nevirapine and zidovudine the inhibition ratio was lower than 50% even at 50 or 100 μmol/L. Sulfaphenazole (CYP2C9 inhibitor) and quinidine (CYP2D6 inhibitor) showed no inhibitory effect on EVG metabolism. Medicinal product no longer authorised

EVG was not predicted to affect the absorption of P-gp substrates. The reference theoretical intestinal concentration for EVG was 10 × 150 mg/250 mL (13.4 mM) but the IC50 of EVG for inhibition of Pgp was &gt; 30 µM.

<div style=\"page-break-after: always\"></div>

The absorption phases of EVG and RTV will overlap. Since Pgp will be inhibited by RTV, the presence of EVG is unlikely to result in additional inhibition of any clinical relevance.

EVG is a substrate for and a weak inhibitor of human OATP1B1 (40% inhibition at 2 µM) and human OATP1B3 (IC50 0.44 μM). Since the OATP-independent permeability of EVG is so high it is not likely to be affected by pharmacogenetic variability or by inhibitors of these transporters. Inhibition of OATP by EVG was assessed in the DDI study with rosuvastatin.

<!-- image -->

| product   | product   |
|-----------|-----------|

Formation of M4 was extensively inhibited by atazanavir (ATV), a selective UGT1A1 inhibitor in vitro . This was investigated in the clinical DDIs with ketoconazole (inhibitor of CYP3A and UGT1A1), ATV/r and LPV/r (both of which inhibit UGT1A1). Chelating of EVG via pharmacophore binding can occur with high concentrations of divalent and trivalent cations, as found in some antacid preparations. In vivo HIV protease inhibitors Atazanavir In GS-US-183-0108 co-administration of 300/100 mg ATV/r with EVG 200 mg once daily in the fed state for 14 days was associated with lower plasma exposures to ATV vs. ATV/r alone and the ATV T½ decreased from 17.75 h to 12.65 h. Table 13. Statistical Comparisons of PK Parameters for Atazanavir Between Treatments (PK Analysis Set). Plasma concentrations of RTV when administered with ATV or with ATV + EVG tended to be higher than the values observed after administration of EVG/r. Compared to EVG/r given alone, the EVG AUCtau, Cmax and Ctau were significantly increased (~2-fold AUCtau and Cmax; ~3-fold Ctau) on co-administration of EVG 200 mg with ATV/r. Since an additional effect of ATV on RTV inhibition of the CYP3A4-mediated metabolism of EVG was unlikely, the increase in EVG plasma levels was ascribed to inhibition of UGT1A1 by ATV. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 14. Statistical Comparisons of PK Parameters for GS-9137 Between Treatments (PK Analysis Set)

| TestversusReferenceComparison ofGS-9137PlasmaPKParameters   | GeometricLeast-Squares Means     | GeometricLeast-Squares Means     | Least-Squares Geometric          | 10 %06                           |
|-------------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                                             | Testb (Mean)                     | Reference (Mean)                 | MeanRatio (%)                    |                                  |
| GS-9137+Atazanavir/rvs.GS-9137/r                            | GS-9137+Atazanavir/rvs.GS-9137/r | GS-9137+Atazanavir/rvs.GS-9137/r | GS-9137+Atazanavir/rvs.GS-9137/r | GS-9137+Atazanavir/rvs.GS-9137/r |

| no   |
|------|

| 85mgGS-9137+Atazanavir/rvs.Atazanavir/r   |   85mgGS-9137+Atazanavir/rvs.Atazanavir/r |   85mgGS-9137+Atazanavir/rvs.Atazanavir/r |   85mgGS-9137+Atazanavir/rvs.Atazanavir/r | 85mgGS-9137+Atazanavir/rvs.Atazanavir/r   |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Cmax (ng/mL)                              |                                   4894.88 |                                   5066.21 |                                     96.62 | 86.58, 107.82                             |
| AUCtau (ng·h/mL)                          |                                  44720.9  |                                  50211.7  |                                     89.06 | 79.98, 99.18                              |
| Ctan (ng/mL)                              |                                    836.41 |                                   1008.6  |                                     82.93 | 72.14, 95.32                              |

<!-- image -->

There was a marginal increase in plasma levels of the glucuronide metabolite M4 on co-administration, which was less than proportional than the increase in EVG exposure. GS-US-183-0106 compared EVG/r 150/100 mg with EVG 85 mg plus ATV/r 300/100 mg and with ATV/r alone, all given once daily for 10 days. The comparisons of EVG Cmax and AUCtau indicated that 85 mg EVG + ATV/r would provide similar AUCtau and Cmax vs. 150/100 mg EVG/r and a slightly higher Ctau. Table 15. Statistical Comparisons of PK Parameters for EVG between Treatments (PK analysis Set) AUCtau and Cmax of the glucuronide metabolite M4 were lower on co-administration of 85 mg EVG with ATV/r (GMRs 68% and 56%, respectively, vs. EVG/RTV alone), which resulted in a lower mean M4:EVG ratio (3.7% vs. 6.0%). This was consistent with study 0108 in which the ratios were 3.5% for EVG + ATV/r and 5.7% with EVG/r alone. The ATV Cmax, AUCtau and Ctau were somewhat lower when ATV/r was co-administered with 85 mg EVG (lower bound below 80 and entire 90% CI below 1.0 for AUCtau and Ctau) vs. ATV/r alone. Table 16. Statistical Comparisons of PK Parameters for Atazanavir Between Treatments (PK Analysis Set) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

ATV increased plasma exposures to RTV regardless of EVG but the RTV AUCtau and Cmax were slightly lower after co-administration with 85 mg EVG vs. ATV/r alone.

GS-US-183-0147 compared EVG/r 300/100 mg once daily with EVG 300 mg plus ATV 400 mg once daily over 10 days. Oral midazolam 5 mg was administered on Day 10. EVG Cmax and AUC were slightly lower when it was given with RTV rather than with ATV but trough values were comparable. Plasma exposures to the glucuronide metabolite M4 were ~37% lower with EVG/r + ATV vs. EVG/r alone with respective M4: EVG ratios of 2.7% and 4.4%.

| longer   |
|----------|

Lopinavir GS-US-183-0116 compared EVG/r 125/100 mg once daily, EVG 125 mg once daily plus LPV/r 400/100 mg twice daily and LPV/r at this regimen alone over 14 days. Co-administration with LPV/r gave significant increases in EVG and M4 AUCtau, Cmax and Ctau compared to EVG/r but the ratios of plasma M4 to EVG with both treatments were &lt; 10% (AUCtau and Ctau). Table 17. Statistical Comparisons of PK Parameters for EVG between Treatments (PK Analysis Set) Table 18. Statistical Comparisons of PK Parameters for M4 between Treatments (PK Analysis Set) Medicinal product no longer authorised

<!-- image -->

LPV AUCtau and Cmax were unaltered in the presence of EVG. There was only a marginal decrease in Ctau while T1/2 increased from 12.8 h to 17.9 h without an effect on AUC.

<div style=\"page-break-after: always\"></div>

Table 19. Statistical Comparisons of PK Parameters for Lopinavir Between Treatments (PK Analysis Set)

|                                                              | GeometricLeast-Squares Means   | GeometricLeast-Squares Means   | Geometric Least-Squares Mean Ratio (%)   |        |
|--------------------------------------------------------------|--------------------------------|--------------------------------|------------------------------------------|--------|
| TestversusReferenceComparison ofLopinavirPlasmaPKParameter's | Testb (Mean)                   | Reference (Mean)               |                                          | I0 %06 |

| longer   |
|----------|

| GS-9137 +Tipranavir/r vs.GS-9137/r   |          |          |       |             |
|--------------------------------------|----------|----------|-------|-------------|
| Cmax (ng/mL)                         | 3084.1   | 2909.3   | 106   | 89.4, 125.7 |
| AUCtau (ng*h/mL)                     | 25,835.3 | 27,962.2 |  92.4 | 78.7, 108.4 |
| Cta (ng*h/mL)                        | 462.4    | 511.7    |  90.4 | 69.8,116.9  |

Table 20. Statistical Comparisons of PK Parameters for Ritonavir Between Treatments (Group 2 PK Analysis Set) Tipranavir GS-US-183-110 compared EVG/r 200/100 mg once daily with EVG 200 mg once daily plus TPV/r (500/200 mg) twice daily, each for 14 days. The addition of TPV/r twice daily gave a reduction in EVG AUC and Ctau compared to EVG/r alone. In contrast, M4 exposures (Cmax, AUCtau, and Ctau) were higher by 32.8%, 32.5% and 49.2%, respectively when EVG was given with TPV/r vs. EVG/r alone. Table 21. Statistical comparisons of Pharmacokinetic Parameters for EVG Between Treatments (PK Analysis Set). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Co-administration did not produce any significant changes in TPV Cmax and AUC based on ratios and 90% CI but means were numerically lower in the presence of EVG. Mean Ctau was also lower. Addition of EVG had no effect on RTV AUC vs. TPV/r while Cmax and Ctau were slightly higher.

Table 22. Statistical Comparisons of Pharmacokinetic Parameters for Tipranavir Between Treatments (PK Analysis Set)

<!-- image -->

Darunavir GS-US-183-0120 compared EVG/r 125/100 mg once daily and DRV/r 600/100 mg twice daily with EVG 125 mg once daily plus DRV/r (600/100 mg) twice daily. EVG Cmax and AUC were slightly higher when given with DRV/r vs. EVG/r alone but the upper bound of the 90% CI fell within 125% while that for the Ctau ratio was 131.4%. M4 levels were also higher in the presence of DRV/r but were still &lt; 10% of those of EVG. The greater effect of DRV on M4 compared to EVG was proposed to reflect inhibition of M4 biliary elimination by DRV. Table 23. Statistical Comparisons of PK Parameters for EVG Between Treatments (PK Analysis Set) DRV exposures were lower when EVG was co-administered vs. DRV/RTV alone with 90% CI around the ratios for Cmax and AUC within limits of 80 - 125 % but not including 100%. Ctau was 17% lower when EVG was added, with 90% CI 74 - 93%. The comparison of RTV Cmax and AUC indicated lower exposures when EVG was added vs. DRV/RTV alone, with lower bounds of 90% CI all below 80%. Medicinal product no longer authorised

## Fosamprenavir

GS-US-183-0123 compared EVG/r 125/100 mg once daily and FPV/r 700/100 mg twice daily with EVG 125 mg once daily plus FPV/r 700/100 mg twice daily. The comparison of EVG PK parameters indicated

<div style=\"page-break-after: always\"></div>

no additional effect of FPV on PK EVG vs. EVG/r and no effect on M4. There was also no appreciable effect of co-administration with EVG 125 mg on PK amprenavir (APV). Addition of EVG to FPV/r resulted in a slightly lower RTV Cmax (90% CI 75, 107%) but comparable AUC and Ctau, indicating no appreciable effect of EVG.

## Other types of antiretroviral agents

Co-administration of zidovudine (ZDV) 300 mg twice daily with EVG/r 200/100 mg had no appreciable effect on PK of ZDV, on zidovudine glucuronide formation or on EVG and RTV plasma levels. Neither didanosine (ddI) 400 mg nor stavudine (d4T) 40 mg affected PK of EVG (given as EVG/r 200/100 mg) except that Ctau was 24% higher on co-administration with d4T. Plasma exposure to ddI was slightly lower (~15% reduction in AUC and Cmax and lower bound of 90% CI below 80%) on coadministration with EVG/r but the ddI median T½ values were 1.64 vs. 1.77 h. The d4T AUCinf and AUC0-last were slightly higher with EVG/r but 90% CI fell within 80, 125. Etravirine (ETV 200 mg once daily) did not affect PK EVG (given as EVG/r 150/100 mg once daily) although plasma exposures to EVG were slightly higher. The RTV AUC and Ctau were slightly lower on co-administration but only for Ctau did the 90% CI fall outside 80 - 125% interval (64, 78). EVG/r did not affect PK of ETV. Abacavir (ABC) 600 mg did not affect PK EVG (given as EVG/r 200/100 mg once daily). Coadministration with EVG/r did not affect ABC. Tenofovir/emtricitabine co-administration with EVG/r 50/100 mg had no effect on PK of EVG, FTC or TFV. Maraviroc (MVC) 150 mg twice daily did not affect PK EVG (given as EVG/r 150/100 mg once daily). RTV was also essentially unaffected. Co-administration with EVG/r resulted in 2-4-fold increases in MVC Cmax, AUC and Ctau due to CYP3A4 and P-gp inhibition by RTV. The recommended dose of maraviroc in the absence of a potent CYP3A inhibitor is 300 mg twice daily. Table 24. Statistical Comparisons of PK Parameters for Maraviroc Between Treatments (PK Analysis Set, study GS-US-183-0118) Medicinal product no longer authorised

## Other medicinal products

Co-administration of EVG/r 50/100 mg with magnesium/aluminium-containing antacid was associated with marked reductions (ratios ~ 50 - 60%) in Cmax and AUC EVG.

<div style=\"page-break-after: always\"></div>

Table 25. Statistical Comparisons of PK Parameters for EVG with and without co-administration of antacid (PK Analysis Set, study GS-US-183-0103)

|                                                      | GeometricLeast-Squares Means   | GeometricLeast-Squares Means   | Geometric Least-Squares   |       |
|------------------------------------------------------|--------------------------------|--------------------------------|---------------------------|-------|
| TestversusReferenceComparison ofPlasmaPK Parametersa | Test (Mean)                    | Reference (Mean)               | Mean Ratio (%)            | ID%06 |

<!-- image -->

| Cmax (ng/mL)     |   2260.2 |   1926.3 |   117.3 | 103.8, 132.6   |
|------------------|----------|----------|---------|----------------|
| AUCtau (ng*h/mL) |  32286   |  21766.3 |   148.3 | 136.2, 161.6   |
| Ctan (ng/mL)     |    804.8 |    482.9 |   166.7 | 148.2, 187.5   |

This was further investigated by comparing administration of EVG/r 50/100 mg alone and after food once daily with groups that received Mg/Al-containing antacid 2 or 4 h before and after dosing. EVG/r was also given as 50/100 2 h after 40 mg omeprazole for 5 days. On dosing EVG/r with a 4 h interval before/after antacid and at 2 h after a daily dose of omeprazole there was no significant effect on EVG exposures. Dosing with a 2 h interval before or after 20 mL antacid gave lower EVG exposures with 90% CI around ratios that did not span zero. The highest RTV exposures occurred when EVG/r was given 2 or 4 h before antacid and the lowest when it given with omeprazole. However, for each comparison with EVG/r alone the 90% CI fell within limits of 80 - 125% and spanned 100 except for omeprazole (which almost spanned 100). Rifabutin dosed at 150 mg every other day did not affect EVG exposures vs. EVG/r 300/100 mg once daily alone. RTV plasma levels were elevated in the presence of rifabutin (e.g. AUC ratio 124.5% [90% CI 109 - 142%]). The rifabutin Cmax and Ctau at 24 h post rifabutin 300 mg once daily alone and at 48 h post rifabutin co-administered with EVG/r were comparable. Median T½ increased from 10.43 h to 24.4 h following co-administration. The estimate derived from 2 × AUC0-24 for rifabutin alone was comparable to AUC0-48 during co-administration. In contrast, 25-O-desacetyl rifabutin AUC0-48, Cmax and Ctau increased 9.5-, 5.4- and 19.4-fold, respectively, on co-administration. The total antimycobacterial activity (calculated from total concentration in µM for rifabutin plus 25-O-desacetyl rifabutin) was increased by 50% during co-administration. Co-administration of EVG/r 150/100 mg once daily with ketoconazole (KTZ) 200 mg twice daily gave KTZ PK values that were comparable with those reported during co-administration with DRV/r. RTV exposures increased on co-administration with KTZ (e.g. AUC ratio 162% [90% CI 143, 184%]). KTZ resulted in increases in EVG plasma concentrations, especially for AUC and Ctau. The EVG T1/2 were comparable (11.8 h vs. 12.6 h with KTZ) but clearance (CL/F) and CL/F/kg showed reductions by about one third in the presence of KTZ. Table 26. Statistical Comparisons of EVG PK Parameters after Administration of EVG/r Alone or EVG/r Plus Ketoconazole (PK Analysis Set) Medicinal product no longer authorised

There was also a modest increase in M4 (GS-9200) plasma levels when KTZ was added to EVG/r.

<div style=\"page-break-after: always\"></div>

In the same study, co-administration of MDZ (5 mg PO) with EVG/r resulted in markedly increased MDZ exposures and there was a further but more modest increase in AUCinf and Clast when KTZ was added. Co-administration with EVG/r resulted in significant decreases in 1′-OH MDZ exposure but there were increases on addition of KTZ.

## EVG boosted with COBI

<!-- image -->

Co-administration of DRV 800 mg with EVG 150 mg and COBI 150 mg for 10 days resulted in DRV mean Ctau (1045.7 ng/mL) that was lower than observed in other studies in which DRV 800 mg daily was co-administered with COBI 150 mg (1332.7 ng/mL) or RTV 100 mg (1866.7 ng/mL) without EVG. Also, the EVG Cmax (2091 ng/mL), AUCtau (18,067 ng.h/mL) and Ctau (242 ng/mL) were slightly lower than observed in another study with EVG/r 125/100 mg alone or EVG 125 mg plus DRV/r 600/100 mg twice daily. Co-administration of EVG/co 150/150 mg with omeprazole (20 mg) or famotidine (40 mg) over 7 days showed no effect on PK of EVG (or COBI) when each was given 12 h after EVG/co. When omeprazole was given 2 h before EVG/co the plasma levels of EVG increased slightly with 90% CI for Cmax and Ctau that exceeded 125% but the AUC ratio was 110 [102, 119]. Co-administration of EVG/co 150/150 mg with famotidine 40 mg once daily showed no discernible effects on PK EVG. Co-administration of EVG/co 150/150 mg with ROS 10 mg showed no effect on PK EVG. The ROS Cmax and AUC were greater (89% and 38%, respectively) when given with EVG/co but the overall concentration-time profile and T½ were comparable vs. ROS alone. Co-administration of EVG/co 85/150 mg with ATV 300 mg did not affect the EVG AUCtau while Cmax was lower (~ 15%) and Ctau was higher vs. EVG/co 150/150 mg alone. The ATV AUCtau was lower (1012%) when given with EVG/co vs. ATV/r. Cmax was ~ 21-24% lower and Ctau was ~ 20-35% lower although it was above the DHHS target (140 ng/mL) in all subjects. Co-administration of EVG/co 150/150 mg with rifabutin 150 mg every other day did not affect the EVG Cmax but the AUCtau was ~ 20% lower and Ctau markedly (~ 63%) lower with an associated shorter T½ vs. EVG/co alone. COBI exposures were substantially lower only at 18 and 24 h following coadministration with rifabutin and an associated shorter T1/2. The AUCtau, Cmax and Ctau rifabutin were comparable between the EVG/co + rifabutin 150 mg dose and 300 mg given alone. The median T½ was 11.7 h when rifabutin was given alone but was 28.6 h following concomitant administration. Coadministration with EVG/co resulted in large increases in AUCtau, Cmax and Ctau of 25O -desacetylrifabutin vs. rifabutin alone. GS-US-216-0125 evaluated methadone PK in HIV-1 uninfected subjects on a stable dose following once-daily co-administration of EVG/co and methadone vs. methadone alone. R-methadone (active enantiomer) and S-methadone exposures were unchanged on co-administration with EVG/co vs. methadone alone. The 90% CIs were within 80% to 125% with the exception of R-methadone Ctau (127.58%). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 27. GS-US-216-0125: Methadone Pharmacokinetics

| PK Parameter                                                              | Test Mean (%CV)                                                           | Reference Mean (%CV)                                                      | GLSM Ratio (%)                                                            | 90% Confidence Interval                                                   |
|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| R-Methadone: EVG/co + Methadone (Test) vs Methadone (Reference), (N = 11) | R-Methadone: EVG/co + Methadone (Test) vs Methadone (Reference), (N = 11) | R-Methadone: EVG/co + Methadone (Test) vs Methadone (Reference), (N = 11) | R-Methadone: EVG/co + Methadone (Test) vs Methadone (Reference), (N = 11) | R-Methadone: EVG/co + Methadone (Test) vs Methadone (Reference), (N = 11) |
| AUC tau (ng•h/mL)                                                         | 6211.6 (43.7)                                                             | 5547.6 (21.3)                                                             | 106.98                                                                    | (96.06, 119.16)                                                           |
| C max (ng/mL)                                                             | 336.9 (46.4)                                                              | 316.4 (21.4)                                                              | 101.41                                                                    | (90.75, 113.32)                                                           |
| C tau (ng/mL)                                                             | 234.0 (55.7)                                                              | 196.6 (25.0)                                                              | 110.00                                                                    | (94.84, 127.58)                                                           |
| S-Methadone: EVG/co + Methadone (Test) vs Methadone (Reference), (N = 11) | S-Methadone: EVG/co + Methadone (Test) vs Methadone (Reference), (N = 11) | S-Methadone: EVG/co + Methadone (Test) vs Methadone (Reference), (N = 11) | S-Methadone: EVG/co + Methadone (Test) vs Methadone (Reference), (N = 11) | S-Methadone: EVG/co + Methadone (Test) vs Methadone (Reference), (N = 11) |
| AUC tau (ng•h/mL)                                                         | 7542.1 (56.1)                                                             | 7036.3 (39.8)                                                             | 100.17                                                                    | (89.38,112.26)                                                            |
| C max (ng/mL)                                                             | 452.4 (51.9)                                                              | 445.8 (35.1)                                                              | 95.92                                                                     | (86.62,106.23)                                                            |
| C tau (ng/mL)                                                             | 260.0 (71.0)                                                              | 229.8 (49.5)                                                              | 102.19                                                                    | (89.24,117.01)                                                            |

| product   |
|-----------|

<!-- image -->

Studies with Stribild One DDI study was conducted with STB and an oral contraceptive containing norgestimate and ethinyl oestradiol (0.025 mg). Co-administration was for 9 days in subjects at least in the second dosing cycle and resulted in increases in norelgestromin AUCtau, Cmax and Ctau but decreases in ethinyl oestradiol (EE) AUCtau and Ctau. EVG and COBI levels were in the expected range. Serum progesterone remained unchanged while FSH decreased to a similar extent and LH showed a larger decrease on coadministration. Table 28. GS-US-236-0106: Statistical Comparisons of Norelgestromin Pharmacokinetic Parameters (NGMN PK Analysis Set) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 29. GS-US-236-0106: Statistical Comparisons of Ethinyl Estradiol Pharmacokinetic Parameters (EE PK Analysis Set)

|                 | Geometric Least-squaresMfeans   | Geometric Least-squaresMfeans       | Geometric Least-squares Means Ratios   |                          |
|-----------------|---------------------------------|-------------------------------------|----------------------------------------|--------------------------|
| EE PK Parameter | NGM/EE Reference (N=15)         | NGM/EE+EVG/COBI/FTC/TDF Test (N=15) | (Test/Reference) (%)                   | %06 Confidence Intervals |

There were no measurable changes in the content of mtDNA and therefore the potential for mitochondrial toxicity is considered low.

2.4.3. Pharmacodynamics Mechanism of action EVG specifically inhibits HIV-1 integrase strand-transfer activity and the integration of viral DNA into host cell chromosomal DNA in cell culture. Primary pharmacology EVG inhibited DNA strand-transfer with an IC50 value of 8.8 nM. It inhibited laboratory strains and various clinical isolates of HIV-1 with an EC50 of 0.38 nM (range, 0.02 to 1.3 nM) in human PBMCs. Activity was shown against multiple subtypes of HIV-1 and against HIV-2. The EC95 value in the presence of HSA and AAG was 100 nM (44.8 ng/mL) in HIV-1 infected human PBMC cultures, representing an 80-fold loss in antiviral activity. In-vitro ARV combination studies showed additive to synergistic interactions with the NRTIs FTC and TFV (as well as others tested), with NNRTIs (EFV, nevirapine and etravirine) and with a range of PIs. In-vitro assays with T-20, RAL and maraviroc also demonstrated additive to synergistic interactions. In-vitro, EVG selected for 3 primary resistance mutations in HIV-1 integrase - T66I/A/K, E92Q/G or Q148R. These conferred 15-, 36- and 109-fold reduced susceptibility, respectively. Additional secondary IN mutations selected by EVG were H51Y, F121Y, S147G, S153Y, E157Q and R263K. These mutations further decreased susceptibility to EVG when they occurred in addition to T66I or E92Q mutations. Elvitegravir did not inhibit replication of HBV or HCV in vitro . Medicinal product no longer authorised

In MT-2 cells the M4 and M1 metabolites showed HIV-1 antiviral activity that was 6.7- and 9.3-fold lower than EVG. However, M4 and M1 selected for EVG-associated resistance mutations.

The EVG dose-escalation studies of selection of resistance-associated mutations were of different methodologies. However, they indicated that T66I could be selected by passage 7 whereas E92Q

<div style=\"page-break-after: always\"></div>

emerged at passage 30. Using the viral breakthrough method Viruses with IN resistance mutations were observed at EVG concentrations corresponding to 10-fold the EC50 (T66I/T) and 40- and 80-fold the EC50 (Q148R). Viruses with emergent IN resistance mutations were also observed for RAL at concentrations corresponding to 5-fold the EC50 (N155H) and 40-fold the EC50 (Q148K).

In GS-US-183-0101 EVG monotherapy at 200, 400 or 800 mg twice daily, at 800 mg once daily or 50 mg + RTV 100 mg once daily for 10 days significantly reduced HIV-1 RNA levels vs. placebo but maximal and comparable mean/median changes were observed with 400 or 800 mg twice daily and 50 mg + RTV 100 mg once daily.

<!-- image -->

<!-- image -->

The estimated inhibitory quotients (IQ; calculated as the observed mean Ctau divided by the protein binding-adjusted in-vitro IC50 of 7.17 ng/mL) were 5.9, 6.7 and 18.8 at 400 mg twice daily, 800 mg twice daily and 50 mg + RTV once daily, respectively. EVG trough concentrations at these doses exceeded the protein binding-adjusted in vitro IC95 (45 ng/mL; 100 nM) for the entire dosing interval.

Figure 4. Mean Change in HIV-1 RNA Through Day 21 EVG Ctau values fitted well to a simple Emax (maximum PD effect) model with an EC50 value at 14.4 ng/mL and an Emax of 2.32 log10 copies/mL reduction from baseline. Figure 5. Pharmacokinetic/Pharmacodynamic Dose-Response Relationship for EVG Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

In the Phase 3 study GS-US-183-0145 EVG (85 or 150 mg) was compared with twice-daily raltegravir (RAL), each administered with a fully active PI/r in the OBR. A pure virological failure (PVF) analysis showed virological response rates ~65% in both treatment groups at Week 48. Exploratory PK/PD evaluations indicated that virological response spanned the observed PVF-based efficacy for all 3 quantile-based analyses (i.e. quartiles, quintiles or octiles of EVG Ctrough for 85 mg and 150 mg doses). Lower response rates were observed in the lowest quantile that may reflect the influence of observations below the LLQ.

The large increase in EVG exposure on co-administration with a single dose of RTV 100 mg was attributed to improved oral bioavailability due to decreased first pass metabolism and to reduced systemic clearance. On multiple dosing of EVG/RTV there were further increases in EVG plasma exposures, including Ctau, with a greater than predicted steady-state AUC. Plasma RTV concentrations were higher after multiple dosing with non-linear PK on dosing to steady state, most likely due to its time-dependent, mechanism-based inhibition of CYP3A. These observations underline the importance of conducting the DDI studies with EVG and RTV at steady-state.

<!-- image -->

Table 30. GS-US-183-0145: Summary for EVG Trough Concentration and Pure Virologic Response at Week 48 (HIV-1 RNA &lt; 50 copies/mL) by EVG Ctau Quartile Subgroups for EVG 85-mg and 150-mg Doses (PK/PD Analysis Set). Secondary pharmacology The TQT study GS-US-183-0128 evaluated the effects of EVG/RTV 125/100 and 250/100 mg on QTc. Moxifloxacin showed the expected positive control effect with a difference in QTcF vs. placebo that was generally between 5 and 10 ms and with an upper limit of the 90% CI &gt; 10 ms at multiple time points. For the QTcF change from baseline in Part 2 of the study the upper limits of the 2-sided 90% CI for the difference in LSMs (EVG/r vs. placebo) were all &lt; 10 ms. Actual differences in LSMs were &lt; 5 ms at all time points for both EVG/r groups. Consistent results were obtained from similar analyses conducted for QTcB, QTcI and QTcN. The categorical analyses were unremarkable. The linear correlations between QTcF, QTcB, QTcN and QTcI and plasma concentrations of EVG and GS-9200 were very weak. 2.4.4. Discussion on clinical pharmacology The oral bioavailability of EVG when administered alone was estimated to be low (&lt; 25%) and increased in a less than dose-proportional manner. Multiple dosing with unboosted EVG showed autoinduction of metabolism. The effect of food on the final formulation was not studied. However, based on the food effect studies using early formulation of EVG or QUAD STR, in all subsequent studies EVG was administered with food. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Plasma concentrations of M1 were below LLQ with RTV 100 mg doses. Concentrations of M4 increased with RTV dose in a non-linear fashion with a ratio M4:EVG maintained &lt; 10%, suggesting that RTV did not affect M4 formation.

The cross-study comparison following multiple-dose administration of EVG/RTV 150/100 mg in healthy (GS-US-183-0140) and HIV-1 infected subjects (GS-US-183-0145) indicated comparable mean exposures based on Cmax, Ctau and AUC.

The results in subjects with renal impairment are difficult to interpret given the overall higher exposures in this study vs. other in healthy subjects. Despite the limitations of the study, less than 8% of EVG is excreted in urine and the free EVG fraction remained just over 1% in patients with severe renal impairment. Therefore, it is supported that no dose adjustment is needed. Taking into account the mean (%CV) EVG exposure parameters AUCtau, Cmax, and Ctau across studies GS-US-183-0133 and GS-US-236-0110 as well as the population PK analyses derived from the STB Phase 2 and 3 studies (GS-US-236-0102, 0103 and 0104) the higher EVG AUC observed in subjects with moderate hepatic impairment is not considered to merit dose adjustment taking into account also the available safety data with EVG. RTV, ATV and EVG share a common pathway for systemic clearance - primarily CYP3A-mediated oxidation. ATV, which is known to inhibit RTV clearance, resulted in higher RTV exposure regardless of whether or not EVG was also given. Addition of EVG to ATV/r had some negative effect on RTV plasma levels vs. ATV/r alone. It appeared that not only did ATV inhibit formation of M4 via its effect on UGT1A1 but also it inhibited elimination of M4. It seems that M4 is a substrate for MRP2 and it was proposed that decreased M4 elimination could reflect altered MRP2-mediated biliary clearance since RTV is known to inhibit this transporter and ATV may also be an inhibitor (since other PIs have this effect). EVG inhibits OATP1B1 and OATP1B3 but the IC50 values (IC50 2.2 μM and 0.44 μM, respectively) exceed unbound plasma EVG (free fraction: ~ 1%, mean Cmax 4.45 μM) so that a strong inhibitory effect on OATP1B1 and OATP1B3 was not expected. Co-administration of 200 mg EVG with ATV/r increased the EVG exposures vs. EVG/r 200/100 mg given alone most likely because of UGT inhibition by ATV. Dose adjustment to EVG 85 mg when coadministered with ATV/r was aimed at matching EVG plasma levels observed with RTV-boosted EVG 150 mg and providing exposures corresponding to antiviral activity with mean Ctau values (overall and by EVG dose) that exceed the protein binding adjusted IC95 (by ~8 to 9-fold). Co-administration of ATV/r + EVG 200 mg gave lower ATV and RTV plasma levels vs. ATV/r alone (all 90% CI below 100). On co-administration with 85 mg EVG there were also lower ATV and RTV plasma levels (90% CI for AUC and Ctau entirely &lt; 100) vs. ATV/r alone. In contrast to the apparent effect of EVG on RTV when given with ATV, there was no depression of plasma RTV when EVG was added to LPV/r, TPV/r or FPV/r and only a very slight depression with DRV/r vs. each of these PI/r combinations given alone. The explanation of the observed effect of EVG on ATV/r remains unclear. Nevertheless, in light of the actual ATV plasma levels observed and the effects of other drugs on ATV plasma levels, as well as the efficacy data, the PK findings were not considered to preclude co-administration of ATV/r 300/100 mg once daily with EVG 85 mg. For example, ATV exposures were similar to therapeutically effective concentrations reported in the literature and in the prescribing information for ATV/r. Additionally, mean ATV trough concentrations in subjects receiving ATV/r plus EVG 85 mg were substantially above (~36 to 62-fold) the protein-binding adjusted IC90 for wild type HIV-1 (14 ng/mL). Medicinal product no longer authorised

EVG 125 mg did not have a notable effect on plasma LPV or RTV vs. LPV/r alone but co-administration with LPV/r increased the EVG AUC by 75% compared to EVG/r alone. A reduced dose of 85 mg EVG was selected through PK simulation and was estimated to provide high trough concentrations and an

<div style=\"page-break-after: always\"></div>

equivalent AUC to EVG/r 150/100 mg. The adequacy of EVG exposures for HIV-1 infected subjects receiving EVG 85 mg (with ATV/r [n = 15] or LPV/r [n = 10]) vs. EVG 150 mg (with other PI/r) was assessed in the intensive PK sub-studies in GS-US-183-0145 (adults) and GS-US-183-0152 (adolescents). The steady-state mean EVG AUCtau and Cmax were comparable following administration of 85 mg EVG vs. 150 mg EVG when each was given with the specified PI/r combinations. The EVG Ctau (Ctrough) was higher with the 85 mg dose vs. the 150 mg dose. Further assessment of the adequacy of EVG exposures to support antiviral efficacy was based on population PK modelling after coadministration of EVG 85 mg with LPV/r in GS-US-183-0145. The mean EVG Ctau values were 7.6-fold above the protein binding-adjusted IC95.  Finally, the efficacy of EVG 85 mg with LPV/r was documented in GS-US-183-0145 (see the results presented according to EVG dose and specific PI/r).

Since a need has been established for EVG dose reduction when it is given with RTV and an agent that inhibits UGT (hence 85 mg is given with ATV/r and LPV/r), the effects of giving EVG with any of the proposed PI/r combinations plus another drug that is a strong inhibitor of UGT1A1/3 should be carefully considered. The potential net affect could be expected to depend on which PI/r is being coadministered with EVG. Co-administration of EVG with medicines that inhibit UGT seems rather less of a concern if the PI/r has already achieved near maximal UGT inhibition. In contrast, addition of a strong UGT inhibitor to 150 mg EVG plus DRV/r, TPV/r or FPV/r might increase EVG plasma levels by at least the same extent as ATV or LPV.

GS-US-183-0120 indicated lower Ctau DRV in the presence of EVG vs. DRV/r alone and 90% CI for Cmax and AUC that did not span 100. However, the largest subset of patients in the efficacy study received EVG with twice daily DRV/r with response rates at least as good as those achieved with this regimen in the RAL group. On this basis, co-administration of EVG with twice daily DRV/RTV can be accepted. It is important to note that the data cannot support use of EVG with once daily DRV/r 800/100 mg. GS-US-183-0123 suggested no important effect of FPV/r on EVG (90% CI for the EVG AUC ratio fell just below 100%) and addition of EVG did not affect plasma levels of amprenavir or RTV. On this basis co-administration can be accepted . In GS-US-183-0110 EVG 200 mg once daily and TPV/r 500/200 mg twice daily gave a lower EVG AUC and Ctau vs. EVG/r alone and lower TPV Ctau vs. TPV/r alone. Population PK modelling taking into account PK data obtained on co-administration of EVG 150 mg with TPV/r in GS-US-183-0145 indicated that the mean EVG Ctau values were 6.3-fold above the protein binding-adjusted IC95. For TPV the lower bound for the Ctau comparison was &lt; 80% but the TPV trough concentrations with both treatments were &gt; 330-fold above the IC90 for HIV-1 (96 ng/mL). Nevertheless, there were too few subjects that received EVG with TPV/r in the Phase 3 study to provide support based on efficacy data (3/6 in the EVG group failed) and no TPV PK data were obtained. There remains concern that this combination may not be appropriate and it is not recommended in the SmPC. The available data indicate that plasma EVG concentrations may increase when co-administered with a PI/r and with an agent that inhibits UGT1A1/3 (which may be the PI). In particular, co-administration of EVG with ATV/r or LPV/r increased EVG plasma levels vs. EVG/r alone, which was ascribed to UGT inhibition by the PI in the presence of near maximal inhibition of CYP3A by RTV. Addition of KTZ (a strong inhibitor of CYP3A4) to EVG/r provided only a small increment in isoenzyme inhibition vs. RTV based on the effects on co-administered MDZ. Taking into account the MDZ data from this study, a maximum increase in EVG AUC of approximately 25% was anticipated due to additional CYP3A inhibition by KTZ. However, the actual increase in EVG AUC was ~ 48% when given with RTV and KTZ and the total increment was ascribed mainly to the additional effect of inhibition of UGT1A1 by KTZ. Medicinal product no longer authorised

Studies have been conducted on possible interactions between EVG and other medicinal products, and the results have been reflected in the SmPC.

<div style=\"page-break-after: always\"></div>

The in-vitro activity of EVG has been adequately investigated and is clearly demonstrated.

There is incomplete cross-resistance between EVG and RAL. For example, viruses carrying only T66I remain susceptible to RAL whereas viruses carrying N155H and/or Q148K show resistance to RAL and EVG. The results of the in-vitro studies suggest that the genetic barrier to resistance of EVG is relatively low, as is that of RAL.

•

The applicant concluded that 85 mg and 150 mg EVG doses, administered with the selected RTVboosted PIs, provided EVG exposures corresponding to the plateau of the dose-response relationship and were associated with antiviral efficacy. Nevertheless, it has to be noted that the PK/PD analysis presented based on GS-US-183-0145 and using EVG 85 or 150 mg depending on the PI are difficult to interpret due to the various regimens and PIs that were allowed and the recognised contribution of boosted PIs to overall efficacy. The TQT study with up to EVG/RTV 250/100 mg delivered supra-therapeutic exposures compared to anticipated plasma levels achieved with 150 mg EVG in the presence of RTV and did not suggest clinically important effects on QTc. 2.4.5. Conclusions on clinical pharmacology EVG is clearly active against HIV in vitro. The PK interactions with PIs/r proposed for coadministration and other medicines likely to be administered in combination have been studied appropriately. However, since EVG is to be coadministered with a PI/r, due to the PK properties of EVG itself and the various PI/r regimens that may be administered with EVG, the ability to assess and predict the total risk of possible interactions is limited. EVG has been evaluated in PK studies with DRV/RTV or LPV/RTV only given twice daily. In addition, the few data available from study 0145 strongly point against using EVG with once daily DRV/RTV. Offlabel use of EVG with these regimens would therefore constitute a major concern and corresponding warning against use of elvitegravir with other PIs or dosing frequencies than those explicitly recommended has been included in the SmPC. 2.5. Clinical efficacy Data to support the efficacy of EVG when co-administered with an RTV-boosted PI and the EVG doses proposed for use with individual PIs were generated in: · DDI studies with EVG plus RTV-boosted PIs (DRV, LPV, ATV, FPV, TPV; see section on PK) · The short-term EVG monotherapy study in HIV-infected subjects GS-US-183-0101 (see section on PD) A Phase 2 study with an open-label follow-up phase (GS-US-183-0105 and 0130, see Dose Response studies and supportive studies). · A single pivotal Phase 3 study GS-US-183-0145 (data reported to Week 96). Medicinal product no longer authorised

- Supportive data for EVG boosted with COBI in combination with TDF/FTC from the Phase 2/3 studies with QUAD STR, which are not discussed in this Assessment Report 1 .

1 for more information, see CHMP Assessment Report / European Public Assessment Report for Stribild

<div style=\"page-break-after: always\"></div>

## 2.5.1. Dose response studies

The 150 mg QD dose of EVG was selected by the Applicant based on results from study GS-US-1830101 (see section on PD), supported by results from Phase 2 study GS-US-183-0105 (see below), and a Phase 1 biopharmaceutics/formulation study (GS-US-183-0140). Drug-drug interaction studies on EVG with RTV-boosted PIs were conducted to identify whether dose adjustment of EVG was required (see section on PK).

<!-- image -->

Study GS-US-183-0105 This was a randomised, partially blinded, multicentre study to assess non-inferiority of EVG/RTV vs. CPI/RTV when administered with an OBR. Treatment-experienced subjects with plasma HIV-1 RNA levels ≥ 1,000 copies/mL with documented presence of at least one of the protease gene mutations (as defined by the IAS-USA 2005 Guidelines) were eligible to enter the study. Subjects were initially randomised to once-daily EVG/RTV 20/100, 50/100 or 125/100 mg or to an investigator-selected RTV-boosted PI, each administered with OBR. The 20/100 mg group was discontinued due to lower than expected responses by Week 8 and subjects switched to 125/100 mg. Due to this and other protocol amendments (e.g. allowance of using DRV or TPV was added by amendment) the virological data are difficult to interpret, especially after Week 16. The Week 24 responses in those who then switched to open label 125/100 mg were comparable with those who started the study on this dose. Maintaining viral suppression was strongly dependent on at least one fully active agent in the OBR and there was a marked effect of co-administering EVG/r with first use of T-20. Subjects with evidence of virological failure developed known INSTI resistance mutations; the most common was E92Q. 2.5.2. Main study (GS-US-183-0145) Methods This Phase 3, double-blind, double-dummy, multicentre, randomized, active-controlled study was a merger of two Phase 3 studies (0144 and 0145) that were consolidated by protocol amendment due to slow enrolment. The study report containing data out to Week 96 was included in this dossier. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 6. Outline of study design for study 183-0145

<!-- image -->

a. Stratification by screening HIV-1 RNA ( ≤ vs. &gt; 100,000 copies/mL) and the 3rd agent (NRTI vs other classes) b. 3rd Agent: NRTI, ETR, MVC, T-20 (If M184V/I, may add 3TC, or FTC) Study Participants Eligible subjects were to have no prior treatment with an integrase inhibitor and: · Plasma HIV-1 RNA ≥ 1000 copies/mL assessed using the COBAS Amplicor HIV-1 Monitor Ultrasensitive Test (Version 1.5; range 50 - 100,000 copies/mL). · A stable ARV regimen for at least 30 days prior to screening and baseline. · A screening HIV-1 genotype report that showed documented resistance (IAS-USA definitions) OR at least 6 months exposure to ≥ 2 classes of ARVs. In this regard, it has to be noted that the CSR stated: Subjects may have had virus resistant to 1 class and at least 6 months experience prior to screening with a second class OR virus resistant to 2 classes OR at least 6 months experience with ≥ 2 classes OR virus resistant to and/or at least 6 months experience with ≥ 3 classes. At screening, the protease/reverse transcriptase (PR/RT) genotype and phenotype were determined using PhenoSense GT (Monogram Biosciences, South San Francisco, CA). Integrase resistance testing was also performed by Monogram Biosciences. Repeat testing was performed for viruses obtained in cases of primary failure or rebound. Those completing at least 96 weeks blinded treatment were eligible for the post-Week 96 extension. Ongoing or perceived need for therapy with any of a lengthy list of potentially interacting medications precluded study participation. Treatments Medicinal product no longer authorised

Prior to the Baseline/Day 1 visit and pre-randomisation, the investigator selected each subject's OBR based on ARV drug history and viral resistance profile. The PI had to be predicted to be fully active against the individual's virus based on phenotyping. Randomisation was to treatment with EVG (see doses below) or RAL 400 mg twice daily. Within the EVG group subjects were dosed according to the selected RTV-boosted PI as follows:

<div style=\"page-break-after: always\"></div>

Table 31. GS-US-183-0145: Total Daily Dose of Elvitegravir, Boosted PI, and Ritonavir

| Elvitegravir+ProteaseInhibitorDosing(TotalDailyDose)                   | RitonavirDosing (Total Daily Dose)   |
|------------------------------------------------------------------------|--------------------------------------|
| Elvitegravir 85 mg once daily + atazanavir 300 mg once daily (300 mg)  | 100 mg once daily (100 mg)           |
| Elvitegravir 150 mg once daily + darunavir 600 mg twice daily(1200mg)° | 100 mg twice daily (200 mg)          |
| Elvitegravir 150 mg once daily +                                       | 100 mg twice daily (200 mg)          |

<!-- image -->

Study drug was to be administered in a blinded fashion up to at least Week 96 and then beyond Week 96 until the unblinding visit. Except for Spain, in which the second agent was to be fully active, the second agent in the OBR may or may not have been fully active and could have been one nucleoside or nucleotide RT inhibitor, etravirine, maraviroc or T-20. Use of any other integrase inhibitor, an NNRTI (due to unknown PK interactions) or FDCs (Atripla or Trizivir) was not allowed. If the M184V/I RT mutation was present on the screening genotype report and an NRTI was used as the second agent, then either FTC or 3TC could be added as a third agent in the OBR and appropriate FDCs were allowed. In case of suboptimal virological response (&lt; 1 log10 reduction and ≥ 50 copies/mL at Week 8) subjects were managed according to the following algorithm, which allowed continuation of the assigned integrase inhibitor with a revised OBR if no integrase resistance was detected. Figure 7. GS-US-183-0145: Suboptimal Virologic Response Schema-Blinded Phase Medicinal product no longer authorised

In case of virological rebound (drop to &lt; 50 copies/mL followed by confirmed rebound to ≥ 400 copies/mL or &gt; 1 log10 increase in HIV-1 RNA from nadir) subjects were managed according to the following algorithm, which allowed continuation of the assigned integrase inhibitor with a revised OBR if no integrase resistance was detected.

<div style=\"page-break-after: always\"></div>

Figure 8. GS-US-183-0145: Virologic Rebound Schema - Blinded Phase

<!-- image -->

•

Objectives The primary objective was to assess non-inferiority of a regimen containing RTV-boosted EVG versus RAL, each administered with OBR in HIV-1 infected, ARV-experienced adult subjects based on percentages achieving and maintaining HIV-1 RNA &lt; 50 copies/mL through Week 48. Outcomes/endpoints The primary efficacy endpoint was the percentage of subjects with HIV-1 RNA &lt; 50 copies/mL at Week 48, as defined by the TLOVR (time to loss of virologic response) algorithm. Secondary efficacy endpoints were as follows: · The percentage of subjects with HIV-1 RNA &lt; 50 copies/mL and &lt; 400 copies/mL at Weeks 48 and 96, as defined by the snapshot analysis algorithm · The achievement and maintenance of confirmed HIV-1 RNA &lt; 50 copies/mL through Week 96, as defined by TLOVR The achievement and maintenance of confirmed HIV-1 RNA &lt; 400 copies/mL through Weeks 48 and 96, as defined by TLOVR Medicinal product no longer authorised

- The time to pure virologic failure (PVF) with HIV-1 RNA cut-off at 50 copies/mL up to Weeks 48 and 96
- The time to PVF with HIV-1 RNA cut-off at 400 copies/mL up to Weeks 48 and 96
- The change from baseline in log10 HIV-1 RNA (copies/mL) at Weeks 48 and 96

<div style=\"page-break-after: always\"></div>

- The change from baseline in CD4 cell count at Weeks 48 and 96

## Sample size

A sample size of 700 subjects was planned to provide at least 85% power to establish non-inferiority of EVG vs. RAL for Week 48 virological response rates (&lt; 50 copies/mL). The pre-defined non-inferiority margin was -10%, assuming both treatments would give a response rate of 0.74. All efficacy analyses were stratified by baseline HIV-1 RNA level (≤/&gt; 100,000 copies/mL) and class of the second agent (NRTI vs. other classes).

Randomisation Randomisation was by IVRS or IWRS in a 1:1 ratio and was stratified by: · Geographic areas US and Puerto Rico vs. Others (Australia, Canada, Europe and Mexico) · Screening HIV-1 RNA level (≤ 100,000 copies/mL vs. &gt; 100,000 copies/mL) · Class of the second agent in the BR (NRTI vs. other classes) Blinding (masking) Blinding was preserved during the conduct of the study and access to unblinded data was limited to designated parties. The IDMC reviewed progress, efficacy and safety throughout study conduct but there were no formal stopping rules applied. Analyses of Week 12 and Week 48 data were conducted and the IDMC recommended that the study should continue with extension of the double-blind period to 96 weeks, as requested by the FDA. Statistical methods The Intent-to-Treat Analysis Set comprised all treated subjects except for site 4390 (see section on Conduct of the study). This was the primary analysis set for efficacy analyses. The Per Protocol Analysis Set comprised all ITT subjects with no major protocol violation. The PP analysis set was used for analyses of virological outcomes at week 48 (at &lt; 400 and &lt; 50 copies/mL) in the FDA TLOVR and snapshot algorithms. The non-inferiority evaluation of proportions that achieved HIV-1 RNA &lt; 50 copies/mL at Week 48 (FDA-defined TLOVR) was the pre-specified primary comparison. The primary analysis was initially conducted using the interim Week 48 data but was re-evaluated using the interim Week 96 data. TLOVR was analysed using the Kaplan-Meier method, stratified by baseline HIV-1 RNA level (≤100,000 copies/mL vs &gt;100,000 copies/mL) and the class of the second agent (NRTI vs other classes). The virological responses at the &lt; 50 and &lt; 400 copies/mL levels were analysed applying the Missing = Failure (M = F) and Missing = Excluded (M = E) methods. Subjects who met the following criteria were classified as pure virological responders (PVRs): Medicinal product no longer authorised

- Had achieved confirmed suppression (&lt; 50 copies/mL) on or prior to the Week 48 visit
- Did not have a confirmed rebound (≥ 50 copies/mL) after a confirmed suppression

<div style=\"page-break-after: always\"></div>

Subjects who did not achieve a PVF were assumed to have failed on Day 1. The relationship between PVF and discontinuation of study drug (DC) by Week 48 and 96 was investigated by classifying subjects according to PVR, PVF or DC alone or PVF + DC. Time to PVF was also analysed.

## Results

<!-- image -->

<!-- image -->

Pa r ticipant flow The interim Week 96 CSR includes all CRF data captured up to 31 October 2011 when the last subject completed 96 weeks of assigned study therapy and all laboratory data up to 1 December 2011. Figure 9. Subject disposition through week 96 in study 183-0145 Recruitment The study enrolled subjects at 161 study sites including 86 in the US and 49 in the EU. Up to the data cut-off more than 40% of subjects in each treatment group had discontinued, the most common reasons being non-adherence to the protocol and LTFU. Conduct of the study After study initiation the protocol (dated 29 April 2008) was amended 5 times. The most important changes included: · Amendment 1, dated 30 July 2008. Added Asia as a region for sites and Mexico as a participating country in North America. Added the criteria regarding the M184V/I RT mutation. Medicinal product no longer authorised

- Amendment 2, dated 18 February 2009. Unified GS-US-183-0144 and GS-US-183-0145. Added several secondary efficacy endpoints.
- Amendment 3, dated 05 August 2009. Changed the HIV-1 RNA reference assay from COBAS TaqMan 1.0 to the Amplicor Assay.
- Amendment 4, dated 06 July 2010. Added the optional 144-week open-label extension.

<div style=\"page-break-after: always\"></div>

- Amendment 5, dated 04 February 2011. At the request from the FDA, the blinded part of the study was extended to 96 weeks.

There were 533 important protocol deviations reported for 320 subjects. Most (203/320) had a single important deviation and the majority concerned missing 2 or more consecutive days of study drug.

Subjects enrolled at site 4390 (3 EVG and 7 RAL) were excluded from the ITT and the PP efficacy analyses due to important protocol deviations identified at that site by the Sponsor.

| no      |
|---------|
| product |

In addition to EVG or RAL &gt; 80% had at least two ARVs predicted to be active (GSS and/or PSS) against their virus in their initial OBR (taken for at least 28 days after baseline), assuming sensitivity for subjects previously naïve to maraviroc or T-20.

<!-- image -->

In the original CSR subjects who discontinued study drug due to lack of efficacy were incorrectly classified within the TLOVR outcomes under 'Drug Discontinuation due to Other Reasons' instead of under 'Virologic Failure.' The Sponsor corrected this with an amendment to the CSR (dated 30 January 2012). The changes in efficacy results are shown in tables on treatment outcomes by TLOVR analysis. Baseline data The majority of subjects were white males with median age 45 years and homosexual. The following pertains to the ITT population in the Week 96 dataset. Table 32. Subject demographics in study GS-US-183-0145 (ITT Analysis Set) About one quarter had &gt; 100,000 copies/ml at baseline with mean/median ~ 4.3 log10 copies/ml. Most subjects had HIV-1 subtype B (94%) while 22 had subtype A, 8 had G and 6 had C. The remaining 7 had other subtypes or recombinant forms of subtype B. Baseline mutational resistance data are presented in the section on Resistance Analysis . Co-infection with HBV occurred in 4.2% but 14% were co-infected with HCV. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| longer   |
|----------|

Table 33. Baseline characteristics in study GS-US-183-0145 (ITT Analysis Set)

| ARV classes of agent received within 6 months prior to screening b   | Baseline Resistance to Any of the 3 ARV Classes (NRTI, NNRTI, and PI) a   | Baseline Resistance to Any of the 3 ARV Classes (NRTI, NNRTI, and PI) a   | Baseline Resistance to Any of the 3 ARV Classes (NRTI, NNRTI, and PI) a   | Baseline Resistance to Any of the 3 ARV Classes (NRTI, NNRTI, and PI) a   | Baseline Resistance to Any of the 3 ARV Classes (NRTI, NNRTI, and PI) a   |
|----------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| ARV classes of agent received within 6 months prior to screening b   | None (N = 120)                                                            | One (N = 146)                                                             | Two (N = 304)                                                             | Three (N = 132)                                                           | Total (N = 702)                                                           |
| None                                                                 | 0                                                                         | 0                                                                         | 1                                                                         | 0                                                                         | 1                                                                         |
| One                                                                  | 5                                                                         | 17                                                                        | 21                                                                        | 9                                                                         | 52                                                                        |
| Two                                                                  | 112                                                                       | 125                                                                       | 275                                                                       | 112                                                                       | 624                                                                       |
| Three                                                                | 3                                                                         | 4                                                                         | 7                                                                         | 11                                                                        | 25                                                                        |

The majority of viruses had resistance to 2 or 3 classes of ARVs (436/702) and the majority of subjects had taken agents in 2 or 3 ARV classes in the 6 months prior to screening (649/702). Table 34. GS-US-183-0145: Number of Subjects by Baseline Resistance and by Number of ARV Drug Classes Within 6 Months Prior to Screening (ITT Analysis Set) a Four mutually exclusive groups of subjects were defined based on their baseline resistance: 1) Subjects had no resistance to all three classes of ARVs (NRTI, NNRTI, and PI); 2) Subjects had resistance to one of the three classes of ARVs; 3) Subjects had resistance to two of the three classes of ARVs; 4) Subjects had resistance to all three classes of ARVs. b Four mutually exclusive groups of subjects were defined based on their ARVs within 6 months prior to screening: 1) Subjects had not taken any of the three classes of ARVs (NRTI, NNRTI, and PI); 2) Subjects had taken only one of the three classes of ARVs; 3) Subjects had taken only two of the three classes of ARVs; 4) Subjects had taken all three classes of ARVs. The most commonly used PI was DRV while ~5% or less used either FPV or TPV and 69% used TDF. Medicinal product no longer authorised

Table 35. Background regimen in study GS-US-183-0145

| Characteristic   | EVG (N=351)   | RAL (N=351)   | Total (N=702）   | p-valuea   |
|------------------|---------------|---------------|-----------------|------------|

<div style=\"page-break-after: always\"></div>

| Type of PI in Background Regimen (Excluding Ritonavir)s.d   |              |              |              |
|-------------------------------------------------------------|--------------|--------------|--------------|
| Dannavir                                                    | 202 ( 57.5%) | 207 ( 58.8%) | 409 ( 58.2%) |
| Kaletra                                                     | 68 ( 19.4%)  | 68 (19.3%)   | 136 ( 19.3%) |
| Atazanavir                                                  | 61 ( 17.4%)  | 51 (14.5%)   | 112 (15.9%)  |
| Fosamprenavir                                               | 14 ( 4.0%)   | 19 ( 5.4%)   | 33 (μ 4.7%)  |
| Tipranavir                                                  | 6 ( 1.7%)    | 7 ( 2.0%)    | 13 (1.8%)    |
| Type ofNRTI in Background Regimen°                          |              |              |              |
| TenofovirDF                                                 | 163 ( 46.0%) | 171 (47.8%)  | 334 ( 46.9%) |

| product   |
|-----------|

About 80% of subjects who received DRV/RTV were dosed twice daily. Small numbers in the ITT analysis set received LPV/RTV or FPV/RTV once daily. Numbers analysed About 75% of the Week 96 dataset were eligible for the PP population analysis. Table 36. GS-US-183-0145: Analysis Sets (All Randomized Set, Week 96 Dataset) a Denominator for percentages is the number of subjects in the all randomized set within the treatment group. b Safety analysis set includes subjects randomized and treated with at least one dose of study drug. c Intent-to-treat (ITT) analysis set includes subjects randomized and treated with study drug and not enrolled at Site 4390. Note that 10 subjects from Site 4390 were excluded from ITT analysis set due to critical and multiple protocol violations. d Per protocol exclusion criteria are only defined for subjects in the ITT analysis set; a subject can meet more than one exclusion criteria. e All GS-9202 concentrations were BLQ and none of PK parameters were estimable. This leads to 0 subject qualified for GS-9202 PK substudy analysis set. Medicinal product no longer authorised

While 72% of all subjects had an adherence rate ≥ 90% the rates were 78.3% for EVG and 65.3% for RAL although percentages with &gt;80 to &lt; 90% adherence were 10.7% and 20.7%, respectively, suggesting broadly comparable proportions with adherence &lt; 80%.

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

The results of the primary analysis of outcomes at Week 48 were identical when using the Week 48 and the Week 96 datasets (ITT, using TLOVR algorithm) and demonstrated non-inferiority for EVG vs. RAL (95% CI -6%, 8.2%). While the rebound rate was lower in the EVG group the rate for primary failure (never suppressed) was slightly higher for EVG vs. RAL.

| no longer   |
|-------------|

Table 37. GS-US-183-0145: Treatment Outcomes at Week 48 for HIV-1 RNA Cut-off at 50 copies/mL, TLOVR Analysis (ITT Analysis Set, Week 96 Dataset). The ITT TLOVR analysis at the cut-off &lt; 50 copies/mL showed that the KM curves separated early. This reflected the subjects that never achieved &lt; 50 copies/mL who were assumed to have failed at Day 1 in the analysis. In contrast, subjects with rebound were counted as failing at the time when this occurred. Total percentages with LOVR were comparable with Week 96 KM estimates of 52% for EVG and 55% for RAL. Median TLOVR was 617 days vs. 562 days (p = 0.86), respectively. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 10. GS-US-183-0145: Time to Loss of Virologic Response with HIV-1 RNA Cut-off at 50 Copies/mL (ITT Analysis Set, Week 96 Dataset)

<!-- image -->

<!-- image -->

| Medicinal   |
|-------------|

Non-inferiority for EVG vs. RAL at Week 48 for percentages achieving &lt; 50 copies/mL was also demonstrated in the PP TLOVR analysis using the Week 96 dataset. Actual success rates were higher vs. the ITT population but the difference between treatments and the 95% CI were almost identical. Table 38. Treatment outcomes at week 48 for HIV-1 RNA cutoff at 50 copies/mL, TLOVR Analysis PP Analysis Set Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

The percentages maintaining &lt; 50 copies/mL at Week 96 (TLOVR analysis, ITT) were comparable between treatments. Virological failure was reported less frequently in the EVG group due to the lower rebound rate.

Table 39. GS-US-183-0145: Treatment Outcomes at Week 96 for HIV-1 RNA Cut-off at 50 copies/mL, TLOVR Analysis (ITT Analysis Set, Week 96 Dataset).

<!-- image -->

Responses at the &lt; 400 copies/ml level at Week 48 were identical using either the Week 48 or Week 96 datasets (TLOVR; ITT) and reflected the corresponding analyses based on the cut-off of &lt; 50 copies/mL. At Week 96 43% EVG and 44% RAL subjects had loss of virological response at the 400 copies/mL level with median TLOVR of 1011 vs. 1009 days, respectively. Percentages maintaining &lt; 400 copies/mL at Week 96 were 57.0% EVG and 56.1% RAL (stratum-adjusted difference 0.9% and 95% CI -6.4% to 8.2%). In the PP analysis percentages maintaining &lt; 400 copies/mL at Week 48 were 85.6% EVG and 85.4% RAL with a stratum-adjusted difference of 0.2% and 95% CI -5.8% to 6.2%. In addition to TLOVR analysis the results were assessed also with snapshot analysis. Using the Week 96 dataset, the percentages with &lt; 50 copies/mL at Week 48 (snapshot analysis, ITT) were identical to those using the Week 48 dataset and comparable between treatments (EVG 59.8% vs. RAL 57.5%; stratum-adjusted difference 2.2%, 95% CI -5.0% to 9.3%). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 40. GS-US-183-0145: Snapshot Analysis of Subjects with HIV-1 RNA &lt;50 copies/mL at Week 48 (ITT Analysis Set, Week 96 Dataset).

|                           |              |             | EVGVs.RAL   | EVGVs.RAL            |
|---------------------------|--------------|-------------|-------------|----------------------|
| VirologicResponseatWeek48 | EVG (N=351)  | RAL (N=351) | p-valuea    | Prop Diff (95% CI)b  |
| VirologicSuccessatWeek48  |              |             |             |                      |
| HIV-1 RNA< 50 copies/mL   | 210 ( 59.8%) | 202 (57.5%) | 0.55        | 2.2% (-5.0% to 9.3%) |

<!-- image -->

Comparability between treatments was maintained in the ITT snapshot analysis for percentages &lt; 50 copies/mL at Week 96. Table 41. GS-US-183-0145: Snapshot Analysis of Subjects with HIV-1 RNA &lt;50 copies/mL at Week 96 (ITT Analysis Set, Week 96 Dataset) Medicinal product no longer authorised

Using the Week 96 dataset and the PP analysis set the percentages with &lt; 50 copies/mL at Week 48 (snapshot analysis) were 76.3% EVG and 72.8% RAL (difference 3.7%, 95% CI -3.6% to 10.9%). The corresponding analyses for percentages at &lt; 400 copies/mL applying the snapshot analysis approach at Week 48 and Week 96 and in the ITT and PP populations gave very comparable findings to those reported above for &lt; 50 copies/mL.

<div style=\"page-break-after: always\"></div>

The KM curves for time to PVF using the cut-off 50 copies/mL separated early for the same reasons as in the primary analysis. At Week 96, the KM estimates for the percentages with PVF were 45% for the EVG group and 46% for the RAL group. The median time to PVF was 1014 days in the EVG group and 961 days in the RAL group (p = 0.99). The KM estimates for the time to PVF using the cut-off 400 copies/mL at Week 96 were comparable between treatments. At Week 96 the KM estimates for the percentages of subjects with PVF were 32% for the EVG group and 31% for the RAL group.

| no      |
|---------|
| product |

Comparable percentages in each treatment group: · Were classified as PVR (Week 48 EVG 59.3% vs. RAL 58.1%; Week 96 47.9% vs. 45.3%). · Had PVF alone (Week 48 EVG 16.5% vs. RAL 17.9%; Week 96 15.7% vs. 17.1%). · Were considered failures due to DC alone (Week 48 EVG 4.6% vs. RAL 6.0%; Week 96 8.3% vs. 9.4%). · Were considered failures due to a combination of PVF and DC (Week 48 EVG 19.7% vs. RAL 17.9%; Week 96 28.2% in each group). The percentage of subjects with HIV-1 RNA &lt; 50 copies/mL was comparable between treatment groups at each time point using M = F or M = E methods and the ITT analysis set. Similar findings resulted from corresponding analyses at the &lt; 400 copies/mL cut-off. Table 42. GS-US-183-0145: Subjects with HIV-1 RNA &lt;50 copies/mL by Study Visit (Missing=Failure and Missing=Excluded) (ITT Analysis Set, Week 96 Dataset). The change from baseline in plasma HIV-1 RNA levels was highly comparable between treatments. At Week 96, the mean (SD) decreases from baseline in HIV-1 RNA were -2.26 (1.078) log10 copies/mL in the EVG group and -2.31 (1.068) log10 copies/mL in the RAL group. The difference in least-squares means (LSM) was 0.05, and the 95% CI was -0.12 to 0.22. Medicinal product no longer authorised

Mean increases from baseline in CD4 cell counts were comparable between treatments at all time points. At Week 96 the mean increases from baseline in CD4 cell count were 205 cells/μL in the EVG group and 198 cells/μL in the RAL group. The difference in LSM was 7 (95% CI: -25, 39).

<div style=\"page-break-after: always\"></div>

## Subgroup analyses

Results according to class resistance at baseline: as only 53 of 702 subjects (7.5%) had received agents from none (1) or 1 ARV class (52) in the 6 months prior to screening, further analyses of efficacy by the various combinations of baseline resistance and treatment history were not considered meaningful.

| Baseline Resistance to ARV Classes   | EVG (N=351)     | RAL (N=351)    | EVG vs. RAL      | EVG vs. RAL                          |
|--------------------------------------|-----------------|----------------|------------------|--------------------------------------|
|                                      |                 |                | p- value a       | Difference in Percentages (95% CI) b |
| None                                 | 31/63 (49.2%)   | 33/57 (57.9%)  | 0.48             | -6.0% (-23.1% to 11.1%)              |
| One                                  | 29/65 (44.6%)   | 32/81 (39.5%)  | 0.44             | 6.3% (-9.7% to 22.2%)                |
| Two                                  | 111/163 (68.1%) | 85/141 (60.3%) | 0.24 6.5% (-4.3% | to 17.2%)                            |
| Three                                | 39/60 (65.0%)   | 52/72 (72.2%)  | 0.42             | -6.5% (-22.7% to 9.6%)               |

The virological success rates at Week 48 were similar in the EVG and RAL treatment groups in each subgroup shown in the table. Table 43. GS-US-183-0145: Virological success at week 48 by Baseline Resistance by Drug Class (Snapshot Analysis; ITT Analysis Set), n/N (%) Baseline Resistance to ARV Classes None One Two Three a The p-value is estimated from a Cochran-Mantel-Haenszel (CMH) test for superiority. b The difference in proportions and its 95% confidence intervals (CIs) between randomized treatment groups are based on stratum-adjusted (by baseline HIV-1 RNA level [ ≤ 100,000 or &gt; 100,000 copies/mL]) Mantel Haenszel (MH) proportions and normal approximation. Virological success rates were slightly higher in both treatment groups for those with resistance to 2 or 3 classes at baseline compared with no resistance or resistance to 1 class. These differences were mainly due to the rates of study drug discontinuation due to other reasons (noncompliance, lost to follow-up, withdrew consent, protocol violation, investigator's discretion, and pregnancy). These discontinuation rates for 2 or 3 class resistance were 14.8% in the EVG group (33/223) and 9.9% (21/213) in the RAL group. Rates for 0 or 1 class resistance were 23.4% in the EVG group (30/128) and 23.9% in the RAL group (33/138). It was hypothesised that subjects with more treatment options at baseline (0 to 1 class resistance) may have been less motivated to remain in the study than subjects with few options (2 or 3 class resistance) due to the availability of active agents outside of the study i.e. motivation to remain in the study may have been strongest for the most treatment-experienced patients failing current therapy. Other subgroup analyses (see summary diagram below for Week 48) revealed generally comparable rates of virological success between treatments. Point estimates mostly favoured the EVG group. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 11. GS-US-183-0145: Forest Plot of Treatment Difference and 95% Cl by Subgroup for Virological response at Week 48, TLOVR outcome (ITT Analysis Set).

<!-- image -->

## Results according to the EVG dose and the PI used

While sample sizes in many cases were small and the breadth of the 95% CI should be taken into account, some observations regarding response rates in various subgroups were as follows (Week 48 at &lt; 50 copies/mL using snapshot approach and ITT analysis): · While higher response rates were observed for those with ≤ 100,000 copies/mL at baseline (EVG 65.5% vs. RAL: 64.4%) vs. &gt; 100,000 copies/mL (43.3% vs. 37.8%) and in those with baseline CD4 &gt; 200 cells/µL (69.8% and 68.1% vs. 47.7% and 46.4%) it was unexpected that higher response rates occurred with baseline GSS ≤ 1 (EVG 75.9% vs. RAL 68.5%) compared to GSS &gt; 1 (57.1% vs. 55.6%). · Higher response rates were observed for those from outside the US and Puerto Rico (EVG 73.3% vs. RAL 64.2%) vs. those in the US and Puerto Rico (52.8% vs. 53.9%). Both treatments gave slightly lower responses in non-white (50.0% and 54.4%) vs. white subjects (66.4% and 59.3%). · Among female subjects the response rate was lower in the EVG group (28/59; 47.5% vs. RAL 42/67; 62.7%). However, response rates among male subjects were 62.3% vs. 56.3%, respectively. · Broadly comparable response rates were observed in subjects &gt; 45 years of age (EVG: 63.3% vs. RAL 60.4%) vs. those aged ≤ 45 years (57.4% vs. 54.9%). · Broadly comparable response rates occurred in subjects who were not taking an NRTI (EVG 66.2% vs. RAL 63.0%) compared to those taking an NRTI (58.2% vs. 56.1%). Lover response rates in women were observed also at week 96. Medicinal product no longer authorised

Responses according to the EVG dose (85 mg or 150 mg) and the PI/r used revealed similar rates of virological success for EVG and RAL within each PI subgroup at Weeks 48 and 96. The 95% CIs for treatment differences in virological success included zero for all PI subgroups and supported similar efficacy of EVG and RAL in combination with a range of PIs.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 44. GS-US-183-0145: Virological Success by PI at Weeks 48 and 96 (Snapshot ITT)

|                                   |                                | RAL                            | EVG vs. RAL                    | EVG vs. RAL                        |
|-----------------------------------|--------------------------------|--------------------------------|--------------------------------|------------------------------------|
| HIV-1 RNA < 50 copies/mL, n/N (%) | EVG (N=351)                    | (N=351)                        | p-value                        | Difference in Percentages (95% CI) |
| Virological Success at Week 48    | Virological Success at Week 48 | Virological Success at Week 48 | Virological Success at Week 48 | Virological Success at Week 48     |
| Darunavir                         | 126/202 (62.4%)                | 122/207 (58.9%)                | 0.48                           | 3.4% (-6.0% to 12.9%)              |
| Lopinavir                         | 39/68 (57.4%)                  | 37/68 (54.4%)                  | 0.73                           | 2.9% (-13.7% to 19.6%) authorised  |
| Atazanavir                        | 34/61 (55.7%)                  | 28/51 (54.9%)                  | 0.93                           | 0.8% (-17.7% to 19.3%)             |
| Fosamprenavir                     | 8/14 (57.1%)                   | 10/18 (55.6%)                  | 0.93                           | 1.6% (-33.0% to 36.2%)             |
| Tipranavir                        | 3/6 (50.0%)                    | 5/7 (71.4%)                    | 0.45                           | -21.4% (-73.6% to 30.7%)           |
| Virological Success at Week 96    | Virological Success at Week 96 | Virological Success at Week 96 | Virological Success at Week 96 | Virological Success at Week 96     |
| Darunavir                         | 105/202 (52.0%)                | 112/207 (54.1%)                | 0.67                           | -2.1% (-11.8% to 7.5%)             |
| Lopinavir                         | 36/68 (52.9%)                  | 37/68 (54.4%)                  | 0.86                           | -1.5% (-18.2% to 15.3%)            |
| Atazanavir                        | 33/61 (54.1%)                  | 23/51 (45.1%)                  | 0.34                           | 9.0% (-9.5% to 27.5%)              |
| Fosamprenavir                     | 7/14 (50.0%)                   | 11/18 (61.1%)                  | 0.54                           | -11.1% (-45.7% to 23.4%)           |
| Tipranavir                        | 3/6 (50.0%)                    | 3/7 (42.9%) longer             | 0.80                           | 7.1% (-47.1% to 61.4%)             |

|                                                                                             | EVG             | EVG               | RAL             | RAL               |
|---------------------------------------------------------------------------------------------|-----------------|-------------------|-----------------|-------------------|
| Virological Outcome by DRV Dosing Frequency, Snapshot Analysis Medicinal                    | DRV QD (N = 37) | DRV BID (N = 165) | DRV QD (N = 41) | DRV BID (N = 166) |
| Virological Success at Week 48                                                              |                 |                   |                 |                   |
| HIV-1 RNA < 50 copies/mL                                                                    | 17 (45.9%)      | 109 (66.1%)       | 24 (58.5%)      | 98 (59.0%)        |
| Virological Failure at Week 48                                                              | 17 (45.9%)      | 45 (27.3%)        | 13 (31.7%)      | 48 (28.9%)        |
| HIV-1 RNA >= 50 copies/mL                                                                   | 4 (10.8%)       | 24 (14.5%)        | 9 (22.0%)       | 31 (18.7%)        |
| Discontinued Study Drug Due to Lack of Efficacy                                             | 1 (2.7%)        | 4 (2.4%)          | 0               | 2 (1.2%)          |
| Discontinued Study Drug Due to Other Reasons and Last Available HIV-1 RNA >= 50 copies/mL a | 11 (29.7%)      | 17 (10.3%)        | 4 (9.8%)        | 13 (7.8%)         |

In the large subset given twice daily DRV the virological response rates were slightly numerically higher with EVG vs. RAL. In contrast, although once daily DRV+RAL gave response rates at least as good as with twice daily DRV there was a markedly lower response rate with EVG. The difference was ascribed mainly to the effect of rates of study drug discontinuation due to other reasons. Table 45. GS-US-183-0145: Virological Outcomes by DRV Dosing Frequency at Week 48 (Snapshot Analysis; ITT Analysis Set) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                                                                                | EVG             | EVG               | RAL             | RAL                  |
|------------------------------------------------------------------------------------------------|-----------------|-------------------|-----------------|----------------------|
| Virological Outcome by DRV Dosing Frequency, Snapshot Analysis                                 | DRV QD (N = 37) | DRV BID (N = 165) | DRV QD (N = 41) | DRV BID (N = 166)    |
| HIV-1 RNA >= 50 copies/mL at Background Regimen Switch and HIV-1 RNA < 50 copies/mL at Week 48 | 1 (2.7%)        | 0                 | 0               | 2 (1.2%)             |
| No Virological Data in Week 48 Window                                                          | 3 (8.1%)        | 11 (6.7%)         | 4 (9.8%)        | 20 (12.0%)           |
| Discontinued Study Drug Due to AE or Death                                                     | 0               | 5 (3.0%)          | 2 (4.9%)        | 12 (7.2%) authorised |
| Discontinued Study Drug Due to Other Reasons and Last Available HIV-1 RNA < 50 copies/mL a     | 3 (8.1%)        | 5 (3.0%)          | 2 (4.9%)        | 6 (3.6%)             |
| Missing Data During Window but on Study Drug                                                   | 0               | 1 (0.6%)          | 0               | 2 (1.2%)             |

Background Regimen Switch and HIV-1 RNA &lt; 50 copies/mL at Week 48 No Virological Data in Week 48 Window Discontinued Study Drug Due to AE or Death Discontinued Study Drug Due to Other Reasons and Last Available HIV-1 RNA &lt; 50 copies/mL a Missing Data During Window but on Study Drug a Discontinued  study  drug  for  other  reason  includes  subjects  who  discontinued  due  to  subject  non-compliance,  lost  to follow-up, withdrew consent, protocol violation, investigator's discretion, and pregnancy. A few subjects received EVG (n = 1) or RAL (n = 5) with LPV/r once daily. The subjects received 800/200 mg LPV/r per administration, which is the same total daily dose of LPV as 400/100 mg twice daily. Resistance analysis Viruses from all subjects screened were analysed for pre-existing resistance in the protease and RT portion of the pol gene using the PhenoSense GT assay. These pre-study isolates showed that the highest level of genotypic resistance observed was in the NAMs category (70%) and the M184V/I mutation was the most prevalent (57%). PI-R mutations were detected in 32%. Only 17% had no resistance mutations in protease or RT at baseline. Overall, 21% had genotypic resistance to a single class (one of PI, NNRTI or NRTI), 43% to two classes of antiviral agents, 64% to one or two classes and 19% to all three classes. Rates were comparable between treatment groups. There were 180 subjects included in the Week 96 cumulative analysis population (RAP) (87 EVG and 93 RAL) and integrase genotypic data were available for 86 and 92, respectively. Development of INSTI-R mutations occurred at similarly low rates (EVG 6.6%, RAL 7.4%). The most frequent mutations observed in the EVG group were T66I/A and E92Q/G while the most frequent in the RAL group were N155H and Q148H. The mutations T66I/A, S147G, and Q148R were found exclusively in the EVG group, Y143R/H/C and Q148H were found exclusively in the RAL group while E92Q/G, T97A and N155H were observed in both treatment groups. Although development of integrase resistance at position Q148 was seen in both treatment groups there were distinct amino acid changes (EVG Q148R, RAL Q148H), suggesting that EVG and RAL may bind the HIV-1 integrase enzyme differentially near that residue. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 46. GS-US-183-0145: Development of HIV-1 Integrase Resistance Mutations (Week 96 Dataset).

|                                 | Number of Subjects (% Subjects; % RAP with Data)   | Number of Subjects (% Subjects; % RAP with Data)   | Number of Subjects (% Subjects; % RAP with Data)   | Number of Subjects (% Subjects; % RAP with Data)   |
|---------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Resistance Development Category | Year 2Analysis (Week48toWeek96)                    | Year 2Analysis (Week48toWeek96)                    | CumulativeAnalysis (Baseline toWeek96)             | CumulativeAnalysis (Baseline toWeek96)             |
| Resistance Development Category | EVG (n =351)                                       | RAL (n =351)                                       | EVG (n =351)                                       | RAL (n=351)                                        |

Approximately 75% in the RAP had no primary HIV-1 integrase resistance mutations in their viruses. The baseline PR/RT resistance profiles of these viruses were significantly less likely to have baseline PR/RT resistance mutations compared to those that acquired INSTI-R or non-RAP subjects. The applicant concluded that these data suggest that those with virological failure without INSTI-R in their viruses may have been non-adherent. While those with INSTI-R were reported to have discontinued from study drug primarily due to lack of efficacy those without INSTI-R primarily discontinued due to study adherence related reasons (e.g. lost to follow-up, noncompliance, protocol violation). In the phenotypic analysis of resistance paired viruses from the 180 RAP subjects and baseline samples from 156 subjects were analysed. Overall, the presence of genotypic resistance correlated well with the presence of phenotypic resistance. Low fold changes were associated with genotypic mutations that were present as mixtures with wild-type. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 47. GS-US-183-0145: Integrase Phenotypic Analyses by Week 96

| Integrase Development   | Phenotypic Data   | BaselineFoldChangefromControl   | BaselineFoldChangefromControl   | BaselineFoldChangefromControl   | BaselineFoldChangefromControl   | BaselineFoldChangefromControl   | BaselineFoldChangefromControl   | PostbaselineFold ChangefromControlb   | PostbaselineFold ChangefromControlb   | PostbaselineFold ChangefromControlb   | PostbaselineFold ChangefromControlb   | PostbaselineFold ChangefromControlb   | PostbaselineFold ChangefromControlb   |
|-------------------------|-------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                         | Treatment         | EVG                             | EVG                             | RAL                             | RAL                             | All                             | All                             | EVG                                   | EVG                                   | RAL                                   | RAL                                   | All                                   | All                                   |
| Categorya               | Drug              | EVG                             | RAL                             | EVG                             | RAL                             | EVG                             | RAL                             | EVG                                   | RAL                                   | EVG                                   | RAL                                   | EVG                                   | RAL                                   |
| INSTI-R                 | N (N with data)   | 20 (17)                         | 20 (17)                         | 21 (21)                         | 21 (21)                         | 41 (38)                         | 41 (38)                         | 23 (20)                               | 23 (20)                               | 26 (23)                               | 26 (23)                               | 49 (43)                               | 49 (43)                               |
| INSTI-R                 | Mean              | 1.3                             | 1                               | 1.2                             | 0.9                             | 1.2                             | 0.9                             | 23.7                                  | 4.8                                   | 75.1                                  | 50.5                                  | 51.2                                  | 29.2                                  |
| INSTI-R                 | Range             | 0.79 -                          | 0.59 -                          | 0.85-                           | 0.37 -                          | 0.79 -                          | 0.37 -                          | 1.63 -                                | 0.6-53                                | 1.21 -                                | 1.08 -                                | 1.21 -                                | 0.6 -                                 |
| INSTI-R                 |                   |                                 |                                 |                                 |                                 |                                 |                                 |                                       |                                       |                                       |                                       |                                       |                                       |

| L90M   | 0   | 1 (1.1%)   | 1 (0.6%)   |
|--------|-----|------------|------------|

In the RAL group 21/23 viruses that developed INSTI-R mutations had phenotypic resistance to RAL and 20/23 exhibited cross-resistance to EVG. In the EVG group 14/20 viruses that developed INSTI-R mutations had phenotypic resistance to EVG and 11/20 displayed cross-resistance to both drugs. Four subjects (2 per treatment group) had virus showing EVG fold-change above 2.5 (range 2.58 to 5.51) at baseline or post-baseline in the absence of INSTI resistance mutations. These increases were thought to reflect natural variability within the assay rather than actual phenotypic resistance. Development of NRTI-R, NNRTI-R, and PI-R occurred in 12.2%, 11.6% and 5.8%, respectively. Ten viruses acquired PI-R mutations (5 per group) of which 6/10 had PI-R at baseline. Table 48. GS-US-183-0145: Development of Protease and RT Genotypic Resistance (Week 96 Dataset). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Open label extension

In the ongoing open-label extension period all subjects wishing to continue on study drug at unblinding were offered an EVG-based regimen. There were 98 subjects (51 EVG and 47 RAL) in the Week 96 dataset for whom data were available up to 144 weeks. Proportions that maintained &lt; 50 copies/mL at week 144 were similar in the EVG and RAL treatment groups. The mean (SD) increases from baseline in CD4 cell counts were also similar between treatment groups at Week 144 (EVG 243 [185.4] cells/mm 3  [n = 49], RAL 246 [156.1] cells/mm 3  [n = 46]).

| Subjects with < 50 copies/mL b   | EVG (N=351)    | RAL (N=351)    | EVG vs RAL Proportion Difference (95% CI) a   |
|----------------------------------|----------------|----------------|-----------------------------------------------|
| HIV-1 RNA < 50 copies/mL         | 44/51 (86.3%)  | 40/47 (85.1%)  | 1.5% ( - 13.9% to 16.9%)                      |
| 95% CI c                         | 73.7% to 94.3% | 71.7% to 93.8% |                                               |

| Title : Safety and Efficacy of Ritonavir-Boosted Elvitegravir Versus Raltegravir Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults   | Title : Safety and Efficacy of Ritonavir-Boosted Elvitegravir Versus Raltegravir Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults   | Title : Safety and Efficacy of Ritonavir-Boosted Elvitegravir Versus Raltegravir Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults   | Title : Safety and Efficacy of Ritonavir-Boosted Elvitegravir Versus Raltegravir Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                              | GS-US-183-0145 (EudraCT No. 2007-004225-26)                                                                                                                                                   | GS-US-183-0145 (EudraCT No. 2007-004225-26)                                                                                                                                                   | GS-US-183-0145 (EudraCT No. 2007-004225-26)                                                                                                                                                   |
| Design                                                                                                                                                                                        | Phase 3, double-blind, double-dummy, multicentre, randomized, active- controlled study                                                                                                        | Phase 3, double-blind, double-dummy, multicentre, randomized, active- controlled study                                                                                                        | Phase 3, double-blind, double-dummy, multicentre, randomized, active- controlled study                                                                                                        |
|                                                                                                                                                                                               | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                | 96 weeks not applicable 144 weeks                                                                                                                                                             |
| Hypothesis                                                                                                                                                                                    | Non-inferiority                                                                                                                                                                               | Non-inferiority                                                                                                                                                                               | Non-inferiority                                                                                                                                                                               |
| Treatments groups                                                                                                                                                                             | Elvitegravir (EVG) group                                                                                                                                                                      | Elvitegravir (EVG) group                                                                                                                                                                      | Treatment: EVG 150 mg once daily (85 mg once daily for subjects taking ATV/r or LPV/r as part of BR) + BR Duration: 96 weeks (double blind phase) Number randomized and treated: 354          |
|                                                                                                                                                                                               | Raltegravir (RAL) group                                                                                                                                                                       | Raltegravir (RAL) group                                                                                                                                                                       | Treatment: RAL 400 mg twice daily + BR Duration: 96 weeks (double blind phase) Number randomized and treated: 358                                                                             |
| Endpoints and definitions                                                                                                                                                                     | Primary endpoint                                                                                                                                                                              | VR W48 TLOVR                                                                                                                                                                                  | Virologic response (percentage of subjects with HIV-1 RNA < 50 copies/mL) at Week 48, by TLOVR algorithm                                                                                      |
|                                                                                                                                                                                               | Secondary endpoint                                                                                                                                                                            | VR W48 snapshot                                                                                                                                                                               | Virologic response at Week 48, by snapshot algorithm                                                                                                                                          |

Table 49. GS-US-183-0145: Subjects with &lt; 50 copies/mL at Week 144 (M=E, ITT Analysis Set, Week 96 Dataset) a The difference in proportions and its 95% CIs between randomized treatment groups are based on stratum-adjusted (by baseline HIV-1 RNA level [ ≤ 100,000 or &gt; 100,000 copies/mL] and the class of second agent [NRTI or other classes]) Mantel Haenszel (MH) proportions and normal approximation. b Denominator for percentage is the number of ITT subjects (subjects with missing HIV-1 RNA data are excluded). c The 95% CIs for the proportion estimate for a treatment group are based on the Exact method. Summary of the main study The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections). Table 5. Summary of Efficacy for trial GS-US-183-0145 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Database lock

Secondary endpoint

Secondary endpoint

Virologic response at Week 96, by snapshot algorithm

Mean change from baseline in CD4 cell count at week 96

01 December 2011 (for week 96 data)

## Results and Analysis

2.5.3. Supportive studies Study GS-US-183-0130 This was an extension study that enrolled 192 HIV-infected subjects who had completed a prior EVG/r study (either GS-US-183-0105 or the adolescent study 0152) and wished to start (30) or continue to receive (162) RTV-boosted EVG as part of their total regimen. The focus was on safety and on evaluating PK in a subset of 40 subjects that received 300 mg daily instead of 150 mg daily. Subjects included had variable past treatment, baseline HIV-1 RNA &lt; 50 copies/mL (n = 84) and ≥ 50 copies/mL (n = 107). There was a high attrition rate (79/192) for reasons other than lack of efficacy or death (50/79). Medicinal product no longer authorised

| Analysis description                            | Primary and Secondary Analysis                                                                                      | Primary and Secondary Analysis                                                                                      | Primary and Secondary Analysis                                                                                      | Primary and Secondary Analysis                                                                                      |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | Modified intent to treat (subjects randomised and treated, excluding subjects from one site (site 4390)) authorised | Modified intent to treat (subjects randomised and treated, excluding subjects from one site (site 4390)) authorised | Modified intent to treat (subjects randomised and treated, excluding subjects from one site (site 4390)) authorised | Modified intent to treat (subjects randomised and treated, excluding subjects from one site (site 4390)) authorised |
| Descriptive statistics and estimate variability | Treatment group                                                                                                     | Treatment group                                                                                                     | EVG group                                                                                                           | RAL group                                                                                                           |
| Descriptive statistics and estimate variability | Number of subject                                                                                                   | Number of subject                                                                                                   | 351                                                                                                                 | 351                                                                                                                 |
| Descriptive statistics and estimate variability | VR W48 TLOVR (%)                                                                                                    | VR W48 TLOVR (%)                                                                                                    | 59.0                                                                                                                | 57.8                                                                                                                |
| Descriptive statistics and estimate variability | variability statistic                                                                                               | variability statistic                                                                                               | Not reported                                                                                                        | Not reported                                                                                                        |
| Descriptive statistics and estimate variability | VR W48 snapshot (%)                                                                                                 | VR W48 snapshot (%)                                                                                                 | 59.8                                                                                                                | 57.5                                                                                                                |
| Descriptive statistics and estimate variability | variability statistic                                                                                               | variability statistic                                                                                               | Not reported                                                                                                        | Not reported                                                                                                        |
| Descriptive statistics and estimate variability | VR W96 snapshot (%)                                                                                                 | VR W96 snapshot (%)                                                                                                 | 52.4                                                                                                                | 53.0                                                                                                                |
| Descriptive statistics and estimate variability | variability statistic                                                                                               | variability statistic                                                                                               | Not reported                                                                                                        | Not reported                                                                                                        |
| Descriptive statistics and estimate variability | CD4 W96 (cells/mm3)                                                                                                 | CD4 W96 (cells/mm3)                                                                                                 | +205                                                                                                                | +198                                                                                                                |
| Descriptive statistics and estimate variability | standard deviation                                                                                                  | standard deviation                                                                                                  | 191.5                                                                                                               | 162.2                                                                                                               |
| Effect estimate per comparison                  | Comparison groups EVG group vs. RAL group                                                                           | Comparison groups EVG group vs. RAL group                                                                           | Comparison groups EVG group vs. RAL group                                                                           | Comparison groups EVG group vs. RAL group                                                                           |
| Effect estimate per comparison                  | Primary endpoint                                                                                                    | Difference in VR W48 TLOVR                                                                                          | Difference in VR W48 TLOVR                                                                                          | 1.1%                                                                                                                |
| Effect estimate per comparison                  | Primary endpoint                                                                                                    | 95% CI                                                                                                              | 95% CI                                                                                                              | -6.0% to 8.2%                                                                                                       |
| Effect estimate per comparison                  | Primary endpoint                                                                                                    | P-value                                                                                                             | P-value                                                                                                             | 0.76                                                                                                                |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                  | Difference in VR W48 snapshot 95% CI longer                                                                         | Difference in VR W48 snapshot 95% CI longer                                                                         | 2.2% -5.0% to 9.3%                                                                                                  |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                  | P-value                                                                                                             | P-value                                                                                                             | 0.55                                                                                                                |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                  | Difference in VR W96 snapshot                                                                                       | Difference in VR W96 snapshot                                                                                       | -0.5%                                                                                                               |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                  | 95% CI                                                                                                              | 95% CI                                                                                                              | -7.9% to 6.8%                                                                                                       |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                  | P-value                                                                                                             | P-value                                                                                                             | 0.88                                                                                                                |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                  | Difference in CD4 W96                                                                                               | Difference in CD4 W96                                                                                               | 7                                                                                                                   |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                  | 95% CI                                                                                                              | 95% CI                                                                                                              | -25 to 39                                                                                                           |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                  | P-value no                                                                                                          | P-value no                                                                                                          | Not reported                                                                                                        |
| Effect estimate per comparison                  |                                                                                                                     |                                                                                                                     |                                                                                                                     |                                                                                                                     |

Among the 84 with &lt; 50 copies/mL at study entry the suppression rates at Weeks 48, 96, 144 and 192 were 86.6%, 76.8%, 72.0% and 68.3%, respectively (M = F analysis). Rates were higher (89.9%, 86.3%, 88.1% and 90.3%) in the M = E analysis with corresponding rates for the 107 subjects with ≥ 50 copies/mL at entry that were 36.1%, 46.0%, 58.8% and 70.5%. CD4 cell counts increased over time in both subgroups.

The majority of resistance development was characterised as an evolution of RT, protease and integrase resistance that had existed prior to study entry in subjects who were not fully suppressed on their regimen. With regards to integrase resistance, mutation patterns were observed to evolve

VR W96

snapshot

CD4 W96

<div style=\"page-break-after: always\"></div>

resulting in a general increase in the level of phenotypic resistance. In subjects who entered the study with fully suppressed HIV-1 RNA, integrase resistance development was infrequent (3/84 subjects) and was observed along with evolution of RT and/or protease resistance that was present prior to EVG therapy.

## 2.5.4. Discussion on clinical efficacy

The subgroup analyses indicated some differences between EVG and RAL as well as unexpected results for both compounds in some subsets (e.g. baseline GSS 0 or 1 vs. &gt; 1, whites vs. non-whites and US/Puerto Rico sites vs. other sites). While it seems difficult to ascribe all these findings to chance and/or to the relatively small sample sizes in some subgroups, the overall comparisons between EVG and RAL and the comparisons by PI subgroup are reassuring. The observed trend towards lower efficacy in women, however, is a potential concern - available data have been highlighted in the SmPC and this has been included in the RMP as a potential risk. Since no possible mechanism could be identified for lower efficacy in women, this is likely to be a chance finding and further action currently is not warranted.

Design and conduct of clinical studies Study GS-US-183-0105 was a randomised, partially blinded, multicentre study to assess non-inferiority of EVG/RTV vs. CPI/RTV when administered with an OBR. These data are not of great relevance to the indication claimed, and are difficult to interpret for efficacy due to the study design. At the time that the protocol for the pivotal study GS-US-183-0145 was developed (with initiation in 2008) boosted PIs were and still are not very commonly used for first line treatment and a study in subjects failing their current ART regimen (HIV-1 RNA ≥ 1000 copies/mL) was planned. Due to the range of new agents that were already available it was not considered possible to use an add-on superiority vs. placebo design therefore as the objective it was chosen to demonstrate non-inferiority for EVG vs. RAL when each was co-administered with one RTV-boosted PI predicted to be fully active plus a third agent. The pre-defined non-inferiority margin was derived by review of the Phase 3 RAL and etravirine (ETV) studies in treatment-experienced subjects. Taking into account differences in study populations and the content of treatment regimens the rationale for the pre-defined non-inferiority margin is questionable. Nevertheless, in a population that was failing treatment at study entry the actual lower bound of the 95% CI around the treatment differences at the &lt; 50 copies/mL level (TLOVR analysis at week 48, using week 96 ITT dataset) was -6.0%. This result serves to differentiate an active treatment regimen from placebo and could be viewed as representing an acceptable difference between integrase inhibitors. These results were supported by the Week 96 data. Efficacy data and additional analyses While the performance of the comparator was not as expected from prior RAL studies in similar populations, GS-US-183-0145 was conducted under very different circumstances. It is pertinent that just over 40% of subjects had discontinued by week 96 (the rate was already ~30% by week 48) and non-adherence, withdrawal of consent and LTFU accounted for the majority of cases. These rates of discontinuation, however, are not surprising in light of the availability of licensed treatments, which likely made it less attractive to comply with the burden of study visits and procedures. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

This study allowed use of any of five RTV-boosted PIs and was not designed (and hence not powered) to assess non-inferiority by PI subset. In principle, this could be acceptable to support the indication claimed taking into account that (with the discussed exception of use of EVG with TPV/r):

- Comparable proportions in EVG and RAL groups received each of the PIs allowed and other features of the population, ART regimens and GSS/PSS scores were comparable between integrase inhibitor groups

With a focus on the safety data for EVG when co-administered with an RTV-boosted PI, the principal safety data come from the Week 96 dataset of GS-US-183-0145. By Week 96 ~ 40% of subjects had discontinued. Additional supportive safety data are provided by studies GS-US-183-0105 and GS-US183-0130. Also, in the Phase 1 studies 1064 subjects were exposed to EVG (not including QUAD STR),

· The use of EVG with each of the recommended PI/r is supported by adequate PK data · There are supportive efficacy data (i.e. from short-term EVG monotherapy and STB studies) The data on use of EVG in combination with TPV/r is very limited, and 3 of the 6 patients in this group failed the treatment. The use of this combination therefore cannot be recommended. 2.5.5. Conclusions on the clinical efficacy EVG achieved a 2-log drop in HIV RNA over 10 days when administered as 50 mg EVG plus 100 mg RTV daily in the short-term monotherapy study. When used at an appropriate dose regimen to treat susceptible virus it could be expected to contribute to the overall effect of an ART regimen, including co-administration with RTV-boosted PIs as proposed by the applicant. Taking into account also the data from study GS-US-183-0145, EVG may be considered as an alternative to the only currently licensed integrase inhibitor (raltegravir). The clinical efficacy programme for EVG was decided upon at a time of transition with regard to study feasibility and regulatory guidance. This led to conduct of a single pivotal study in which EVG was coadministered with one of five RTV-boosted PIs predicted to be active against the individual subject's virus plus at least one other agent. Overall, this study demonstrated comparable efficacy for EVG vs. RAL, with a lower bound of the 95% CI around the treatment difference (&lt; 50 copies/mL at Week 48) of -6.0%. The sensitivity and secondary analyses support a conclusion of comparable efficacy for EVG vs. RAL. The study was not designed to provide PI-specific efficacy data although the numerical comparisons suggest no major differences between EVG and RAL for the PI/r subgroups. Nevertheless, much of the justification for use rests on the PK data indicating the need for either 150 mg or 85 mg EVG with individual PI/r combinations. At present there are doubts regarding co-administration of EVG 150 mg with TPV/RTV, however, TPV/RTV has been excluded from the recommended combinations. Lower efficacy was observed in women, however, numbers are too limited to draw firm conclusions. At present the virological data, including the resistance analysis population data, suggest that EVG is not associated with a higher risk of selecting for INSTI-R mutations compared to RAL and there is incomplete cross-resistance between the two. The experience is currently too limited to discern whether in practise EVG has a similarly low genetic barrier to resistance as RAL. 2.6. Clinical safety Patient exposure Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

boosted or not. Supportive safety data were provided also from studies with QUAD STR, which are not discussed in details in this Assessment Report 2 .

Table 50. GS-US-183-0145, 0105, and 0130: Summary of Treatment Groups and Exposure

| Study   | Duration   | Treatment Group   | Number of Subjects   |
|---------|------------|-------------------|----------------------|

| product   |
|-----------|

Adverse events Treatment emergent adverse events in study GS-US-183-0145 At least one TEAE was reported by 90.1% EVG and 88.8% RAL subjects with comparable rates for TEAEs of any severity considered related to study drug as well as those of Grades 2, 3 or 4. Table 51. GS-US-183-0145: Overall Summary of Treatment-Emergent Adverse Events (Safety Analysis Set, Week 96 Dataset). Medicinal product no longer authorised

b Adverse events with onset after the last dose date plus 30 days are excluded from analysis.

C Treatment-emergent death refers to the deaths occuring between the first dose date and the last dose date plus 30 days （inclusive).A total of 12 subjects died by Week 96 data cutoff date(Appendix 16.2,Listing 23).Three deaths (EVG Subject 0595-4154 and RAL Subjects 0744-3151 and 1543-3294) were not treatment-emergent.

2 for more information, see CHMP Assessment Report / European Public Assessment Report for Stribild

<div style=\"page-break-after: always\"></div>

The most frequently reported AEs in each group (see below) were as follows:

- EVG: diarrhoea (33.6%), URTI (18.9%) and headache (13.3%)
- RAL: diarrhoea (21.8%), URTI (15.6%) and cough (13.1%)

The majority of the diarrhoea reported in both groups was mild to moderate in severity. No subjects discontinued study drug due to diarrhoea. Two cases (both in the RAL group) were SAEs.

<!-- image -->

|         | longer   |
|---------|----------|
|         | no       |
| product |          |

Grade 3 or 4 AEs reported for &gt; 1% of subjects in either treatment group were as follows:

The most frequently reported Grade 2, 3, or 4 AEs in each group were as follows: · EVG: diarrhoea (13.3%, 47) and back pain and depression (each reported for 5.9%, 21) · RAL: diarrhoea (7.8%, 28), bronchitis (5.9%, 21) and depression (5.6%, 20) Table 52. GS-US-183-0145: Treatment-Emergent Adverse Events Reported for ≥5% Subjects in Either Treatment Group (Safety Analysis Set, Week 96 Dataset). Medicinal product no longer authorised

- Pneumonia (EVG 1.7%, 6; RAL 1.4%, 5)
- Cellulitis (EVG 1.1%, 4; RAL 0.3%, 1)
- Blood bilirubin increased, diarrhoea and hypercholesterolaemia (1 each EVG; RAL 1.1%; 4)

<div style=\"page-break-after: always\"></div>

- Liver function test abnormal (EVG 0 subjects; RAL 1.4%, 5 subjects).

In both treatment groups, the most frequently reported AEs considered related to study drug by the investigator were diarrhoea (EVG 7.1%, 25; RAL 5.3%, 19), nausea (EVG 4.0%, 14; RAL 2.5%, 9) and headache (EVG 2.8%, 10; RAL 2.5%, 9).

| product                                            | EVG 85 mg QD with ATV/r or LPV/r N= 125      | EVG 150 mg QD with DRV/r, FPV/r, or TPV/r N = 229   | RAL Overall N = 358                          |
|----------------------------------------------------|----------------------------------------------|-----------------------------------------------------|----------------------------------------------|
| Subjects Experiencing Any Treatment-Emergent       | Subjects Experiencing Any Treatment-Emergent | Subjects Experiencing Any Treatment-Emergent        | Subjects Experiencing Any Treatment-Emergent |
| AE                                                 | 111 (88.8%)                                  | 208 (90.8%)                                         | 318 (88.8%)                                  |
| Grade 3 or 4 AE                                    | 28 (22.4%)                                   | 58 (25.3%)                                          | 85 (23.7%)                                   |
| Study-Drug-Related AE                              | 27 (21.6%)                                   | 57 (24.9%)                                          | 73 (20.4%)                                   |
| Grade 3 or 4 Study-Drug-Related AE                 | 2 (1.6%)                                     | 6 (2.6%)                                            | 11 (3.1%)                                    |
| Subjects Experiencing Any Treatment- Emergent SAE  | 19 (15.2%)                                   | 52 (22.7%)                                          | 84 (23.5%)                                   |
| Study-Drug-Related SAE                             | 1 (0.8%)                                     | 3 (1.3%)                                            | 7 (2.0%)                                     |
| AE Leading to Premature Study Drug Discontinuation | 1 (0.8%)                                     | 10 (4.4%)                                           | 15 (4.2%)                                    |
| AE Leading to Study Drug Interruption              | 6 (4.8%)                                     | 10 (4.4%)                                           | 32 (8.9%)                                    |
| Treatment-Emergent Death                           | 1 (0.8%)                                     | 1 (0.4%)                                            | 7 (2.0%)                                     |

Table 53. GS-US-183-0145: Treatment-Emergent Adverse Related to Study Drug Reported in &gt;1% of subject in Either Treatment Group (Safety Analysis Set, Week 96 Dataset). The table below summarises safety by EVG dose. However, since the EVG 85 mg group received ATV/r or LPV/r and the 150 mg group received DRV/r, FPV/r or TPV/r there are differences between regimens that are inherently aligned with the dose of EVG. Table 54. GS-US-183-0145: TEAEs by EVG Dose (Week 96 Safety Analysis Set) Rates for the most frequently reported AEs ( ≥ 10% in either EVG dose group) were generally similar between EVG dose groups and also generally similar to those for the overall RAL group except that the rate of diarrhoea was higher for both EVG groups vs. the RAL group. Medicinal product no longer authorised

Table 55. GS-US-183-0145: TEAEs Reported for ≥ 10.0% with EVG (Week 96 Safety Set)

|          | EVG                               | EVG                                        | RAL             |
|----------|-----------------------------------|--------------------------------------------|-----------------|
| AE by PT | 85 mg with ATV/r or LPV/r N = 125 | 150 mg with DRV/r, FPV/r, or TPV/r N = 229 | Overall N = 358 |

<div style=\"page-break-after: always\"></div>

| Diarrhoea                         | 40 (32.0%)   | 79 (34.5%)   | 78 (21.8%)   |
|-----------------------------------|--------------|--------------|--------------|
| Upper Respiratory Tract Infection | 28 (22.4%)   | 39 (17.0%)   | 56 (15.6%)   |
| Cough                             | 9 (7.2%)     | 28 (12.2%)   | 47 (13.1%)   |
| Nausea                            | 13 (10.4%)   | 31 (13.5%)   | 41 (11.5%)   |
| Headache                          | 14 (11.2%)   | 33 (14.4%)   | 37 (10.3%)   |
| Bronchitis                        | 14 (11.2%)   | 22 (9.6%)    | 36 (10.1%)   |
| Back Pain                         | 8 (6.4%)     | 31 (13.5%)   | 35 (9.8%)    |
| Depression                        | 14 (11.2%)   | 15 (6.6%)    | 31 (8.7%)    |
| Nasopharyngitis                   | 10 (8.0%)    | 23 (10.0%)   | 30 (8.4%)    |
| Fatigue                           | 11 (8.8%)    | 26 (11.4%)   | 26 (7.3%)    |

|                                                    | EVG                | EVG          | EVG            | EVG          | EVG         |                 |
|----------------------------------------------------|--------------------|--------------|----------------|--------------|-------------|-----------------|
|                                                    | 85 mg QD           | 85 mg QD     | 150 mg QD      | 150 mg QD    | 150 mg QD   | RAL             |
|                                                    | ATV/r N = 64       | LPV/r N = 68 | DRV/r N = 202  | FPV/r N = 14 | TPV/r N = 6 | Overall N = 358 |
| Any TEAE                                           | 56 (87.5%)         | 62 (91.2%)   | 181 (89.6%) no | 14 (100.0%)  | 6 (100.0%)  | 318 (88.8%)     |
| Grade 3 or 4 AE                                    | 15 (23.4%)         | 16 (23.5%)   | 49 (24.3%)     | 4 (28.6%)    | 2 (33.3%)   | 85 (23.7%)      |
| Study-Drug-Related AE                              | 16 (25.0%)         | 14 (20.6%)   | 50 (24.8%)     | 3 (21.4%)    | 1 (16.7%)   | 73 (20.4%)      |
| Grade 3 or 4 Study- Drug-Related AE                | 2 (3.1%)           | 0            | 4 (2.0%)       | 2 (14.3%)    | 0           | 11 (3.1%)       |
| SAE                                                | 13 (20.3%) product | 8 (11.8%)    | 47 (23.3%)     | 2 (14.3%)    | 1 (16.7%)   | 84 (23.5%)      |
| Study-Drug-Related SAE                             | 1 (1.6%)           | 0            | 2 (1.0%)       | 1 (7.1%)     | 0           | 7 (2.0%)        |
| AE Leading to Premature Study Drug Discontinuation | 2 (3.1%)           | 0            | 8 (4.0%)       | 1 (7.1%)     | 0           | 15 (4.2%)       |
| AE Leading to Study Drug Interruption              | 3 (4.7%)           | 3 (4.4%)     | 8 (4.0%)       | 2 (14.3%)    | 0           | 32 (8.9%)       |
| Treatment-Emergent Death                           | 1 (1.6%)           | 0            | 1 (0.5%)       | 0            | 0           | 7 (2.0%)        |

a Denominator for percentages is the number of subjects in the safety analysis set within the treatment group of the subgroup of interest. b Preferred terms are sorted in decreasing order of frequency in the Overall RAL group. c Adverse events are mapped according to MedDRA Version 14.0. The overall safety profile for subjects treated with EVG was generally similar to that for the overall RAL treatment group. In the three largest PI sub-groups the most notable difference observed was a lower rate of SAEs with LPV/r (11.8%) compared with ATV/r (20.3%) and DRV/r (23.3%). Table 56. GS-US-183-0145: TEAEs by Protease Inhibitor (Week 96 Safety Analysis Set) In the three largest PI sub-groups diarrhoea occurred at a higher ( ≥ 5% treatment difference) rate with EVG + LPV/r (47.1%) compared with EVG given with DRV/r (30.2%) or with ATV/r (21.9%). Rates for nausea and headache were comparable across EVG + PI sub-groups. Compared to the overall RAL group, diarrhoea occurred more frequently with EVG + LPV/r or DRV/r. Rates of nausea and headache were similar across PI groups and RAL. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 57. GS-US-183-0145: Most Common TEAEs by PI/r (Week 96 Safety Analysis Set)

|                                 | EVG 85 or 150 mg QD   | EVG 85 or 150 mg QD   | EVG 85 or 150 mg QD   | EVG 85 or 150 mg QD   | EVG 85 or 150 mg QD   | RAL             |
|---------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------|
| Adverse Event by Preferred Term | ATV/r N = 64          | LPV/r N = 68          | DRV/r N = 202         | FPV/r N = 14          | TPV/r N = 6           | Overall N = 354 |
| Diarrhoea                       | 14 (21.9%)            | 32 (47.1%)            | 61 (30.2%)            | 10 (71.4%)            | 2 (33.3%)             | 78 (21.8%)      |
| URTI                            | 15 (23.4%)            | 15 (22.1%)            | 33 (16.3%)            | 3 (21.4%)             | 1 (16.7%)             | 56 (15.6%)      |
| Nausea                          | 8 (12.5%)             | 7 (10.3%)             | 23 (11.4%)            | 5 (35.7%)             | 1 (16.7%)             | 41 (11.5%)      |
| Headache                        | 8 (12.5%)             | 10 (14.7%)            | 27 (13.4%)            | 1 (7.1%)              | 1 (16.7%)             | 37 (10.3%)      |

The commonest TEAEs considered drug-related were diarrhoea, nausea and vomiting but there was no consistent pattern for rates in relation to EVG dose.

Nausea Headache Rates of AEs, SAEs and AEs leading to discontinuation were similar to or lower for EVG vs. RAL regardless of the dosing frequency of the PI/r but interpretation of these data is very limited by the small sample size of several groups. Overall, the incidence of diarrhoea was higher when EVG was given with twice-daily RTV (36.8%, 93/253) compared to once-daily RTV (25.7%, 26/101). No other clinically significant differences between RTV dosing frequencies were noted. Treatment emergent adverse events in study GS-US-183-0130 At least one TEAE was reported by 92% (177/192) of subjects. The most frequently reported were URTI (25.5%), diarrhoea (22.4%), sinusitis (18.2%), bronchitis (17.7%), nasopharyngitis (13.0%), nausea (13.0%), fatigue (12.5%), arthralgia (10.9%), depression (10.9%) and back pain (10.4%). Grade 3 or 4 AEs were reported for 38% but those reported in &gt; 1 subjects were very wide-ranging in nature. Drug-related TEAEs were experienced by 24 subjects (12.5%). Four subjects (2.1%) experienced a Grade 3 AE considered to be drug-related (acute pancreatitis, hepatitis B and peripheral neuropathy [2 subjects]). The case of Grade 3 HBV was HBsAg negative at baseline but had Grade 4 ALT with Grade 3 AST and GGT elevations, which resolved during temporary interruption of ARV and did not occur following resumption of therapy (EVG, DRV/RTV, TDF and ABC). Treatment emergent adverse events in study GS-US-183-0105 At least one TEAE was reported by the majority of subjects with broadly comparable rates across treatments. The most frequently reported were diarrhoea, nausea, constipation, vomiting, fatigue, injection site reactions, pyrexia, URTI, sinusitis, headache, cough and pharyngolaryngeal pain. Table 58. Number of subjects experiencing any TEAE in study GS-US-183-0105 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 59. GS-US-183-0105: Treatment-Related Adverse Events Reported by at Least 5% of Subjects by Treatment through Week 48 (Randomised and Treated Analysis Set).

| Number (%) of Subjects with Adverse Events by Systeim Organ Class,High- LevelTerm,and Preferred Term   | CPI/r (N = 63)   | EVG/r 20/100mg QD (N = 71)   | EVG/r 50/100mg QD (N = 71)   | EVG/r 125/100mg QD (N = 73)   | CPI/r-> EVG/r (N = 30)a   |
|--------------------------------------------------------------------------------------------------------|------------------|------------------------------|------------------------------|-------------------------------|---------------------------|

Phase 1 studies in non HIV-infected subjects The applicant did not summarise AEs from the Phase 1 studies but SAEs and discontinuations due to SAEs are described (see below). For the most part the TEAEs observed in the various studies in healthy subjects were as expected in these study populations. In several of the DDI studies the AEs observed on co-administration of EVG with other medicinal products reflected the known safety profiles of the other drugs (e.g. jaundice with ATV). In some studies rates for certain AEs were higher on coadministration. Serious adverse event/deaths/other significant events Deaths Twelve male subjects died during GS-US-183-0145 up to the cut-off date for the CSR (EVG 3; RAL 9 subjects). Nine of these 12 deaths were considered treatment-emergent (EVG 2; RAL 7). The AEs associated with treatment-emergent death in the EVG group (acute myocardial infarction and rectal haemorrhage) were not considered related to study drug. Three deaths occurred during GS-US-183-0105 but these were not considered related to study drugs by the investigators. One in the EVG/RTV 50/100 mg group died of cardiorespiratory failure on Day 221. The two deaths in the EVG/RTV 20/100 mg group were due to B-cell lymphoma on Day 159 and Pneumocystis jirovecii pneumonia on Day 143. Eleven deaths occurred during GS-US-183-0130 but none was considered to be related to study drug. Causes of death included subdural hematoma, complications from Pneumocystis pneumonia, presumptive self-asphyxiation, perforated ulcer, colorectal carcinoma, sepsis, coronary arterial sclerosis and dilated cardiomyopathy, advanced HIV disease, strangulation, progressive multifocal leucoencephalopathy and Hodgkin lymphoma. Medicinal product no longer authorised

## Serious adverse events

## In Phase 1 studies:

- A 20-year-old healthy female subject experienced intrauterine foetal death on day 44 after the last dose of EVG 125 mg and RTV 50 mg.

<div style=\"page-break-after: always\"></div>

- Spontaneous abortion occurred in a subject who received EVG/RTV who was discovered to be pregnant in the latter part of the study due to failure of contraception. She was immediately discontinued but had a spontaneous abortion 14 days later.
- One SAE of diabetic foot ulcer not considered to be related to EVG/COBI occurred in a 71 year-old subject with severe renal impairment and type 2 diabetes.

| no longer   |
|-------------|

In GS-US-183-0145 SAEs were reported for 20.1% (71 subjects) in the EVG group and 23.5% (84 subjects) in the RAL group. The majority concerned infections (mostly pneumonia and cellulitis) and were not considered to be related to study drug by investigators. SAEs considered related to study drug were reported for 4 EVG and 7 RAL subjects. Those in the EVG group concerned type 1 diabetes, cerebral infarction plus subarachnoid haemorrhage, haemolytic anaemia and cholestatic hepatitis. Convulsion was the only SAE considered related to study drug by the investigator that was reported for &gt; 1 subject in a treatment group (2 subjects in the RAL group). Table 60. GS-US-183-0145: Treatment-Emergent Serious Adverse Events Reported in &gt;1% of Subjects in Either Treatment Group (Safety Analysis Set, Week 96 Dataset). Of note, all subjects who experienced an AE related to suicidal ideation or suicide attempt when receiving EVG in different studies had a pre-existing history of depression or psychiatric illness. There were 52 subjects who had at least one SAE in GS-US-183-0105 (including the 3 deaths) and 41 occurred in one of the EVG groups. Another 6 subjects who switched to open-label EVG had SAEs. The only SAEs reported in &gt; 1 subject within a treatment group were pneumonia (2 in the 125/100 mg group) and B-cell lymphoma (2 in the 20/100 mg group). Three SAEs assessed as related or possibly related to study drugs included two in EVG-treated subjects (syncope and hypersensitivity reaction). In GS-US-183-0130 72 subjects (37.5%) who received EVG/RTV experienced at least one SAE. Those reported in &gt; 1% included pneumonia (3.1%), cellulitis (2.1%), myocardial infarction (1.6%), chest pain (1.6%), gastro-enteritis (1.6%), influenza (1.6%) and acute renal failure (1.6%). All of these SAEs were considered by the investigators to be not related to study drug. The two SAEs considered by the investigator to be related to study drug involved acute pancreatitis on Day 496 and acute necrotising retinitis on Day 1220. Pregnancies Medicinal product no longer authorised

In Phase 1 studies five pregnancies were reported in subjects who received EVG and two more in subjects who received EVG during Phase 1 studies with COBI. See above section on SAEs. Two have resulted in healthy infants and one had a termination. One infant born to a subject with a positive pregnancy test on Day 7 of 125 mg EVG with DRV/RTV had bilateral extra fingers at the fifth digit.

<div style=\"page-break-after: always\"></div>

There was a family history of extra fingers and the congenital abnormality was deemed to be unrelated to treatment.

In GS-US-183-0145 seven pregnancies were reported (4 EVG and 3 RAL). Two subjects were determined to have been pregnant before study drug administration was initiated, of which one had a spontaneous abortion and the other had an induced abortion. Of 5 exposed to study drug during pregnancy, 2 subjects in the EVG group delivered healthy babies while one in the RAL group had a spontaneous abortion. Two were ongoing at the time of the report. In GS-US-183-0130 one pregnancy occurred that ended in spontaneous abortion.

Laboratory findings In GS-US-183-0145 the numbers with TE laboratory abnormalities of any Grade were comparable between treatment groups. Grade 3 or 4 laboratory abnormalities were reported for EVG 36.7% vs. RAL 41.8% and the difference primarily reflected lower rates in the EVG group for LFT abnormalities. Grade 3 or 4 abnormalities were reported for a higher percentage of subjects in the EVG group for lipase (13.6% vs. 6.9%; although rates for amylase were 6.3% vs. 5.9%) and creatinine kinase (6.0% vs. 3.7%). The most frequently reported Grade 3 or 4 treatment-emergent laboratory abnormalities were: · EVG: lipase (only performed if amylase &gt; 1.5 ULN; 13.6%); amylase (6.3%); haematuria (6.0%); hyperbilirubinaemia and creatinine kinase (each 6.0%) · RAL: hyperbilirubinaemia (8.5%); lipase (6.9%); GGT and haematuria (each 6.5%) Marked laboratory abnormalities were reported for comparable percentages in each group (EVG 27.5%; RAL 30.2%). Thirteen subjects (EVG 6, RAL 7) had ALT or AST values &gt; 3 × ULN and total bilirubin &gt; 2 × ULN occurring at the same study visit. The likely causes for these liver laboratory abnormalities are shown in the table below. No subject in the study met the definition of Hy's law. Two subjects (one per treatment group) had changes in liver laboratory values potentially associated with drug-induced chemical hepatitis. The enzymatic elevations were transient, resolved after discontinuation and had no sequelae. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 61. Summary of Subjects with ALT or AST Values &gt;3 x ULN and Total Bilirubin Values &gt;2 x ULN at the Same Study Visit (Safety Analysis Set, Week 96 Dataset).

| Subject   | Treatment Group   | Event                                          | Likely Cause                                                     |
|-----------|-------------------|------------------------------------------------|------------------------------------------------------------------|
| 0566-3310 | EVG               | No liver-related AE;Grade 3 laboratory results | OnATV;acutemyocardialinfarctionwith AST elevation but normal ALT |
| 0595-4154 | EVG               | Chronic hepatic failure (SAE)                  | Chronic hepatitis C,with liver cirrhosis                         |

In study GS-US-183-0130 the most frequent Grade 3 and 4 laboratory abnormalities involved CK, GGT, serum amylase, fasting triglycerides and urine glucose. Most were not considered to be clinically relevant (e.g. CK elevation or amylase elevation without associated TEAEs) or were due to underlying conditions (e.g. diabetes, HCV).

Serum creatinine increased with median change from baseline at Week 96 of 0.10 mg/dL in both groups. Treatment-emergent serum creatinine abnormalities were reported for 32 EVG subjects and 36 RAL subjects while Grade 3 or 4 abnormalities were reported for 2 subjects in each group. Blood creatinine increased was reported as an AE for 2 EVG and 3 RAL subjects and considered related to study drug for one EVG subject. There was a decrease in median values for eGFRCG in both treatment groups (EVG median change at Week 96 of -10.8 mL/min; RAL -11.7 mL/min). Hypophosphataemia was reported for EVG 41 vs. RAL 31 subjects. Grade 3 hypophosphataemia was reported for 2 EVG subjects. Hypophosphataemia was reported as an AE for 2 subjects in each group but no case was considered related to study drug and no action was taken. Glycosuria was reported for EVG 31 vs. RAL 26 subjects and Grade 3 glycosuria was reported for 13 (3.7%) vs. 11 (3.1%). Proteinuria was reported in EVG 170 and RAL 176 subjects (Grade 3 in one EVG subject). Similar numbers in each treatment group had treatment-emergent abnormalities reported for fasting total cholesterol or fasting triglycerides. AEs of blood triglycerides increased or hypertriglyceridaemia were reported for comparable percentages per group. In study GS-US-183-0105 parameters for which &gt; 1 subject per treatment had a TE Grade 3 or 4 abnormality included cholesterol, triglycerides, CK, GGT, lipase, amylase, total bilirubin, phosphorus, raised serum glucose, haemoglobin, neutrophils, platelets, WBC count, urine blood and urine glucose but no treatment-related trends were apparent. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

Discontinuations due to TEAS in the Phase 1 studies did not show treatment-related trends.

Up to the Week 96 CSR cut-off date for GS-US-183-0145 the rates of premature study drug discontinuation due to TEAEs were EVG 3.1% (11) vs. RAL 4.2% (15). TEAEs leading to discontinuation reported in &gt; 1 EVG subject were nausea (2) and vomiting (2). In six EVG and nine RAL subjects TEAEs leading to study drug discontinuation were considered related to study drug by the investigator, including cases of nausea and abdominal pain in the EVG group.

<!-- image -->

Table 62. GS-US-183-0145: Treatment-Emergent Adverse Events Leading to Premature Study Drug Discontinuation (Safety Analysis Set, Week 96 Dataset). Medicinal product no longer authorised

|         | longer   | longer   |
|---------|----------|----------|
|         | no       |          |
| product |          |          |

In GS-US-183-0105 discontinuation from study due to TEAEs occurred in 2 subjects (3.2%) in the CPI/r group compared to 3 (4.2%), 2 (2.8%) and 1 (1.4%) in each of the EVG/r 20/100, 50/100, and 125/100 mg groups, respectively. These included cases of hypersensitivity (EVG/r 20/100 mg) and convulsion (EVG/r 50/100 mg) that were considered by the investigators to be study drug related.

<div style=\"page-break-after: always\"></div>

In GS-US-183-0130 10 subjects (5.2%) had TEAEs that led to premature discontinuation of study drug but none was reported in &gt; 1 subject or considered by the investigator to be related to study drug. All except one were SAEs.

## 2.6.1. Discussion on clinical safety

<!-- image -->

The total exposure of HIV-infected subjects to EVG specifically when administered in conjunction with RTV-boosted PIs is limited to 354, of which ~60% had been exposed for &gt; 96 weeks when the CSR was finalised. This is not an overly large database for a new agent but it is supported by considerable numbers exposed to EVG as part of QUAD STR and in the Phase 1 and 2 studies. Results from study GS-US-183-0145 suggested comparable overall AE/SAE rates between EVG and RAL except for slightly higher rates for AEs considered drug-related, including those of Grades 2-4 (but not 3-4). Taking into account the data for EVG + PI/r in this study and the STB data there seems to be a particular association between EVG and diarrhoea, including Grades 2-4. Rates were higher for EVG vs. RAL in study GS-US-183-0145 but no subject in the EVG group discontinued due to this AE. Although one third had Grade 2-4 diarrhoea, no case was serious. Diarrhoea also occurred more often with STB vs. Atripla (although not vs. ATV/r + TVD). Rates of nausea and vomiting were generally comparable for EVG vs. RAL in GS-US-183-0145. EVG and STB have been associated with several cases of elevated ALT and AST. The available data do not suggest that EVG was more likely to trigger LFT abnormalities than RAL or that STB is associated with higher rates of abnormal liver parameters compared to Truvada or Atripla. For other laboratory parameters there was no indication that EVG was associated with a higher rate of abnormal values vs. RAL except that hypophosphataemia was reported for 41 EVG and 31 RAL subjects. Urinary phosphate excretion was not measured. Very few subjects had co-existing hypophosphataemia and urinary abnormalities and in the EVG group subjects the most likely explanation was the co-administered TDF. From the safety database all the adverse events reported in clinical trials that are deemed by the CHMP to be adverse reactions have been included in the Summary of Product Characteristics 2.6.2. Conclusions on the clinical safety There are no major safety concerns for use of EVG raised by the data. For the most part the safety profile of EVG was comparable with that of RAL when each was co-administered with RTV-boosted PIs and other agents in GS-US-183-0145. There seems to be a clear association between EVG and diarrhoea and this is one of the few AEs that occurred at a higher rate vs. RAL but it was not identified as the trigger for discontinuations due to AEs. 2.7. Pharmacovigilance system Medicinal product no longer authorised

The  CHMP  considered  that  the  Pharmacovigilance  system  as  described  by  the  applicant  fulfils  the legislative requirements.

## 2.8. Risk Management Plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan: The PRAC

<div style=\"page-break-after: always\"></div>

considered that the risk management system version 0.3 could be acceptable with revisions required as described in the attached PRAC endorsed PRAC Rapporteur assessment report.

The CHMP endorsed this advice without changes.

The Applicant implemented the changes in the RMP as requested by PRAC. The CHMP endorsed the updated Risk Management Plan version 0.4 with the following content:

<!-- image -->

| Important Identified Risks   | Suicidal ideation/suicide attempt in patients with a pre-existing history of depression or psychiatric illness   |
|------------------------------|------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks   | Drug resistance to EVG                                                                                           |
| Important Potential Risks    | Concurrent use of drugs whose coadministration with EVG is contraindicated                                       |
| Important Potential Risks    | Medication errors that may result in reduced exposure to EVG                                                     |
| Important Potential Risks    | Reduced efficacy in women                                                                                        |
| Missing Information          | Safety in children                                                                                               |
| Missing Information          | Safety in elderly patients                                                                                       |
| Missing Information          | Safety in pregnancy                                                                                              |
| Missing Information          | Safety in lactation                                                                                              |
| Missing Information          | Safety in severe hepatic impairment (CPT score C) longer                                                         |
| Missing Information          | PK of EVG in subjects with UGT1A1 polymorphisms                                                                  |
| Missing Information          | Long-term suppression of HIV-1 infection                                                                         |

Safety concerns Table 6. Summary of Safety Concerns Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plans

Table 7. Ongoing and Planned Additional Pharmacovigilance Studies/Activities in the Pharmacovigilance Plan

<!-- image -->

| Study/Title                                                                                                                                                                                                                                                                              | Objectives                                                                                                                                                                                          | Safety Concerns Addressed                                            | Status (Planned, Started)                    | Date for Submission of Interim or Final Reports (Planned or Actual) authorised        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------|---------------------------------------------------------------------------------------|
| Category 3 (Interventional clinical studies)                                                                                                                                                                                                                                             | Category 3 (Interventional clinical studies)                                                                                                                                                        | Category 3 (Interventional clinical studies)                         | Category 3 (Interventional clinical studies) | Category 3 (Interventional clinical studies)                                          |
| GS-US-183-0145 A Phase 3, multicenter, randomized, double-blind, double-dummy, study of the safety and efficacy of ritonavir-boosted elvitegravir (EVG/r) versus raltegravir (RAL) each administered with a background regimen in HIV- 1 infected, antiretroviral treatment-experienced  | To evaluate the long- term efficacy of EVG administered with a background regimen in adults                                                                                                         | Missing information: Long-term suppression of HIV-1 infection longer | Ongoing                                      | Q2 2015 (Final report)                                                                |
| adults GS-US-183-0160 A Phase 2/3, open-label, 2- part study evaluating the pharmacokinetics, safety, and antiviral activity of EVG administered with a background regimen containing a RTV-boosted PI in HIV-1 infected, antiretroviral treatment- experienced children aged < 18 years | To evaluate the PK, safety, and antiviral activity of EVG administered with a background regimen containing a PI/r in HIV-1 infected, ARV treatment-experienced children aged < 18 years product no | Missing information: Safety in children                              | Planned                                      | April 2016 (48-week report [adolescents]) December 2016 (48-week report [0-12 years]) |

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study/Title                                                                                                                                                                                                                                                                                                                                                              | Objectives                                                                                                                                                                                                                               | Safety Concerns Addressed                                                                            | Status (Planned, Started)               | Date for Submission of Interim or Final Reports (Planned or Actual)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|-----------------------------------------|-----------------------------------------------------------------------|
| CO-US-183-0165 (PENTA 17) A Phase 2/3, multicenter, randomized, open-label, multicohort study comparing the safety and antiviral activity of current therapy versus EVG administered with RTV-boosted darunavir (DRV/r) or versus DRV/r in HIV-1 infected, antiretroviral treatment-experienced, virologically suppressed pediatric subjects aged 6 to < 18 years of age | To compare the safety and antiviral activity of current therapy versus EVG administered with DRV/r or versus DRV/r in HIV-1 infected, ARV treatment-experienced, virologically suppressed pediatric subjects aged 6 to < 18 years of age | Missing information: Safety in children                                                              | Planned                                 | September 2017 (final report) authorised                              |
| GS-US-183-0154 A Phase 2/3, open-label, 2- part study evaluating the pharmacokinetics, safety, and antiviral activity of EVG coadministered with COBI and 2-first-line NRTIs in HIV-1 infected, antiretroviral treatment-naive children aged < 18 years                                                                                                                  | To evaluate the PK, safety, and antiviral activity of EVG coadministered with COBI and 2-first-line NRTIs in HIV-1 infected, ARV treatment-naive children aged < 18 years product no                                                     | Missing information: Safety in children longer                                                       | Planned                                 | October 2021 (final report)                                           |
| Planned PK study of EVG following administration of STB in subjects with UGT1A1*28/*28 genotype Medicinal                                                                                                                                                                                                                                                                | To evaluate the PK of EVG in subjects with UGT1A1*28/*28 genotype administered STB                                                                                                                                                       | Missing information: PK of EVG in subjects with UGT1A1 polymorphisms                                 | Planned                                 | Q2 2015 (final report)                                                |
| Category 3 (Non-interventional studies)                                                                                                                                                                                                                                                                                                                                  | Category 3 (Non-interventional studies)                                                                                                                                                                                                  | Category 3 (Non-interventional studies)                                                              | Category 3 (Non-interventional studies) | Category 3 (Non-interventional studies)                               |
| Drug utilization study                                                                                                                                                                                                                                                                                                                                                   | To determine the use of rifampicin, St. John's wort, carbamazepine, phenobarbital and phenytoin with EVG in the postmarketing setting.                                                                                                   | Important potential risk: Concurrent use of drugs whose coadministration with EVG is contraindicated | Planned                                 | 25 February 2014 (Feasibility assessment report)                      |

<div style=\"page-break-after: always\"></div>

| Study/Title                       | Objectives                                                                                                                                      | Safety Concerns Addressed                                                              | Status (Planned, Started)   | Date for Submission of Interim or Final Reports (Planned or Actual)    |
|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------|------------------------------------------------------------------------|
|                                   | To determine the incidence/prevalence and outcome of medication errors in the postmarketing setting that may result in reduced exposure to EVG. | Important potential risk: Medication errors that may result in reduced exposure to EVG |                             | authorised                                                             |
| Antiretroviral Pregnancy Registry | To determine the risk of birth defects in patients exposed to ARVs, including EVG, during pregnancy                                             | Missing information: Safety in pregnancy longer                                        | Ongoing                     | Interim reports available every 6 months (June and December each year) |

| Safety Concern                                                                                                           | Routine Risk Minimization Measures                                                                                                                                                                                                                                                                                                            | Additional Risk Mini- mization Measures   |
|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| Important identified risks                                                                                               | Important identified risks                                                                                                                                                                                                                                                                                                                    | Important identified risks                |
| Suicidal ideation/suicide attempt in patients with a pre-existing history of depression or psychiatric illness Medicinal | The SmPC (section 4.8) lists suicidal ideation and suicide attempt (in patients with a pre-existing history of depression or psychiatric illness) as an uncommon ADR.                                                                                                                                                                         | None                                      |
| Drug resistance to EVG                                                                                                   | The SmPC (Section 4.4) states that EVG has a relatively low genetic barrier to resistance when used as part of a suboptimal regimen, and that, whenever possible, EVG should be administered with a fully active PI/r and a second fully active ARV agent to minimize the potential for virological failure and the development of resistance | None                                      |

Risk minimisation measures Table 8. Summary Table of Risk Minimization Measures Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                             | Routine Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Additional Risk Mini- mization Measures   |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| Important potential risks                                                  | Important potential risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                           |
| Concurrent use of drugs whose coadministration with EVG is contraindicated | The SmPC (Sections 4.3 and 4.5) includes information that coadministration with strong CYP3A inducers (rifampicin, St. John's wort, carbamazepine, phenobarbital and phenytoin) is contraindicated due to the potential for loss of virologic response and possible resistance. The Package Leaflet instructs patients that rifampicin, St. John's wort, carbamazepine, phenobarbital and phenytoin should never be taken with EVG authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | None                                      |
| Medication errors that may result in reduced exposure to EVG               | The SmPC (Section 4.2) states that EVG must be administered in combination with a PI/r, and includes information on the recommended dosing regimens for EVG and the coadministered PI/r and that no data are available to recommend the use of EVG with dosing frequencies or PIs other than those recommended in the Vitekta SmPC. The SmPC (Section 4.4) contains warnings that the dose of EVG should be decreased from 150 mg once daily to 85 mg once daily when used in combination with ritonavir-boosted atazanavir (ATV/r) and ritonavir-boosted lopinavir (LPV/r), that EVG should only be used in combination with a PI/r, that EVG should not be used with a PI boosted by another agent, that boosting EVG with an agent other than ritonavir may result in inadequate plasma levels of EVG and/or the PI, leading to loss of therapeutic effect and possible development of resistance, and that EVG should not be used in combination with products containing elvitegravir or pharmacokinetic boosting agents other than ritonavir. The Package Leaflet contains information on the appropriate EVG dose for each recommended PI and instructs patients to product no longer | None                                      |
| Reduced efficacy in women                                                  | change the dose unless instructed to do so by the doctor. None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | None                                      |
| Missing information                                                        | Missing information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                           |
| Safety in children Medicinal                                               | The SmPC (Section 4.2) states that the safety and efficacy of EVG in children aged 0 to less than 18 years have not yet been established and that no data are available. The SmPC (Section 4.8) states that no safety data are available for children below 18 years of age and that EVG is not recommended in this population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | None                                      |
| Safety in elderly patients                                                 | The SmPC (Section 4.2) states that no data are available on which to make a dose recommendation for patients over the age of 65 years.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | None                                      |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                    | Routine Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Additional Risk Mini- mization Measures   |
|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| Safety in pregnancy                               | The SmPC (Section 4.6) states that there are no or limited clinical data with EVG in pregnant women and that EVG should not be used during pregnancy unless the clinical condition of the woman requires treatment with EVG.                                                                                                                                                                                                                                                                                                                                                                              | None                                      |
| Safety in lactation                               | The SmPC (Section 4.6) states that it is unknown whether EVG is excreted in human milk, that a risk to the newborns/infants cannot be excluded and therefore EVG should not be used during breast-feeding, and that in order to avoid transmission of HIV to the infant it is recommended that HIV infected women do not breast-feed their infants under any circumstances.                                                                                                                                                                                                                               | None                                      |
| Safety in severe hepatic impairment (CPT score C) | The SmPC (Sections 4.2 and 4.4) states that EVG has not been studied in patients with severe hepatic impairment (Child Pugh Class C). The SmPC (Section 4.4) includes a class warning for ARVs that patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice, and that if there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered. no longer | None                                      |
| PK of EVG in subjects with UGT1A1 polymorphisms   | None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | None                                      |
| Long-term viral suppression of HIV-1 infection    | None product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | None                                      |

<!-- image -->

2.9. User consultation The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

At present the virological data, including the resistance analysis population data, suggest that EVG is not associated with a higher risk of selecting for INSTI-R mutations compared to RAL and there is incomplete cross-resistance between the two. However, the experience is currently too limited to discern whether EVG has a similarly low genetic barrier to resistance as RAL in practice. Furthermore, there is sufficient evidence to support a warning regarding the need to ensure use in combination with other known active agents.

EVG is clearly active against HIV in vitro and achieved a 2-log drop in HIV RNA over 10 days when administered as 50 mg EVG plus 100 mg RTV daily in the short-term monotherapy study. When used at an appropriate dose regimen to treat susceptible virus it could be expected to contribute to the overall effect of an ART regimen, including co-administration with RTV-boosted PIs as proposed by the applicant. Taking into account also the data from study GS-US-183-0145, EVG may be considered as an alternative to the only currently licensed integrase inhibitor raltegravir. Overall, this study demonstrated comparable efficacy for EVG vs. RAL, with a lower bound of the 95% CI around the treatment difference (&lt; 50 copies/mL at Week 48) of -6.0%. The sensitivity and secondary analyses support a conclusion of comparable efficacy for EVG vs. RAL. Uncertainty in the knowledge about the beneficial effects EVG is intended to be used only in co-administration with a PI/r. Due to the PK properties of EVG itself and the various possible PI/r regimens the total risk of possible interactions is difficult to assess and to predict. EVG has only been evaluated in PK studies with twice daily DRV/RTV or LPV/RTV. In addition, the few data available from study 0145 strongly point against using EVG with once daily DRV/RTV. Off-label use of EVG with these regimens therefore constitutes a major concern and respective warning has been included in the SmPC. The clinical efficacy programme for EVG was decided upon at a time of transition with regard to study feasibility and regulatory guidance. This led to conduct of a single pivotal study in which EVG was coadministered with one of five RTV-boosted PIs predicted to be active against the individual subject's virus plus at least one other agent. The study was not designed to provide PI-specific efficacy data although the numerical comparisons suggest no major differences between EVG and RAL for the PI/r subgroups. Nevertheless, much of the justification for use rests on the PK data indicating the need for either 150 mg or 85 mg EVG with individual PI/r combinations. At present there are doubts regarding only co-administration of EVG 150 mg with TPV/RTV, and this combination has therefore been excluded from the recommended combinations in the SmPC. Although the numbers are too limited to draw firm conclusions, the observed lower efficacy in women warrants close attention and has been added to the RMP as a potential risk. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Risks

## Unfavourable effects

The safety profile of EVG is mostly unremarkable among the HIV agents and is generally comparable with that of RAL. While EVG has a particular propensity to be associated with diarrhoea, thus far diarrhoea does not seem to have been a treatment-limiting issue. Although the final reasons for study discontinuation that are captured on CRFs sometimes mislead (e.g. subjects may be recorded as 'lost to follow-up' when in reality they had AEs in the clinical trial that prompted them to seek other treatment outside of the study and fail to attend further visits) there was not an overall excess of discontinuations from EVG vs. from RAL.

Despite the limitations of the data available, taking into account the lack of serious safety concerns and the need for alternative treatments for the proposed target population there is sufficient evidence to support use of EVG with the four proposed PI/r combinations.

Uncertainties regarding the possible antibacterial effects of EVG and its impact have been identified from non-clinical data, but in absence of clinical findings those are regarded as minor. Uncertainty in the knowledge about the unfavourable effects Strictly with regard to use of EVG with boosted PIs in HIV-infected subjects the safety database is limited to 354 subjects, of which ~40 % discontinued before week 96. Despite of the overall safety profile of elvitegravir not being of any major concern, this limits the reliance that can be placed on the identification of adverse reactions and their rates. Benefit-risk balance Importance of favourable and unfavourable effects The activity of EVG against HIV-1 has been clearly demonstrated, including in a confirmatory phase III study in comparison with another active treatment. Therefore, EVG has a potential to address the medical need that exists in the proposed HIV-1 infected target population. No major unfavourable effects have been identified for EVG. However, the amount of safety data currently available limits the knowledge about the exact safety profile of EVG. Longer term data are expected to be available from additional pharmacovigilance activities agreed in the RMP. Even though the possible PK interactions of EVG have been extensively studied, due to the many different possible combinations of co-administered medicines, the exact nature and extent of interactions is difficult to predict. The risks related to possible coadministration of EVG in nonrecommended combinations or medication errors is to be addressed in a drug utilisation study agreed in the RMP. The experience is currently too limited to discern whether in practise EVG has a similarly low genetic barrier to resistance as RAL, however the risk of resistance development does not prevent use of EVG in combination with other known active agents. Development of resistance has been included as an identified risk in the RMP. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Benefit-risk balance

Current evidence suggests that the benefit-risk balance is in favour of use of EVG at the recommended dose with once daily ATV/r or with twice daily LPV/r, DRV/r or FPV/r and with other retroviral agents for treatment of HIV-1 infection in adults who are infected with HIV-1 without known mutations associated with resistance to EVG.

Discussion on the benefit-risk balance The PK data and the evidence for efficacy, including the actual 95% CI observed in GS-US-183-0145, support use of EVG with RTV-boosted PIs as discussed above. There are no safety concerns that would preclude use of EVG as recommended, however, there is a considerable potential for drug-drug interactions to occur, which has been reflected in the SmPC. Efficacy results in women were numerically lower, but the number of subjects was too low to draw any firm conclusions. In addition, no potential mechanism has been identified that would explain such differences. Furthermore, even if numerically lower, efficacy was seen also in the subgroup of women. 4. Recommendations Outcome Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the risk-benefit balance of Vitekta co-administered with ritonavir-boosted protease inhibitor and with other antiretroviral agent in the treatment of HIV-1 infection in adults who are infected with HIV1 without known mutations associated with resistance to elvitegravir is favourable and therefore recommends the granting of the marketing authorisation subject to the following conditions: Conditions or restrictions regarding supply and use Medicinal products subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). Other conditions and requirements of the Marketing Authorisation Periodic safety update reports The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation. Subsequently, the marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal. Medicinal product no longer authorised

## Conditions or restrictions with regard to the safe and effective use of the medicinal product Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

<div style=\"page-break-after: always\"></div>

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.

New Active Substance Status Based on the CHMP review of data on the quality properties of the active substance, the CHMP considers that elvitegravir is to be qualified as a new active substance at the time of submission of the Application for Marketing Authorisation. Medicinal product no longer authorised